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ABSTRACT 
 
Although initially identified as an “activator” of follicle-stimulating hormone release from the 
pituitary, activin A can also function as a paracrine factor in many tissue contexts.   As a member of the 
transforming growth factor ! (TGF!) superfamily, activin A can elicit changes in target cell proliferation, 
differentiation, and function via the SMAD signaling pathway.  Inhibin !A (Inhba), the gene encoding 
activin A, is expressed within the interstitial compartment of murine and human fetal testes; however, the 
role of Inhba/activin A during testis morphogenesis is unknown.  To investigate whether Inhba is 
required for testis development in the mouse, I analyzed fetal testis morphogenesis in Inhba
-/-
 mice.  In 
the absence of Inhba
 
expression, I observed significant reductions in Sertoli cell proliferation leading to 
impairment of testis cord elongation and coiling.  Using a conditional knockout approach, I was able to 
pinpoint the murine fetal Leydig cells as the primary source of interstitial Inhba/activin A.  To identify the 
cellular targets of fetal Leydig cell-derived activin A, I produced mouse models lacking expression of 
Smad4, a central component of TGF! superfamily signaling, in specific cell types within the testis.  
Deletion of Smad4 from the Sertoli cell epithelium recapitulated the fetal testis cord dysgenesis present in 
Inhba
-/-
 mice, indicating the Sertoli cells are likely the direct targets of activin A signaling.  I have thus 
identified a novel mesenchymal-epithelial crosstalk in the developing testes wherein interstitial fetal 
Leydig cells produce activin A that acts upon the Sertoli cell epithelium to promote proliferation.  This 
testicular activin A pathway is critical for elongation and convolution of the testis cords during late 
embryogenesis.  Furthermore, I have uncovered the first evidence of an active role for fetal Leydig cells 
during testis cord development.  Fetal testis cord dysgenesis resulting from disrupted testicular activin A 
signaling persists into adulthood, confirming the importance of this signaling pathway in laying the 
groundwork for normal testicular development and function during postnatal life.  
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CHAPTER 1:  LITERATURE REVIEW 
 
 
1.1:  MAMMALIAN TESTIS DETERMINATION 
1.1.1:  Early gonad development in the mouse 
The mouse has long served as the preferred model species in which to study mammalian 
gonadogenesis.  Although gonad formation in other mammalian species is understudied, the information 
available thus far indicates gonadal morphogenesis in species such as the rat and human follows a similar 
developmental course as has been observed in the mouse [1].  Unlike other organs in the developing 
embryo, the gonads originate from bipotential primordia that are capable of becoming either ovaries or 
testes depending upon the signaling cues present.  The gonads are formed from bilateral intermediate 
mesodermal structures known as the urogenital ridges.  In the mouse, the urogenital ridges arise by 
embryonic day 9.5 (E9.5) and initially consist of three overlapping regions – the pronephros, 
mesonephros, and metanephros [2].  Although the pronephros is vestigal in mammals and rapidly 
regresses, its associated ductal derivatives persist and become the mesonephric (Wolffian) ducts.  The 
gonadal primordia originate around E10 as a single layer of cells on the medial surface of the 
mesonephros whereas the metanephros, the caudal-most region, gives rise to the embryonic kidney.  
Somatic cells of the murine gonads arise via proliferation of epithelial cells found along the coelomic 
surface of the mesonephros [3].  While gonadal somatic cells are thought to be of mesonephric origin, the 
primordial germ cells are specified in the embryonic epiblast as early as E6.25 [4].  The primordial germ 
cells undergo a journey of proliferation and migration from the base of the allantois through the dorsal gut 
mesentery and intermix with the somatic cell precursors of the newly-formed gonads between E10 and 
E11 [4]. 
 Although the precise mechanisms controlling initial formation of the gonadal primordia are not 
fully understood, several genes have been recognized as playing critical roles in the maintenance of these 
structures.  In the mouse, mutations or deletions of Steroidogenic factor 1 (Sf1, also known as Nr5a1), 
Wilms tumor 1 (Wt1), Lim homeobox 9 (Lhx9), or Empty spiracles homolog 2 (Emx2) result in complete 
gonadal agenesis [5-9].  Some degree of cooperativity has been shown to exist among these transcription 
factors in the developing gonads; for example, both WT1 and LHX9 function as direct activators of Sf1 
[9].  Thus, even at the bipotential stage, maintenance of the gonads is an actively regulated process. 
 
2 
 
1.1.2:  Sex determination and establishment of the Sertoli cell lineage  
 
 Prior to the 20
th
 century it was commonly believed sex determination in mammals must rely upon 
environmental cues as was observed to be the case in many lower vertebrates [10].  It was not until the 
identification of the Y chromosome in the early 1900s that the concept of a chromosomal component to 
sex determination was born [11-12].  Over the next 50 years, it was confirmed that the sexual identity of 
the fetal gonads is defined according to presence or absence of the Y sex chromosome [13-14].  However, 
identification of the single gene on the Y chromosome responsible for testis determination did not occur 
until the early 1990s.  SRY (sex-determining region of the Y chromosome) was determined to be the sole 
gene on the Y chromosome necessary and sufficient to secure testis fate in the fetal gonads [15-16].  
Since the discovery of SRY it has been determined that XY individuals in nearly all mammalian species 
develop testes due to the presence of the SRY gene [17-18]. 
SRY is a male-specific high mobility group (HMG) box transcription factor regarded as the 
“master switch” to initiate testis determination and differentiation.  Although the SRY gene is critical for 
testis development in most mammals, many of the structural domains of SRY genes are not conserved 
among species.  For example, the only conserved domain between human SRY and mouse Sry is the HMG 
box [19].  In the mouse, Sry expression is first detected at E10.5, peaks by E11.5, and declines beyond the 
limit of detection by E12.5 [20]. Expression of Sry is limited to a subset of somatic cells that also express 
the transcription factors thought to be required for Sry upregulation – Sf1, Wt1, GATA binding protein 4 
(Gata4), friend of GATA2 (Fog2) and Sp1 transcription factor [17, 21-29].  Although the exact 
mechanism that stimulates SRY expression is not known, SF1 and a specific variant of WT1 (known as 
the +KTS form) can bind to and activate the human and mouse SRY promoters [22, 25, 30-31].  The 
transcription co-factor Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 
(CITED2) has recently been shown to work together with WT1 and SF1 to increase the level of Sry 
expression in the mouse [32]. 
The HMG box domain of SRY is shared by the transcription factor SRY-related HMG box gene 9 
(SOX9), which is the primary target of SRY action in testis determination [33-37].  In contrast to SRY, the 
structural domains of SOX9 have proven to be highly conserved among vertebrates [38-42].  The critical 
function of Sry and its downstream target Sox9 in murine sex determination has been established 
experimentally through both gain-of-function and loss-of-function experiments.  Transgenic expression of 
Sry or Sox9 in the gonadal primordia of XX mice results in complete female-to-male sex reversal, 
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confirming that Sry and Sox9 are upstream of all known aspects of testis morphogenesis [33-34, 36, 43-
44].  Likewise, duplication of SOX9 can lead to XX male sex-reversal in humans [45].  Confirming their 
essential actions during sex determination, loss of either SRY or SOX9 activity due to deletion or mutation 
results in XY male-to-female sex reversal in both mice and humans [35, 46-50].  The ability of SOX9 to 
fully substitute for SRY with regard to securing testis fate verifies that the upregulation of SOX9 is a 
critical function of SRY [51].  Recently, SRY has been confirmed to directly upregulate Sox9 expression  
in the mouse by working cooperatively with SF1 upon a Sox9 enhancer [37].  
Although SRY is necessary and sufficient to induce all aspects of testis differentiation, there are 
cases in which SRY is present and testes fail to form.  In general, abandonment of the testis pathway in 
the presence of SRY is indicative of a failure of SRY to properly upregulate SOX9 expression.  In normal 
mouse XY gonads, Sry expression is downregulated by E12.5 but Sox9 levels remain elevated.  One 
known regulator of SOX9 expression is fibroblast growth factor 9 (FGF9).  In Fgf9-null XY mice, Sry 
expression and subsequent upregulation of Sox9 occurred normally; however, Sox9 expression was not 
maintained following the downregulation of Sry [52-53].  This failure to maintain Sox9 expression led to 
abandonment of the testis pathway and thus ovaries developed despite normal Sry expression [52-53].  
Another signaling molecule shown to be important for proper Sox9 expression is wingless-type MMTV 
integration site family member 4 (WNT4).  Wnt4 is expressed in the early gonads of both sexes but 
becomes ovary-specific after the time of Sry expression [54]. Although generally regarded as an ovary-
specific factor, male mice carrying Wnt4-null alleles show temporary defects in testis development that 
occur downstream of Sry but upstream of Sox9 [55]. Studies of human cases with a loss-of-function 
mutation in chromobox homolog 2 (CBX2, the human homolog of mouse M33) place this gene upstream 
of SRY, as mutations result in male-to-female sex reversal with ovaries in SRY-positive humans and mice 
[56-57].  Male-to-female sex reversal with normal SRY expression has also been observed in triple 
knockout mice lacking insulin receptor (Ir), insulin receptor-related receptor (Irr), and insulin-like growth 
factor 1 receptor (Igf1r) [58].  Male mice possessing a mutant allele of the dosage-sensitive sex reversal, 
adrenal hypoplasia critical region on chromosome X, gene 1 (Dax1) gene also express Sry but fail to 
upregulate Sox9, leading to male-to-female sex reversal (59- 62].  Although mutations in the 
aforementioned genes result in deviation from the testis morphogenesis pathway, the relationships 
between SRY and these factors have yet to be fully understood.  Interestingly, there may also be a 
metabolic aspect to SOX9 maintenance as glucose starvation has been shown to negatively impact the 
maintenance of Sox9 expression in the mouse [63].  Regardless of the reason, it is clear that the failure to 
maintain SOX9 expression derails the testis morphogenesis pathway.  
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Expression of both SRY and SOX9 is restricted to somatic cell precursors that give rise to the 
epithelial Sertoli cell lineage of the testis. One known effect of SRY on SOX9 function is the transfer of 
SOX9 from the cytoplasm to the Sertoli cell nuclei [64]. It has been postulated this accumulation of 
SOX9 within the nucleus of Sertoli cell precursors may be all that is needed to trigger testis 
differentiation [39].  Studies conducted in chimeric XX-XY mice have provided tremendous insight into 
the dynamics of Sertoli cell fate determination in the developing gonad.  These chimeric studies have 
indicated Sertoli cells are the only testicular cell type with a bias for the XY genotype [65].  Chimeric 
studies have also revealed that if a threshold number of Sertoli cells are present they can recruit all other 
gonadal cells (XX or XY) to follow the testis fate [66-67].  Although all SRY-positive cells will become 
SOX9-positive, not all newly differentiated Sertoli cells will themselves express Sry [68-69].  It is 
therefore hypothesized that the minority population of Sry-expressing cells must recruit other somatic 
cells to turn on either Sry and/or Sox9 and therefore differentiate into Sertoli cells.  Prostaglandin D2 
(PGD2) has been considered as a possible paracrine factor produced by the Sry-expressing Sertoli cells 
that functions to recruit additional Sertoli cells [70-73].  PGD2 was able to induce phosphorylation and 
subsequent nuclear importation of SOX9 in somatic cells of female gonads, leading to partial female-to-
male sex reversal [71].  Sertoli cells also expand their initial population via proliferation.  In addition to 
its role in the maintenance of Sox9 expression, FGF9 has been shown to stimulate proliferation of the 
Sertoli cell pool.  In the absence of FGF9, a dramatic decrease in Sertoli cell proliferation results in male-
to-female sex reversal [52, 67].  FGF9 is thought to signal via the FGF receptor 2 (FGFR2), which is co-
localized with SOX9 in Sertoli cell nuclei [67].  These observations suggest FGF9 acts downstream of Sry 
to initiate testis development by inducing cell proliferation and localization of FGFR2 in the nucleus of 
Sertoli cell precursors [67]. 
Once the Sertoli cell population has reached a threshold level, the Sertoli cells are thought to 
produce all of the signaling factors necessary to drive subsequent steps in testis morphogenesis.  In fact, 
the major function of SOX9 in the newly-differentiated Sertoli cells is to upregulate the expression of a 
number of hormones and growth factors required for further testis development [74-76].  Thus, under 
normal circumstances the establishment of a threshold population of Sertoli cells is sufficient to ensure 
proper testicular morphogenesis.  Upon their differentiation, the Sertoli cells begin to produce growth 
factors and hormones thought to perform several critical and related functions:  elicit cell migration from 
the mesonephros, establish the testis-specific vasculature, trigger the differentiation of other testis-specific 
cell lineages, and promote organization of the testis cords, embryonic precursors to the seminiferous 
tubules.  Development of the testis cords depends upon the migration of cells from the adjacent 
mesonephros [77-79].  This process occurs exclusively in male gonads and while the donor tissue must be 
mesonephric, the genetic sex of the mesonephros is irrelevant [80].  Experiments in which a physical 
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barrier was placed between XY gonads and mesonephroi prevented formation of testis cords; similarly, 
testis cords fail to form properly in early-stage XY gonads when cultured without mesonephroi [77-78, 
81].  Induction of this mesonephric cell migration appears to be mediated via chemotactic signals from 
the Sertoli cells [77, 82]. Growth factors such as neurotropin 3 (NT3), platelet-derived growth factors 
(PDGFs), nerve growth factors (NGFs), and anti-Müllerian hormone (AMH, also known as Müllerian 
inhibiting substance or MIS), have all been implicated in the process of mesonephric cell migration. NT3 
is expressed in Sertoli cells and treatment with NT3 inhibitors has been found to block both mesonephric 
cell migration and testis cord formation in vitro [83]. PDGF ligands and receptors are also expressed in 
the embryonic testes at the time of testis cord formation. Inhibitors specific to PDGF receptors (PDGFRs) 
cause abnormal testis cord formation in the fetal rat [84]. Recombinant experiments performed using 
Pdgfr!-null gonads and wild-type mesonephroi demonstrated expression of Pdgfr! is required in the 
gonads for proper migration to occur [85]. The potential involvement of NGFs in mesonephric cell 
migration was first indicated by receptor inhibitor treatment in vitro, suggesting that NGF signaling is 
essential for testis cord formation. However, deletion of the NGF receptor resulted in only minor defects 
in testis cord and interstitial development [86].  AMH, another potential player in mesonephric cell 
migration, was named for its ability to promote regression of the Müllerian ducts, precursors to the female 
reproductive tract [87-88].  Sertoli cell-derived AMH can induce mesonephric cell migration, a critical 
event in early testis cord development, in vitro but it is unclear whether AMH serves a similar function in 
vivo [89].   
Identification of the migrating cell population has been a subject of tremendous speculation; 
initially, the migratory cells were thought to be precursors to the testis-specific smooth muscle cells 
known as peritubular myoid cells.  Recent studies have revealed the critical migrating cell population to 
be endothelial cells rather than peritubular myoid cells [90-91].  This migration of endothelial cells from 
the mesonephros is essential for the development of the testis-specific vasculature pattern.  At the 
bipotential stage of gonadal development, there are no obvious differences between XX and XY gonads 
with regard to vasculature patterning [92-93].  Differentiation of the fetal Sertoli cells leads to the 
migration of extra endothelial cells into the developing testis, resulting in the formation of a testis-specific 
arterial network known as the coelomic vessel.  This patterning of vasculature occurs during the same 
time as testis cord organization, between E11.5 and E12.5.  This coincidence has led to the hypothesis 
that endothelial cells may play an instructive role in testis cord development [94].  In support of this 
hypothesis, Pdgfr!–/– embryonic mouse testes display altered testis cord formation coincident with 
disruptions in endothelial migration and coelomic vessel development [94]. In addition to its role in 
endothelial cell migration and subsequent testis cord organization, Pdgfr! is required for normal 
differentiation of the steroidogenic cells of the developing testis, the fetal Leydig cells [85]. 
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1.1.3:  Determination of other testicular cell lineages  
 The fetal Leydig cells arise within the interstitial compartment around E12.5 in the 
mouse, after the time of Sertoli cell differentiation [95].  The fetal Leydig cells are the steroidogenic cell 
population of the embryonic testis and produce androgens critical for maintenance of the Wolffian duct, 
embryonic precursor of the male reproductive tract [87].  Fetal Leydig cell-derived androgens and insulin-
like growth factor 3 (INSL3) are also essential for testicular descent during embryogenesis. [96-98].  Fetal 
Leydig cells are thought to share a common primordial origin with the steroidogenic cells of the adrenal 
cortex, as both hormone-producing cell types express SF1 at early stages of differentiation and throughout 
steroidogenesis [99-101].  The precise origin of the fetal Leydig cells remains a mystery, although 
proposed sources have included migrating neural crest cells, migrating mesonephric cells, coelomic 
epithelial cells, or resident somatic cell precursors of the gonad [102]. Evidence for a potential neural 
crest origin is limited, with only the fact fetal Leydig cells express a number of neural markers to support 
this claim [103-106].  In fact, analysis of neural crest-specific reporter transgenic mouse lines by Brennan 
et al. (2003) revealed no significant contribution of neural crest cells to the fetal Leydig cell population 
[85].  These findings, coupled with the fact it is not uncommon for cells of non-neural crest origin to 
express ‘neural’ markers, suggests fetal Leydig cells are unlikely to arise from neural crest cells.  
Although coelomic epithelial cells are known to contribute to both the Sertoli cell and general interstitial 
cell populations, that interstitial cell contribution does not appear to include a significant number of fetal 
Leydig cells [3, 85].  Migratory cells from the mesonephros have been reported to have the potential to 
differentiate into fetal Leydig cells, suggesting the mesonephros could be the source of fetal Leydig cell 
precursors [79, 104, 107].  However, experimental manipulation has revealed that a normal fetal Leydig 
cell population can develop even if the developing gonad is mechanically separated from the 
mesonephros at E11.5, prior to mesonephric migration [78].  These experiments do not entirely preclude 
the mesonephros as the source of fetal Leydig cell progenitors; however, if the fetal Leydig cells do 
originate from mesonephric cells the migration of said mesonephric cells must occur prior to E11.5.  On 
the other hand, the appearance of fetal Leydig cells in the absence of migrating mesonephric cells 
supports the hypothesis that fetal Leydig cells may arise from unspecified somatic cells already present 
within the testis.  
True to their reputation as the “master organizers” of the embryonic testes, Sertoli cells directly 
specify the fetal Leydig cell lineage via desert hedgehog (DHH) protein.  DHH from the Sertoli cells 
signals to its receptor patched 1 (PTCH1) on fetal Leydig cell precursors in the testis interstitium [108-
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112].  This DHH signaling also induce the expression of genes encoding steroidogenic enzymes within 
the newly-differentiated fetal Leydig cells [111].  Similarly, insulin-like growth factor 1 (IGF1) has been 
shown to stimulate fetal Leydig cell differentiation and function [113-116].  Expression of Pdgfr! by the 
fetal Leydig cell precursors is additionally required for normal fetal Leydig cell differentiation, indicating 
a critical role for PDGF signaling in this process [85].  IGF1 and PDGF signaling have also been 
implicated in the proliferative expansion of the fetal Leydig cell precursor population [85, 113-116].  The 
X-linked aristaless-related homeobox gene (Arx) is another factor shown to be required for normal fetal 
Leydig cell development, although its precise role is not well understood [117].  Expression of Arx is 
restricted to peritubular myoid cells, endothelial cells and interstitial fibroblasts, suggesting these cells 
may also be involved in fetal Leydig cell differentiation [117]. 
 The peritubular myoid cells are testis-specific smooth muscle cells with important functions 
throughout fetal and adult life.  The ability of the adult seminiferous tubules to undergo contractions was 
first reported in the 1950s, and it was later determined that peritubular myoid cells were responsible for 
this action [118-119].  In rodents and humans, peritubular myoid cells contain abundant "-smooth muscle 
actin filaments as well as a number of other cytoskeletal proteins including myosin filaments, 
intermediate filaments, and desmin [120-123].  In adulthood, the contractile ability of the peritubular 
myoid cells is thought to promote the release of sperm into the seminiferous tubule lumen as well as 
regulate the movement of sperm and testicular fluid [123-124].  During fetal development, the peritubular 
myoid cells work in concert with the Sertoli cells to deposit the basal lamina that serves as a barrier 
between the newly-formed epithelial and mesenchymal compartments of the testis [125].   
 Since the appearance of the peritubular myoid cell population in the embryonic testis 
coincides with mesonephric cell migration, it has been hypothesized that the peritubular myoid cells are 
the migrating cell population critical for testis cord formation.  It is now known that endothelial cells are 
in fact the essential migrating cell population [90-91].  It is therefore likely that peritubular myoid cells 
are induced within the testis from mesenchymal precursors.  However, whether the differentiation of 
peritubular myoid cells relies upon signals from the Sertoli cells or requires some other signaling inputs 
remains to be determined. Transgenic mouse models displaying improper peritubular myoid cell 
differentiation and/or function provide some insight into the process of peritubular myoid cell 
development.  Dhh has been shown to be important for peritubular myoid cell differentiation and 
function; specifically, disruption of Dhh in mice leads to the focal absence of the basal lamina resulting in 
anastomotic testis cords/seminiferous tubules [126].  This disruption in basal lamina formation is first 
observed at E13.5 and becomes progressively more severe [109].  The testis cord malformations in Dhh-
null mice are thought to result from improper development of the peritubular myoid cell population, 
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resulting in the laydown of a weak basal lamina, rather than from defects in Sertoli cell function [109, 
126].  In Dax1-deficient male mice, the early stages of testis development also occur normally but by 
E13.5 the testis cords appear disorganized and are incompletely formed [61].  The number of Sertoli cells 
is not altered in Dax1-deficient mice but there is a defect in peritubular myoid cell proliferation.  The 
resulting reduced population of peritubular myoid cells proceed to encircle the developing testis cords and 
work together with the Sertoli cells to deposit the basal lamina; however, the basal lamina produced in the 
absence of Dax1 is discontinuous, leading to open and incompletely-formed testis cords [61].  Dax1 
therefore appears to be an important regulator of peritubular myoid cell proliferation.  DAX1 has also 
been shown to work together with SF1 to induce Dhh expression in the Sertoli cells, suggesting that the 
testis cord dysgenesis in Dax1-deficient mice could be at least partially the result of disrupted Dhh 
expression [127].  
 
 
1.2:  TESTIS CORD MORPHOGENESIS 
1.2.1:  Formation of the tubular testis cords 
Once the Sertoli cell lineage has been established, it rapidly organizes the fetal testis into tubular 
“cords” consisting of an epithelial layer (the Sertoli cells) and a mesenchyme commonly referred to as the 
testis interstitium.  The testis cords, embryonic precursors to the seminiferous tubules, originate between 
E11.5 and E12.5 as a series of side-by-side transverse circular loops separated from one another by 
interstitial cells [128-130].  The precise cellular mechanisms involved in this complicated process are 
largely unknown.  The propensity to organize into cordlike structures appear to be an intrinsic property of 
the Sertoli cells, since Sertoli cells cultured in vitro in extracellular matrix-containing gels are able to self-
assemble into cordlike structures [131].  However, formation of the testis cords in vivo is critically 
dependent upon cell migration from the mesonephros and proper establishment of the testis vasculature 
[77-78, 80, 90-91, 132-134].  In the absence of this mesonephric cellular contribution, Sertoli cells are 
present but the organizational cues required for testis cord formation appear to be lost [78].  Initial 
establishment of the testis cords involves cooperation between the Sertoli cells and the peritubular myoid 
cells.  These two testis-specific cell types work together to deposit the basal lamina that serves as a 
structural barrier between the testis cords and the interstitium [125].  Not surprisingly, the disruption of 
genes involved in peritubular myoid cell differentiation, such as the Sertoli cell product DHH, results in 
aberrant testis cord formation [126].  Interestingly, although testis cord formation serves to sequester the 
germ cells within the lumen of the cords, the presence of germ cells is not required for normal cord 
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organization [135].  The ability of testis cords to form in agametic gonads also indicates germ cells do not 
serve as nucleation points for Sertoli cells to aggregate during testis cord morphogenesis.  However, 
signals from the somatic cells must somehow direct germ cell development, as XY germ cells undergo 
mitotic arrest by E13.5 [70].  The precise reason for this mitotic arrest is unclear but cellular aggregation 
studies have revealed that the presence of meiotic XX germ cells, obtained from embryonic ovaries, can 
block testis cord formation when aggregated with XY somatic cells [136].  These experiments suggest 
that XX germ cells committed to the ovarian pathway are capable of somehow antagonizing the testicular 
pathway. 
 
1.2.2:  Testis cord expansion 
The murine fetal testes undergo a rapid increase in size following the organization of the testis 
cords at E12.5; however, the testis cords retain their original simple transverse loop structure until E15.5. 
Between E15.5 and birth (E19.5), the testis cords undergo extensive elongation and convolution, the end 
result of which is the highly-coiled appearance of the seminiferous epithelium in newborn and adult 
testes.  This dramatic phenotypic change coincides with, and is presumably driven by, the rapid 
proliferation of the Sertoli cells [137-138].  Convolution and elongation of the fetal testis cords have been 
proposed to occur due to some intrinsic property of the Sertoli cells, since thus far no signaling pathway 
has been shown to be specifically required for this process.  Although pituitary-derived gonadotropins are 
required for normal Sertoli cell proliferation in postnatal life, fetal development of Sertoli cells in the 
mouse occurs independently of gonadotropins [137, 139-140].  For example, testis volume in the 
hypogonadal (hpg) mouse model, which lacks GnRH and thus endogenous circulating gonadotropins, did 
not differ from that of control mice during fetal life [140-141].  The observation of similar fetal testis size 
between control and hpg mice provides indirect evidence that Sertoli cell proliferation and number were 
grossly normal in the absence of gonadotropins.  Thus, factors produced within the testes themselves are 
likely the key regulators of fetal Sertoli cell proliferation.  
The requirement of mesenchymal factors for epithelial proliferation is a conserved mechanism for 
tube elongation during the development of many tubular organs [142]. During the formation of tubular 
structures it is typically the mesenchymal compartment that provides the instructive cues that promote 
differentiation of the tubular epithelium [142-143].  Mesenchymal contribution to epithelial 
differentiation has been elegantly demonstrated in vitro by tissue recombination experiments.  By 
culturing mesenchyme of a specific origin in physical contact with epithelium of a second, different origin 
it was found that the mesenchyme could instruct epithelial fate.  For example, branching morphogenesis 
was induced in salivary gland epithelium, normally a non-branching tissue, when cultured as a tissue 
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recombinant with lung mesenchyme [144].  Similar tissue recombination experiments have established 
the instructive nature of the ureteric bud mesenchyme in determining the epithelial fate of the kidneys and 
lower urinary tract [145-147].  Although mesenchymal factors promote epithelial development in many 
tubular tissues, all factors identified thus far as being critical for testis cord development come from the 
epithelial Sertoli cells.  In this dissertation, I describe my work investigating activin A as a candidate 
mesenchyme-derived signal essential for proper testis cord development.  
 
 
1.3:  THE ACTIVIN A SIGNALING PATHWAY 
1.3.1:  Introduction to activin A 
Activins are dimeric signaling peptides that share common protein subunits with inhibins [148].  
Specifically, activins consist of either homodimers or heterodimers of inhibin ! subunits whereas inhibins 
arise through the dimerization of an inhibin " subunit with an inhibin ! subunit.  Activins are members of 
the transforming growth factor ! (TGF-!) superfamily and are known to signal canonically via the Smad 
pathway; in contrast, inhibins are not known to have an active signaling function but instead antagonize 
activin signaling [149-150].  During adult life, activins and inhibins play critical roles in the 
hypothalamic-pituitary axis; specifically, activins stimulate follicle-stimulating hormone (FSH) release 
from the pituitary whereas inhibins selectively suppress FSH secretion in both males and females [151-
152]. In the adult male rodent, pituitary gonadotrophs serve as a local source of activins to promote FSH 
secretion, whereas testicular Sertoli cells produce inhibin that suppresses FSH production [153-154].  
Activins produced within the adult testes are also known to have local signaling functions, such as 
enhancing the postnatal FSH-mediated stimulation of Sertoli cell proliferation, although many of these 
actions are not fully understood [155-156].  Similarly, the functions of activins and inhibins during 
embryonic development of the male gonads are not well characterized.  In the mouse, both inhibin !A 
(Inhba) and inhibin !B (Inhbb), genes that encode subunits for activins and inhibins, are expressed within 
fetal testes but not in the developing ovaries [157-158].  In both human and mouse embryonic testes, 
Inhba mRNA is localized to the testis interstitium whereas inhibin "B (Inhbb) mRNA is produced by the 
Sertoli cells located within the testis cords [157-162].  Since activin protein dimers are assembled 
intracellularly, activin A is the only possible activin protein produced by the fetal testis interstitium and 
activin B is the only possible activin product of the Sertoli cells [163-164].  Previous research conducted 
in the mouse has demonstrated the involvement of Sertoli cell expression of Inhbb/activin B in formation 
of the testis-specific coelomic vessel early in testis morphogenesis [157].  Although the function of 
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Inhba/activin A in embryonic testes is not known, the onset of Inhba expression around E12.5 suggests 
that activin A may be involved in some aspect of testis cord development [158, 160].   Interestingly, 
although activin A is best-known as a protein hormone in the adult animal, activin A also serves as a 
localized growth factor during organogenesis.  In numerous tissue contexts, activin A has established 
roles in the mesenchymal-epithelial interactions that drive tubulogenesis [165].  
 
1.3.2:  Activin A is a conserved regulator of tubulogenesis 
Activin A has been implicated in the epithelial-mesenchymal interactions required for the 
formation of tubular structures in many embryonic tissues, including the kidneys, pancreas, lungs, 
salivary glands, prostate, dentition, and Wolffian ducts [158, 166-169].  During kidney, salivary gland, 
pancreas, and prostate development, the main function of activin A is to prevent branching of the primary 
tubular structure [166, 168]. In murine embryonic lungs, activin A has been localized to the epithelial 
bronchiole tubes [170]. A potential role for activin A in the prevention of epithelial branching in fetal 
mouse lungs is supported by data indicating that inhibition of SMAD 2/3, downstream targets of activin 
A, results in branching morphogenesis [171]. However, organ culture experiments using embryonic rat 
lung explants indicate that in this tissue context it is TGF!2 and not activin A which signals via 
SMAD2/3 to prevent ectopic branching of the lung epithelium [172]. It remains to be determined whether 
epithelial expression of activin A prohibits bronchiole branching during embryonic development in the 
mouse [165]. During tooth development, the mesenchyme produces activin A that is required for 
epithelial cell proliferation and subsequent development of the incisors and mandibular molars beyond the 
tooth bud stage [167, 173]. Interestingly, whether activin A is localized to the epithelium or the 
mesenchyme depends upon the specific tissue context and in some tissues, such as the pancreas, activin is 
expressed by both compartments [165-166].  Given the essential roles for activin A in tubulogenesis, it 
appears likely that interstitial activin A could influence testis cord development in the embryonic testes. 
 
1.3.3:  Activin A and estrogens 
 In addition to its actions as a local signaling factor in tubular embryonic organs, activin A is also 
known to interact with estrogen signaling in several tissues.  In cultured murine gonadotropes, activin A 
has been shown to stimulate the activity of 17!-hydroxysteroid dehydrogenase type I (HSD17b1), the 
enzyme that converts estrone to 17!-estradiol [174].  Activin A is also able to induce both estrogen 
receptor " (ER", formally known as Esr1) and ER! (Esr2) mRNA and protein in murine granulosa cells 
cultured in vitro [175].  Under these experimental conditions, activin A stimulated estradiol-induced 
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estrogen response element promoter activity, consistent with increased levels of ER" and ER!.  This 
activin A-induced increase in ER expression was demonstrated to be a direct effect at the level of gene 
transcription [175].  These studies confirm activin A can modulate estrogen signaling at the levels of 
estradiol production and estrogen receptor expression.  Interestingly, estrogen signaling has been shown 
to influence activin A signaling as well.  Estrogen treatment was found to increase activin A mRNA and 
protein expression in the endometrium of ovariectomized rats, indicating a link between these two 
pathways [176].  In contrast, early postnatal exposure of female mouse pups to estrogens decreased 
activin A mRNA and protein levels in the ovaries and sera at postnatal day 19 [177].  Although the 
precise interaction between activin A and estrogen signaling appears to depend upon the specific tissue 
context, the relationship between these two pathways certainly warrants further research.  In embryonic 
mouse testes, both ER" and ER! are expressed; ER" is localized to the Leydig cells whereas ER! is 
found in the Leydig, Sertoli, and germ cells [178].  Estrogenic compounds have long been known to result 
in abnormal fetal testis development in humans and animal models but the specific mechanisms involved 
are not fully understood [179-183].  Since activin A is expressed in both human and mouse fetal testes, it 
is possible that alteration of activin A signaling is one causal mechanism behind estrogen-induced 
testicular dysgenesis. 
 
1.4:  Summary 
In humans as well as animals, fetal disruption of testis development has been demonstrated to 
result in testicular dysfunction in adulthood [184-191].  These dysfunctions can range from infertility and 
poor semen quality to testicular cancers [192]. Although many endocrine disruptors could potentially 
disrupt fetal testis morphogenesis, estrogenic toxicants are of particular concern.  It has been known for 
decades that in utero exposure of both rodents and humans to estrogenic compounds such as DES can 
lead to various testicular abnormalities but only recently have we begun to understand many of the 
cellular and molecular processes involved [179-183, 192-200].  The fetal testis dysgenesis phenotypes 
observed in rodents exposed to estrogenic toxicants can vary depending upon the type of estrogen used, 
suggesting that multiple mechanisms could mediate estrogenic effects in the developing testes.  To be 
able to prevent and/or treat testicular dysgenesis, we need to first understand the cellular and molecular 
pathways involved in normal development of the embryonic testes.  The activin A pathway is a promising 
candidate for involvement in testis cord morphogenesis due to its male-specific expression pattern after 
the time of testis cord organization.  Activin A is additionally an attractive signaling factor to study with 
regard to the relationship between estrogenic endocrine disrupters and testicular dysgenesis, since activin 
A expression can be altered by exposure to estrogenic compounds in other tissue contexts.  Thus, my 
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overall hypothesis is that activin A is a critical factor for normal fetal testis development.  The first 
specific objective of my doctoral studies is to determine the role of the activin A signaling pathway 
during fetal testis morphogenesis using the mouse as a model.  My second specific objective is to 
investigate whether disruption of the activin A signaling pathway during embryonic development leads to 
testicular dysfunction in adulthood.  My third and final specific objective is to explore whether in utero 
exposure to estrogenic endocrine disruptors alters the testicular activin A signaling pathway.  I anticipate 
my research will provide valuable insight regarding the role of activin A during fetal testis development, 
as well as the role of this signaling pathway within the context of testicular dysgenesis. 
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CHAPTER 2:  THE ACTIVIN A SIGNALING PATHWAY CONTROLS FETAL TESTIS CORD 
EXPANSION IN THE MOUSE 
 
 
2.1:  ABSTRACT 
 Proper development of the fetal testis cords is presumed critical for normal testicular function and 
sperm production in mammals.  During organogenesis, formation of tubular structures results from 
complex interactions between adjacent epithelium and mesenchyme.  In mammalian fetal testes, dramatic 
reorganization leads to compartmentalization of tubular epithelial testis cords and the surrounding 
interstitium.  I became specifically interested in the potential functions of the activin A signaling pathway 
during fetal testis development due to its regulation of tubulogenesis in other organs.  In addition, the 
interstitial expression pattern of inhibin !A (Inhba, also known as activin !A), the gene encoding activin 
A, provided the intriguing possibility that an interstitial factor might regulate some aspect of testis cord 
morphogenesis.  To uncover the functions of activin A in testis morphogenesis, I analyzed the testes of 
mouse embryos lacking global expression of Inhba (Inhba
-/-
).  I also developed two conditional knockout 
(cKO) mouse models in which Inhba expression was deleted in either the steroidogenic factor 1- (Sf1-) 
positive somatic cell population (Inhba SF1-cre cKO) or specifically within the interstitial fetal Leydig 
cells (Inhba fetal Leydig cell cKO, also referred to as Inhba FLC cKO).  My analysis of these transgenic 
mouse models revealed fetal Leydig cell-derived activin A promotes the Sertoli cell proliferation required 
for elongation and coiling of the epithelial testis cords during late gestation.  To determine whether 
activin A signals directly to the Sertoli cell epithelium, I produced cKO mice lacking expression of 
Smad4, the central downstream regulator of canonical transforming growth factor ! (TGF!) superfamily 
signaling, within the Sertoli cells (Smad4 Sertoli cKO).  The similarities I observed between my mouse 
models lacking interstitial expression of Inhba and the Smad4 Sertoli cKO model suggested activin A is 
likely to act directly upon the Sertoli cells to promote their proliferation.  My findings not only provide 
insight into the mechanisms driving fetal testis cord expansion, but also uncover a novel mesenchymal-
epithelial crosstalk in the developing testes.  Most intriguingly, this mesenchymal activin A signal comes 
from the fetal Leydig cells, a population not previously known to influence testis cord morphogenesis. 
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2.2:  INTRODUCTION 
While numerous instances of epithelium-to-mesenchyme signaling have been discovered during 
formation of the tubular testis cords, very little is known about mesenchyme-derived factors that might act 
upon the Sertoli cell epithelium.  In many organs, development and maintenance of tubular structures 
requires crosstalk between adjacent epithelial and mesenchymal compartments [142-143].  Tissue 
recombination experiments, in which epithelium from one organ is placed in physical contact with 
mesenchyme from a different organ, have elegantly demonstrated the instructive abilities of mesenchyme 
upon epithelium [144-147].  For example, in vitro culture of salivary gland epithelium in contact with 
mesenchyme from the lung is sufficient to induce branching morphogenesis in this normally non-
branching salivary epithelium [144].  The instructive nature of the ureteric bud mesenchyme in 
determining epithelial fate during kidney and urinary tract formation has been similarly demonstrated via 
tissue recombination experiments [145-147].  Although mesenchymal signals are critical for directing 
epithelial proliferation and patterning during tubulogenesis, factors from the mesenchyme often continue 
to influence epithelial development and function even after initial tubule formation.  One such factor with 
conserved roles in epithelial proliferation and patterning is activin A, a member of the TGF! superfamily 
of signaling proteins.  Loss-of-function experiments in a multitude of organs, including the kidney, 
dentition, pancreas, salivary glands, and prostate, have demonstrated that inhibition of activin A signaling 
results in ectopic branching of the epithelial compartment [165-166, 168].  Although activin A is 
frequently involved in the epithelial-mesenchymal communications necessary for the proper development 
of tubular organs, whether activin A is produced by the epithelium or the mesenchyme depends upon the 
particular tissue context.  For example, activin A is expressed by the mesenchyme in the dentition and 
Wolffian ducts (precursors to the epididymides) whereas it is expressed by both the epithelium and 
mesenchyme of the developing pancreas [158, 166-167, 173].  Interestingly, mRNA for Inhba, the gene 
encoding activin A, also localizes to the mesenchymal compartment in murine fetal testes [157, 162].  
Given the importance of activin A during tubulogenesis in other organs, I hypothesized that interstitial 
activin A is a novel regulator of fetal testis cord development in the mouse.  I therefore sought to uncover 
the role of this activin A signaling pathway during testis morphogenesis. 
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2.3:  MATERIALS AND METHODS 
2.3.1:  Generation of global and conditional knockout mice 
Inhba
-/-
 global knockout mice: 
Inhba
+/-
 mice (kindly provided by Dr. Martin Matzuk, Baylor College of Medicine) were 
intercrossed to produce Inhba
+/+
, Inhba
+/-
, and Inhba
-/-
 embryos [201]. 
Conditional knockout mice:  
All conditional knockout (cKO) mice produced for this study were generated using the standard 
Cre/loxP recombination system [202-203].  To produce Amhr2
cre/+
;Inhba
fl/-
 (Inhba fetal Leydig cell cKO 
or Inhba FLC cKO) mice, Amhr2
cre/+
 transgenic mice (generously provided by Dr. Richard Behringer, 
M.D. Anderson Cancer Center) were first crossed to Inhba
+/-
 mice [204].  The resulting 
Amhr2
cre/+
;Inhba
+/-
 males were then mated to Inhba
fl/fl
 females (obtained from Dr. Martin Matzuk, Baylor 
College of Medicine) [205]. Sf1
cre/+
;Inhba
fl/-
 (Inhba SF1-cre) cKO mice were produced via the same 
breeding scheme [206]. 
In order to obtain Amh
cre/+
;Smad4
fl/-
 (Smad4 Sertoli) and Amhr2
cre/+
;Smad4
fl/-
 (Smad4 FLC) cKO 
mice, I needed to first derive the Smad4
+/-
 mouse strain.  Smad4
+/-
 mice were generated by crossing male 
Smad4
fl/fl
 mice (kindly provided by Dr. Chuxia Deng, NIDDK) to female EIIa
cre/cre
 mice that carry a 
systemically expressed cre recombinase transgene [207-208].  Resulting EIIa
cre/+
;Smad4
+/-
 mice were 
backcrossed to C57BL/6J (Jackson Laboratories, Bar Harbor, ME) to remove the cre allele.  To generate 
Amh
cre/+
;Smad4
fl/-
 or Amhr2
cre/+
;Smad4
fl/-
 cKO mice, Smad4
+/-
 mice were first mated to Amh
cre/+
 or 
Amhr2
cre/+
 transgenic mice [204, 209]. The resulting Amh
cre/+
;Smad4
+/-
 and Amhr2
cre/+
;Smad4
+/-
 mice 
were then crossed to Smad4
fl/fl
 animals [208]. Amh
cre/+
 mice were generously provided by Dr. Florian 
Guillou at the Université de Tours-Haras Nationaux, France. 
Genotyping: 
 For breeding stock, tail or ear tissue samples were collected from 10-12 day old pups.  For 
dissected embryos, tail tissue was collected.  In both instances, tissues were digested in 400#L of 50 mM 
sodium hydroxide at 95ºC until completely dissolved (typically 30-60 minutes).  Following digestion, 200 
#L of 1M Tris-HCl (pH 8.0) was added to each sample.  Samples were centrifuged for 5 minutes at 
12,000 rpm at room temperature and resulting genomic DNA stored at -20º C.  For all mouse strains, 
genotyping was accomplished via standard PCR using a 25 #L reaction volume. MangoMix (Bioline, 
Taunton, MA), a pre-made reaction mix containing Taq polymerase, dNTPs, reference dyes, and MgCl2, 
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was used to carry out PCR.  The volume of PCR reagents per individual reaction were determined as 
follows, depending upon the number of primers required: 
Number of 
primers 
Volume of MangoMix 
reaction mix 
Volume of primers   
(20 !M concentration) 
Volume of 
autoclaved ddH20 
Volume of 
genomic DNA 
2 primers 12.5 #L 0.625 #L each         
(1.25 #L total) 
10.25 #L 1 #L 
3 primers 12.5 #L 0.633 #L each           
(1.9 #L total) 
9.6 #L 1 #L 
 
For the mouse strains described in this chapter and elsewhere, the following primer sequences 
and protocols were used for genotyping: 
Allele/s Primer sequences Band size/s Protocol 
Inhba floxed or 
wild-type (WT) 
AcBa exon3 forward:  5’ACA GAA 
CCA GGA CCA AAG TCA CCA-3’ 
AcBa exon3 reverse:  5’-TCC AGT 
CAT TCC AGC CAA TGT CCT-3’ 
516 bp       
(WT and 
floxed allele) 
1. 94ºC – 3 minutes                          
2. 94ºC – 30 seconds                        
3. 58ºC – 30 seconds                        
4. 72ºC – 30 seconds              
(Repeat 2-4 for 36 total cycles)                                        
5. 72ºC – 7 minutes                          
6. 25ºC – 2 minutes                          
7. Keep at 10ºC 
Inhba null HPRTa:  5’GGA CCT CTC GAA 
GTG TTG GAT AC-3’ 
HPRTb:  5’-CTT GCG CTC ATC 
TTA GGC TT-3’ 
170 bp      
(Null allele) 
1. 94ºC – 3 minutes                         
2. 94ºC – 30 seconds                       
3. 50ºC – 30 seconds                       
4. 72ºC – 30 seconds             
(Repeat 2-4 for 36 total cycles)                                 
5. 72ºC – 7 minutes                        
6. 25ºC – 2 minutes                        
7. Keep at 10ºC 
Smad4 floxed, 
null, or wild-
type  
Smad4b:  5’-GGG CAG CGT AGC 
ATA TAA GA-3’ 
Smad4d:  5’-AAG AGC CAC AGG 
GTC AAG CAG ATT-3’ 
Smad4e:  5’-GAC CCA AAC GTC 
ACC TTC ACT TT-3’ 
390 bp       
(WT allele) 
450 bp   
(Floxed allele) 
500 bp      
(Null allele) 
1. 94ºC – 3 minutes                        
2. 94ºC – 45 seconds                       
3. 55ºC – 1 minute                         
4. 72ºC – 1.5 minutes             
(Repeat 2-4 for 35 total cycles)                                 
5. 72ºC – 1 minute                         
6. Keep at 10ºC 
Cre          
(Amh-cre, 
Amhr2-cre, 
Sf1-cre) 
328:  5’-GAG TGA ACG AAC CTG 
GTC GAA ATC AGT GCG-3’ 
329:  5’- GCA TTA CCG GTC GAT 
GCA ACG AGT GAT GAG-3’ 
408 bp       
(Cre positive) 
 
no band      
(Cre negative) 
1. 94ºC – 2 minutes                        
2. 94ºC – 45 seconds                       
3. 60ºC – 45 seconds                       
4. 72ºC – 1 minute                
(Repeat 2-4 for 40 total cycles)                                 
5. 72ºC – 2 minutes                     
6. Keep at 10ºC 
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Mating and fetal tissue collection: 
Timed matings were produced by housing female mice with males overnight and checking for 
vaginal plugs the next morning (E0.5 = noon of the day when a vaginal plug was found). Fetal tissue was 
collected from E12.5-E19.5. For fetal analysis, no differences were observed between Inhba
+/-
, 
Sfl
cre/+
;Inhba
+/fl
, Amhr2
cre/+
;Inhba
+/fl
, Amh
cre/+
;Smad4
+/fl
, and Amhr2
cre/+
;Smad4
+/fl
 control genotypes; 
therefore, data from Inhba
+/-
 embryos is presented.  For experiments requiring wild-type tissue (such as 
evaluation of endogenous expression patterns), embryos were obtained by intercrossing outbred CD-1 
mice (Charles River Laboratories, Wilmington, MA) All procedures described were reviewed and 
approved by the Institutional Animal Care and Use Committee, and were performed in accordance with 
the Guiding Principles for the Care and Use of Laboratory Animals. 
 
2.3.2:  Immunohistochemistry of murine testes 
 Testes were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4) for either 1-
2 hours at room temperature or overnight at 4°C.  After fixation, testes were washed three times for 15 
minutes each in PBS with shaking and stored in PBS at 4ºC.  For cryosectioning, samples were 
dehydrated through a PBS/sucrose gradient and embedded in a 3:1 mixture of Tissue-Tek O.C.T. 
embedding compound (Sakura Finetek USA, Torrance, CA) and 20% sucrose solution.  Frozen sections 
were cut  to 10 #m thick and placed onto Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA).  
Slides were stored at -20ºC. 
 For laminin immunohistochemistry, slides were allowed to dry for 15 minutes at room temperature.  
Sections were circled with an ImmEdge hydrophobic barrier pen (Vector Laboratories, Burlingame, CA) 
and rinsed with PBS to remove excess O.C.T. compound.  Sections were blocked for 1 hour at room 
temperature in PBS containing 5% heat-inactivated normal donkey serum (Jackson ImmunoResearch, 
West Grove, PA) and 0.1% Triton X-100 (Fisher Scientific, Pittsburgh, PA).  After blocking, sections 
were incubated with primary antibody specific to laminin (Sigma, St. Louis, MO) diluted 1:200 in 
blocking solution for 1-2 hours at room temperature.  Sections were washed three times for 10 minutes 
each in PBS containing 1% heat-inactivated normal donkey serum and 0.1% Triton X-100.  Slides were 
then incubated with FITC-conjugated donkey anti-rabbit secondary antibody (Jackson Immunologicals, 
West Grove, PA) diluted 1:500 in blocking solution for 30 minutes to 1 hour at room temperature.  
Sections were washed again and slides were then mounted with Vectashield mounting medium containing 
DAPI nuclear dye (Vector Laboratories, Burlingame, CA).  Slides were stored at 4ºC.   
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 INHBA immunohistochemistry was performed on testis sections following the manufacturer’s 
instructions included with the TSA Fluorescein System Kit (Perkin Elmer, Waltham, MA).  Slides 
containing frozen tissue sections were dried for 15 minutes at room temperature and sections were circled 
with an ImmEdge hydrophobic barrier pen.  Sections were then blocked in TNB blocking buffer solution 
(0.1M Tris-HCl (pH 7.5), 0.15M NaCl, and 0.5% blocking reagent supplied in Perkin Elmer TSA 
Fluorescein System Kit, Waltham, MA) for 30 minutes at room temperature.  After blocking, sections 
were incubated for 1 hour at room temperature in INHBA primary antibody (a gift from Dr. Wylie Vale, 
Salk Institute, La Jolla, CA) diluted 1:1500 in TNB blocking buffer.  Slides were then washed three times 
for five minutes each in TNT wash buffer (0.1M Tris-HCl (pH 7.5), 0.15M NaCl, 0.05% Tween 20 
(Fisher Scientific, Pittsburgh, PA)).  Next, sections were incubated with biotinylated donkey anti-rabbit 
secondary antibody (Jackson Immunologicals, West Grove, PA) diluted 1:500 in TNB blocking buffer for 
30 minutes at room temperature.  Slides were washed again, then incubated in streptavidin-HRP 
(provided in the Perkin Elmer TSA Fluorescein System Kit) diluted 1:100 in TNB blocking buffer for 30 
minutes at room temperature.  Sections were washed, then incubated for 3 minutes at room temperature in 
tyramide diluted 1:50 in amplification diluent (reagents provided in Perkin Elmer TSA Fluorescein 
System Kit).  Sections underwent a final washing and were mounted with Vectashield mounting medium 
(Vector Laboratories, Burlingame, CA).  Slides were stored at 4ºC. 
 
2.3.3.  Histology of murine testes 
 Newborn testes were fixed for 1-2 hours at room temperature in Bouins fixative (Sigma, St. Louis, 
MO).  After fixation, testes were washed three times for 15 minutes each in 70% ethanol with shaking.  
Samples were then stored in 70% ethanol at room temperature.  For histological processing, testes were 
dehydrated through an ethanol gradient followed by immersion in Histo-Clear  (National Diagnostics, 
Atlanta, GA).  Testes were then embedded in paraffin wax and sectioned at 5 µm thick.  Sections were 
stained for 3 minutes with Richard-Allan hematoxylin (Thermo Fisher Scientific, Waltham, MA) and 30 
seconds with Surgipath eosin (Surgipath Medical Industries, Richmond, IL).  Slides were mounted with 
Permount mounting medium (Fisher Scientific, Pittsburgh, PA) diluted 50% with xylene. 
 
2.3.4:  Analysis of murine Sertoli cell proliferation  
 Ki67 (Abcam, Cambridge, MA) immunohistochemistry was performed on sections of E19.5 
testes following the manufacturer’s instructions included with the TSA Fluorescein System Kit (Perkin 
Elmer, Waltham, MA).  Slides were processed as described in Chapter 2.3.2 with slight modifications.  
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After sections were circled with an ImmEdge hydrophobic barrier pen, endogenous peroxidases were 
quenched by application of 0.6% H2O2 in ddH2O for 30 minutes at room temperature.  Sections were then 
blocked in TNB blocking buffer solution for 30 minutes at room temperature.  After blocking, sections 
were incubated for 30 minutes at room temperature in Ki67 primary antibody diluted 1:1500 in TNB 
blocking buffer.  The remainder of the protocol was carried out as described in Chapter 2.3.2. 
   For quantification of Sertoli cell proliferation, a minimum of three animals per genotype were 
analyzed. Per animal, at least three alternating testis cross-sections a minimum of 40 µm apart were 
photographed. The percentage of proliferation was calculated as the number of Ki67-positive Sertoli cells 
divided by the total number of Sertoli cell nuclei (as determined manually via DAPI nuclear staining). 
 
2.3.5:  Human fetal testis culture and analysis of Sertoli cell proliferation 
 Paraffin-embedded human fetal testis fragments were generously provided by Drs. Andrew J. 
Childs (MRC Human Reproductive Sciences Unit) and Richard A. Anderson (Division of Reproductive 
and Development Sciences) from the Centre for Reproductive Biology at the University of Edinburgh.  
Human fetal testes were retrieved from morphologically normal fetuses 14-19 weeks gestational age 
following medical termination of pregnancy with informed consent.  At the University of Edinburgh, 
testes were dissected into sterile PBS and cut into fragments of approximately 1 mm
3
. Fragments were 
cultured in MEM" medium with phenol red (GibcoBRL, Life Technologies, Carlsbad, CA) supplemented 
with 2 mM pyruvate, 2 mM glutamine, 1 x ITS supplement (Lonza, Basel, Switzerland) and 3 mg/mL 
BSA, penicillin, streptomycin, and amphotericin. For each embryo, 6-10 testis fragments were cultured in 
medium only and 6-10 fragments were cultured in medium containing 100 ng/mL human recombinant 
activin A protein (R&D Systems, Minneapolis, MN). Testis fragments were cultured for 24 hours in a 
humidified incubator at 37ºC and 5% CO2 at an air-liquid interface on 24-well plate permeable tissue 
culture inserts (Greiner Bio-One, Frickenhausen, Germany). In each well, 450 µL medium was placed 
below the membrane and 50 µL above to prevent drying. Following culture, fragments were retrieved, 
washed briefly in PBS, and fixed in Bouins solution for 1 hour before processing into paraffin blocks. 
This study received approval from the Lothian Research Ethics Committee.    
 Upon my receipt of paraffin blocks, samples were sectioned at 5 #m thick and mounted onto 
Superfrost Plus glass slides.  Slides were stored at room temperature.  Ki67 immunohistochemistry was 
performed using the Perkin Elmer TSA Fluorescein System kit (as described in Chapter 2.3.2) with 
modifications.  Slides were dewaxed and rehydrated through a xylene/ethanol gradient then subjected to 
antigen retrieval.  Specifically, slides were placed into 10 mM citrate buffer (pH 6.0) and microwaved 
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until the citrate buffer began to boil.  Slides were boiled for two minutes then immediately rinsed in cold 
H2O.  Sections were circled with an ImmEdge hydrophobic barrier pen and endogenous peroxidases were 
quenched via incubation with 0.5% H2O2 in 10% methanol/90% PBS for 10 minutes at room temperature.  
Slides were rinsed in PBS then blocked in TNB blocking buffer for 1 hour at RT.  Sections were 
incubated in Ki67 primary antibody BD Pharmingen, Franklin Lakes, NJ) diluted 1:500 in TNB blocking 
buffer for 2 hours at room temperature.  Slides were then washed as described in Chapter 2.3.2.  Next, 
sections were incubated with biotinylated donkey anti-mouse secondary antibody (Jackson 
ImmunoResearch, West Grove, PA) diluted 1:500 in TNB blocking buffer for 30 minutes at room 
temperature.  The remainder of the protocol was carried out as described in Chapter 2.3.2. 
 For quantification of human fetal Sertoli cell proliferation, at least seven testis fragment cross-
sections from five independent experiments were analyzed per treatment group. The percentage of 
proliferation was calculated as the number of Ki67-positive Sertoli cells divided by the total number of 
Sertoli cell nuclei (as manually determined via DAPI nuclear dye staining).  
 
2.3.6:  Testosterone radioimmunoassay 
 For testosterone analysis, testes were collected from newborn Inhba
-/-
 and control mice and 
each epididymis removed.  Testes were analyzed individually for both testosterone and total protein.  
Testosterone levels were determined in individually homogenized testes via a previously-validated 
radioimmunoassay [210].  The sensitivity of the testosterone assay is 8 pg and cross-reactivity of the 
antiserum was reported by Bahr et al. (1983) [211].  Testosterone concentrations were determined using 
the RIAEIA Parallelism Program with Hot Recovery written by M-C. J. Wu (Taiwan Livestock Research 
Institute, Hsinhua, Taiwan). 
 
2.3.7:  Statistical analysis 
 Statistical differences were determined via two-tailed t-test comparisons. 
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2.4:  RESULTS 
2.4.1: INHBA, the subunit of activin A protein, exhibits a compartment-specific expression pattern in 
murine fetal testes 
Previously, our lab and others have demonstrated the expression patterns of activin mRNAs 
within the developing murine testes.  Specifically, activin "B (Inhbb) mRNA localizes to the Sertoli cell 
epithelium of mouse fetal testes whereas activin "A (Inhba) mRNA has been detected in the testis 
interstitium [157, 162]. This compartment-specific expression of activin " subunits indicated activin B is 
the only possible activin protein product of the Sertoli cell epithelium; conversely, activin A is the only 
possible interstitial activin ligand.  To confirm the expression pattern of activin A protein, I performed 
immunohistochemistry with an antibody specific to INHBA, the subunit of activin A protein. I detected 
INHBA/activin A protein primarily within the interstitium of E14.5 mouse testes (Fig. 2.1A), consistent 
with its mRNA expression. Although I observed dispersed staining for activin A within the testis cords, 
activin A was probably not produced by cell types within the testis cords based upon previous 
observations that activin "A mRNA is absent from testis cords [157].  This interstitial expression pattern 
of INHBA was still evident at E19.5, around the time of birth (Fig. 2.1B).  My findings confirmed the 
presence of INHBA/activin A protein within the murine testis interstitium during the last several days of 
gestation. 
 
2.4.2:  Testis cord development is stunted in Inhba global knockout mouse embryos 
In order to investigate the physiological role/s of activin A during testis morphogenesis, I utilized 
an Inhba global knockout (Inhba
-/-
) mouse model generously provided by Dr. Martin Matzuk at Baylor 
College of Medicine.  In this model, a targeting vector was used to delete exon 2 of the Inhba gene, which 
encodes 181 amino acids of the propeptide and the 116 amino acid mature INHBA peptide [201].  Since 
Inhba
-/-
 mice die perinatally, I produced Inhba
-/-
 embryos by intercrossing Inhba
+/-
 mice that were 
themselves viable and fertile.  To determine whether global loss of Inhba expression altered fetal testis 
development, I analyzed histological sections from E19.5/newborn control (Inhba
+/+
 and Inhba 
+/-
; only 
Inhba
+/-
 is shown) and Inhba
-/-
 testes. Whereas numerous testis cord cross-sections could be observed in 
sagittal sections from control testes (Fig. 2.2A), the testis cords of E19.5 Inhba
-/-
 embryos were visibly 
stunted (Fig. 2.2B). The extension of linear sections of testis cords from the rete testis was easily 
identified in Inhba
-/-
 testes (yellow arrowheads in Fig. 2.2B) but not in controls.  In addition, a general 
decrease in the number of testis cord cross-sections was apparent in Inhba
-/-
 testes, as was a gross increase 
in cord cross-sectional diameter (Fig. 2.2B).   
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2.4.3:  Conditional removal of Inhba in the interstitial fetal Leydig cells or Smad4 in the Sertoli cell 
epithelium results in testis cord dysgenesis similar to that of Inhba
-/-
 embryos 
Analysis of Inhba
-/-
 mouse embryos confirmed loss of systemic Inhba expression led to 
dysgenesis of the fetal testis cords.  However, the specific cellular source/s of testicular Inhba could not 
be determined by study of Inhba
-/-
 embryos since this mouse model lacks Inhba expression in all tissues.  
In addition, the perinatal lethality of Inhba
-/-
 mice precluded the study of postnatal testicular development 
in the absence of Inhba.   To address both of these issues, I generated two Inhba conditional knockout 
(cKO) mouse models in which Inhba was removed specifically within interstitial cells of the fetal testes.  
To create the first cKO strain, I utilized two transgenic mouse lines – one expressing cre recombinase 
under the control of the steroidogenic factor 1 (Sf1) promoter and the second in which exon 2 (the entire 
mature peptide domain) of Inhba has been flanked by loxP sites [205, 206].   In the resulting 
Sf1
cre/+
;Inhba
fl/-
 cKO (hereafter referred to as Inhba SF1-cre cKO) mouse model, Inhba expression is 
ablated within the Sertoli cell epithelium, interstitial fetal Leydig cells, and other unidentified SF1-
positive interstitial cells [206].  Since fetal Sertoli cells do not express Inhba mRNA or protein, the Inhba 
SF1-cre cKO mouse model should serve as a useful tool in which to study the role of interstitial Inhba 
during fetal testis development [157, 162].  I also conditionally inactivated the Inhba gene using the anti-
Müllerian hormone type 2 receptor-cre (Amhr2-cre) mouse strain, in which cre recombinase activity is 
targeted specifically to fetal Leydig cells [204-205].  I anticipated analysis of resulting Amhr2
cre/+
;Inhba
fl/-
 
(Inhba fetal Leydig cell cKO or Inhba FLC cKO hereafter) embryos would allow me to determine 
whether fetal Leydig cells are an important source of INHBA/activin A in murine fetal testes. 
Although INHBA can serve as a subunit of both activin A and inhibin A, I hypothesized the fetal 
testis cord dysgenesis present in Inhba global and conditional knockout mice resulted from loss of activin 
A specifically.  Activin A has established roles during the development of many organs, whereas inhibin 
A is not known to have an active signaling function of its own.  I therefore sought to determine the 
cellular target/s of activin A signaling in the developing testes.  Underdevelopment of the epithelial testis 
cords in Inhba
-/-
 embryos suggested the fetal Sertoli cells could be direct targets of interstitial activin A 
protein.  I decided to test this theory by creating a mouse model lacking Smad4 expression specifically 
within the Sertoli cell epithelium.  SMAD4 serves as the central component of canonical TGF! 
superfamily signaling and its deletion should eliminate all canonical TGF! superfamily signaling to the 
Sertoli cells [212]. Although numerous TGF! superfamily ligands, including AMH, TGF!1, TGF!2, 
TGF!3, and activin B are produced in embryonic testes, testis cord dysgenesis has not been reported in 
mouse models lacking these genes [157, 213-215].  I therefore hypothesized that any changes in testis 
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cord development in the Sertoli-specific Smad4 conditional knockout model (Amh
cre/+
;Smad4
fl/-
 or Smad4 
Sertoli cKO) would result from the inability of Sertoli cells to respond to interstitial activin A.  To create 
this conditional knockout model, I utilized a transgenic mouse line carrying a Smad4 allele in which exon 
8 is flanked by loxP sites, resulting in a presumably null allele after recombination [208].  By crossing the 
Smad4 floxed mouse line to a mouse strain expressing cre recombinase under the control of the anti-
Müllerian hormone promoter (Amh-cre), I was able to conditionally remove Smad4 specifically within the 
Sertoli cell epithelium [208, 209].  In addition to investigating the role of Smad4 within fetal Sertoli cells, 
I wondered whether Smad4 expression might be important within the fetal Leydig cells as well.  Although 
expression of TGF! superfamily receptors has not been fully characterized in fetal Leydig cells, 
observations that TGF! ligands can influence fetal Leydig cell functions indicate there is likely a role for 
SMAD4 signal transduction in this lineage [216-220].  I therefore crossed the Smad4 loxP mouse line to 
the aforementioned Amhr2-cre mouse strain to produce a fetal Leydig cell-specific Smad4 conditional 
knockout model (Amhr2
cre/+
;Smad4
fl/-
 or Smad4 FLC cKO) [204, 208]. 
Upon histological analysis, I found the appearance of testis cords in E19.5 Inhba SF1-cre cKO 
(Fig. 2.2C), Inhba FLC cKO (Fig. 2.2D), and Smad4 Sertoli cKO (Fig. 2.2E) mice significantly differed 
from those of controls (Fig. 2.2A).  In control testes, sagittal sections contained many small round or oval 
testis cord cross-sections, indicative of normal testis cord coiling (Fig. 2.2A).  Testis histology was clearly 
abnormal in Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO testes, whereas testes of 
Smad4 FLC cKO mice (Fig. 2.2F) were grossly similar to control testes (Fig. 2.2A).  Observations in 
histological sections from Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO embryos 
included fewer testis cord cross-sections, enlarged testis cord diameter, and a visible increase in 
interstitial area per section.  In addition, straight lengths of testis cords could be seen emerging from the 
rete testis in Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO testes (yellow arrowhead in 
Fig. 2.2C-E).  Similar projections of testis cords from the rete testis were not observed in Smad4 FLC 
cKO (Fig. 2.2F) or control testes (Fig. 2.2A).  Study of higher magnification images (40X) reinforced the 
histological similarities among Inhba
-/-
, Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO 
E19.5 testes (Fig. 2.3).  In control testes, testis cord cross-sections were typically circular and contained 
only a few germ cells within their lumen (Fig. 2.3A).  Both testis cord cross-sectional diameter and the 
number of germ cells per cross-section were visibly increased in Inhba
-/-
 (Fig. 2.3B), Inhba SF1-cre cKO 
(Fig. 2.3C), Inhba FLC cKO (Fig. 2.3D), and Smad4 Sertoli cKO testes (Fig. 2.3E) compared to controls 
(Fig. 2.3A).  In addition, occasional Sertoli cells were observed within the testis cord lumen in Inhba
-/-
, 
Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO embryos (black arrows in Fig. 2.3B-E), 
suggesting a possible sloughing of Sertoli cells from their usual position along the basal lamina.  These 
aberrantly-localized Sertoli cells were not observed in testes from control mice (Fig. 2.3A).  
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Overall, the testis cord dysgenesis phenotype in Inhba SF1-cre cKO mice was reminiscent of, but 
not identical to, that of Inhba
-/-
 embryos (Fig. 2.2B). Specifically, the testes of Inhba
-/-
 appeared more 
severely stunted than those of any cKO testes, with fewer visible testis cord cross-sections. In addition, 
testis cord diameter in Inhba SF1-cre cKO (Fig. 2.2C), Inhba FLC cKO (Fig. 2.2D), and Smad4 Sertoli 
cKO (Fig. 2.2E) testes was generally enlarged compared to Inhba
-/-
 testis cords (Fig. 2.2B).  However, the 
characteristic impairment of testis cord coiling near the rete testis was clearly evident in all four 
aforementioned mouse models.  Taken together, the phenotypic similarities between Inhba
-/-
, Inhba SF1-
cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO testes outweighed the subtle differences and strongly 
suggested these genetic mouse models were targeting a common developmental pathway.  My analysis 
indicates fetal Leydig cell expression of Inhba is critical for normal testis cord expansion prior to birth.  
These results also suggest INHBA/activin A protein from the fetal Leydig cells likely acts upon Sertoli 
cells to regulate testis cord elongation and coiling.  My observation of normal testis development in 
Smad4 FLC cKO newborn mice indicates expression of Smad4 within fetal Leydig cells is not required 
for testis cord formation or expansion.  
In addition to activin A, two other important products of fetal Leydig cells are androgens and 
insulin-like growth factor 3 (INSL3).  Androgens secreted by the fetal Leydig cells are essential for 
proper development and maintenance of the male reproductive tract as well as testis descent [87].  Leydig 
cell-derived INSL3 is required for the transabdominal phase of testis descent [96-98].  At all stages 
analyzed, development of the reproductive tract in Inhba SF1-cre cKO, Inhba FLC cKO, Smad4 Sertoli 
cKO, and Smad4 FLC cKO embryos was indistinguishable from that of controls.  Epididymal coiling was 
altered in Inhba
-/-
 embryos, as was previously reported by our lab [158].  Testicular descent was not 
grossly affected by loss of Inhba or Smad4 expression in any of the mouse models analyzed.  My 
observations of normal male reproductive tract development in my cKO mouse models indicated 
disruption of Inhba or Smad4 expression in my targeted cell lineages did not significantly diminish 
androgen and/or INSL3 secretion. 
 
2.4.4:  The timing of testis cord dysgenesis in Inhba
-/-
, Inhba cKO, and Smad4 Sertoli cKO embryos 
coincides with the onset of testis cord elongation and convolution 
Since testis cord abnormalities were apparent by the time of birth in Inhba
-/-
, Inhba SF1-cre cKO, 
Inhba FLC cKO, and Smad4 Sertoli cKO mice, I wanted to determine the time of onset for this testicular 
dysgenesis.  I collected testes from control and knockout embryos between E12.5 and E19.5, obtained 
transverse cross-sections, and immunostained for laminin to demarcate the basal lamina of the testis cords 
(Fig. 2.4).  From E12.5 through E15.5, the testis cords of control and knockout embryos appeared as 
26 
simple transverse circular loops and no obvious differences were observed among genotypes (only E15.5 
is shown in Fig. 2.4A-E). After E15.5, testis cord coiling became apparent in control testes, eventually 
leading to numerous circular cross-sections by birth (Fig. 2.4F & 2.4K).  This result indicates coiling and 
expansion of the murine testis cords is a rapid process that occurs exclusively between E15.5 and the time 
of birth (E19.5).  In contrast to the extensive testis cord coiling found in controls, I observed the testis 
cords of Inhba
-/-
 embryos to be underdeveloped during the later stages of fetal development (white arrows 
in Fig. 2.4G & 2.4L).  Only minimal coiling was present by E17.5 (Fig. 2.4G) and the circular loop shape 
typical of early-stage testis cords was still evident in E19.5 Inhba
-/-
 testes (Fig. 2.4L).  I observed 
similarly stunted testis cord development in E17.5 Inhba SF1-cre cKO (Fig. 2.4H), Inhba FLC cKO (Fig. 
2.4I), and Smad4 Sertoli cKO (Fig. 2.4J) testes.  Testis cords from Inhba cKO and Smad4 Sertoli cKO 
embryos largely retained their initial circular shape, indicating impairment of testis cord expansion 
between E15.5 and E17.5.  Morphological similarities among Inhba
-/-
 (Fig. 2.4L), Inhba SF1-cre cKO 
(Fig. 2.4M), Inhba FLC cKO (Fig. 2.4N), and Smad4 Sertoli cKO testes were still visible at E19.5, with a 
general decrease in testis cord coiling and elongation evident in all genotypes.  The gross recapitulation of 
the Inhba
-/-
 testis cord dysgenesis phenotype in mice lacking either Inhba expression in the fetal Leydig 
cells (Inhba SF1-cre cKO and Inhba FLC cKO) or Smad4 expression in the Sertoli cell epithelium 
indicated my various knockout models were targeting different aspects of a single pathway.  Taken 
together, these data indicated Inhba is not essential for initial formation of the testis cords but is essential 
for coiling and expansion of the testis cords between E15.5 and birth.  My results also implicate the fetal 
Leydig cells as the major source of activin A in the fetal testes since testis development in Inhba FLC 
cKO embryos resembles that of Inhba
-/-
 embryos.  The Sertoli cells are likely direct targets of fetal Leydig 
cell-derived activin A since disruption of a downstream component of activin signaling (SMAD4) within 
the Sertoli cells results in testicular phenotypes very similar to those observed in Inhba
-/-
 and Inhba cKO 
mice. 
 
2.4.5:  Fetal Sertoli cell proliferation is reduced in the absence of fetal Leydig cell Inhba expression or 
Sertoli cell expression of Smad4 
Late in fetal development, elongation and coiling of the testis cords coincides with and is 
presumably driven by the rapid proliferation of Sertoli cells [138]. I thus examined whether defective fetal 
testis cord expansion in Inhba
-/-
, Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO embryos 
arose due to changes in Sertoli cell proliferation during this critical phase.  In each mouse strain, I 
performed immunohistochemistry for the proliferation marker Ki67 and quantified the percentage of 
proliferating Sertoli cells.  In control mice, numerous proliferating Sertoli cells outlined the testis cords at 
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E19.5 (Fig. 2.5A).  In E19.5 Inhba
-/-
 (Fig. 2.5B), Inhba SF1-cre
 
cKO (Fig. 2.5C), Inhba FLC cKO (Fig. 
2.5D), and Smad4 Sertoli cKO testes (Fig. 2.5E), proliferation within the Sertoli cell epithelium was 
dramatically reduced.  Quantitative analysis revealed the percentage of Ki67-positive Sertoli cells was 
significantly decreased in Inhba
-/-
 (Fig. 2.5F, 26.60 ± 3.17%), Inhba SF1-cre
 
cKO (29.93 ± 2.96%), Inhba 
FLC cKO (42.03 ± 5.67%), and Smad4 Sertoli cKO (28.01 ± 4.63%) testes compared to controls (69.83 ± 
2.81%; p<0.0001 for global knockout and cKO genotypes compared to control; n=3 for Inhba
-/-
, Inhba 
SF1-cre cKO, and Smad4 Sertoli cKO strains; n=7 for control and Inhba FLC cKO).  These data 
suggested reduced Sertoli cell proliferation could be the source of defects in testis cord elongation and 
convolution in Inhba
-/-
, Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO embryos.  Sertoli 
cell proliferation was also significantly decreased in E19.5 Inhba
-/-
, Inhba SF1-cre cKO, and Smad4 
Sertoli cKO testes compared to Inhba FLC cKO testes (p<0.01) despite the similarities in histological 
defects among these mouse models (Fig. 2.2B-E).  The increased rate of Sertoli cell proliferation in Inhba 
FLC cKO testes may be due to the timing and/or efficiency of cre recombinase expression in this mouse 
strain.  It is also possible that in the absence of activin A, other TGF! superfamily ligands may be able to 
partially compensate, leading to a higher rate of Sertoli cell proliferation in Inhba FLC cKO testes.  
 
 
2.4.6:  Activin A can modulate human fetal Sertoli cell proliferation in vitro 
As in the mouse, INHBA/activin A protein localizes to the interstitial compartment of human fetal 
testes [161].  This compartment-specific expression of activin A expression suggests the stimulatory 
effect of activin A upon Sertoli cell proliferation could be conserved between mice and humans.  To test 
this hypothesis, I collaborated with Drs. Richard Anderson and Andrew Childs at the University of 
Edinburgh.  Drs. Anderson and Childs were kind enough to culture 14-19 week gestational age human 
fetal testes for 24 hours in the presence or absence of exogenous human recombinant activin A protein 
(100 ng/mL of medium).  Following culture, testis fragments were paraffin-embedded and mailed to me 
for further analysis.  I sectioned the samples and immunostained for the proliferation marker Ki67.  
Unlike murine fetal testes, wherein the Sertoli cell epithelium forms an organized layer along the basal 
lamina of the testis cords, the Sertoli cells of human fetal testes are found mixed with the germ cells 
within the testis cord lumen.  Therefore, Sertoli cells were distinguished from germ cells based upon 
differences in nuclear size and shape (as evident from DAPI nuclear dye staining).  In untreated human 
fetal testes collected and fixed at time=0, the average percentage of proliferating Sertoli cells was 10.27 ± 
0.90% (Fig. 2.6A, n=5).  Interestingly, I observed the percentage of proliferating Sertoli cells to be 
significantly higher in human fetal testes cultured in the presence of activin A (Fig. 2.6C, 10.49 ± 1.80%) 
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compared to untreated control testes (Fig. 2.6B, 6.20 ± 1.39%, p<0.005, n=5).  This result, coupled with 
my mouse genetic data, suggests activin A is a conserved stimulatory factor acting upon the fetal Sertoli 
cell epithelium in mice and humans.  Specifically, treatment with 100 ng/mL activin A was able to 
maintain Sertoli cell proliferation in cultured human fetal testes at the levels observed in uncultured, 
time=0 samples (Fig. 2.6D). 
  
 
2.5:  DISCUSSION 
2.5.1:  Disruption of testicular activin A signaling reveals novel aspects of testis cord morphogenesis 
 Testis morphogenesis is a fascinating process, providing the unique opportunity to study 
biological mechanisms as diverse as cellular migration, vasculogenesis, and tubule formation.  Although 
the origins of the fetal testis cords as simple circular loops has been known for over 50 years, only 
recently has it been possible to produce visual evidence of the architectural changes that occur during the 
early stages of murine testis formation [128-129, 134, 221]. However, the structural transformations of 
the testis cords during late fetal development remain largely unstudied.  In this chapter, I have 
demonstrated testis cord coiling and expansion occur only during the last few days of in utero 
development, between E15.5 and E19.5.  In addition, I have identified activin A as the primary factor 
promoting these events. 
 
2.5.2:  Fetal Leydig cells actively promote Sertoli cell proliferation, and thus testis cord expansion, via 
activin A 
As the genetic pathways governing testis morphogenesis have gradually come to light, Sertoli 
cells have been firmly established as the master organizers of this process.  The ability of Sertoli cells to 
regulate seemingly every aspect of testis morphogenesis, coupled with the failure to identify other 
relevant mechanisms, led to the general assumption that testis cord elongation and coiling are the result of 
intrinsic programming of the Sertoli cell epithelium.  Fetal Leydig cells, on the other hand, are solely 
regarded as the steroid factories of the testis, a characterization that has seemed fair considering fetal 
Leydig cells are not known to have roles outside of steroid production and the promotion of testis descent 
via INSL3 [96].  In addition to the production of androgens and INSL3, fetal Leydig cells are also 
reported to express several neural-related proteins, including nestin, neurofilament protein 200, neural cell 
adhesion molecule (NCAM), and S-100 [104, 106, 222].  However, the potential contribution of these 
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neural factors to testis morphogenesis remains to be determined.  My studies have uncovered a novel and 
active role of fetal Leydig cells during testis cord expansion.  To my knowledge, activin A is the first fetal 
Leydig cell-produced factor shown to promote Sertoli cell proliferation and thus testis cord elongation 
and coiling (Fig. 2.7).   
It is important to note that although Sertoli cell proliferation is dramatically decreased in embryos 
with disruption of either activin A or SMAD4, Sertoli cell proliferation is not entirely abolished, 
suggesting other unidentified signaling factors may compensate for the loss of fetal Leydig cell-derived 
activin A signaling.  In addition, my study design does not rule out the possibility that other TGF! 
superfamily ligands may influence Sertoli cell proliferation via non-canonical pathways (those not 
requiring SMAD4).  The presence of low levels of Sertoli cell proliferation in Inhba global and 
conditional knockouts as well as Smad4 Sertoli cell cKO testes implies factors coming from the Sertoli 
cells and/or other cell populations may also promote proliferation, particularly in the absence of activin A 
signaling.   My findings therefore bring to light the major contribution of fetal Leydig cell-derived activin 
A to Sertoli cell proliferation and testis cord expansion. 
 
2.5.3:  Activin A is involved in the mesenchymal-epithelial crosstalk required for testis cord expansion 
 Although many communications from epithelium to mesenchyme have been elucidated during 
fetal testis morphogenesis, activin A is one of the only factors shown to signal from the mesenchyme to 
the epithelium.  This mesenchymal-epithelial crosstalk is better understood in the adult testis, where adult 
Leydig cells produce signals critical for the maintenance of Sertoli cell function and ultimately sperm 
production.  For example, the actions of interstitial adult Leydig cell-derived testosterone upon Sertoli 
cells are critical for the normal progression of spermatogenesis in the adult animal [223-227].  However, 
this crosstalk does not exist in the fetal testes since fetal Sertoli cells do not express androgen receptor and 
therefore do not respond to fetal Leydig cell-derived androgens [228-229].  My discovery of the actions 
of mesenchymal activin A on epithelial development raises the possibility that other unidentified 
mesenchyme-derived factors could play essential roles in fetal testis cord development. 
 In addition to identifying activin A as a novel product of the fetal Leydig cells, I have also 
uncovered an unusual role for this signaling protein during tubulogenesis.  In many tubular organs, 
including the kidney, pancreas, salivary gland, and prostate, loss of activin A function results in ectopic 
epithelial branching; therefore, activin A is thought to primarily function as an inhibitor of branching 
morphogenesis [165-166, 168].  Although activin A frequently inhibits branching, this role is not 
dependent upon the compartmental expression pattern of activin A.  In the embryonic kidney and lungs, 
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activin A is actually produced by the epithelium, whereas pancreatic activin A is expressed in both the 
epithelium and mesenchyme [165-166, 170, 230].  However, in all three of these tissue contexts, 
disruption of activin A signaling leads to ectopic branching of the tubular structures.  Within the context 
of the embryonic testes, I have identified activin A as a stimulatory factor driving proliferation of the 
Sertoli cell epithelium.  I did not observe ectopic epithelial branching in the testis cords of my mouse 
models lacking testicular activin A signaling.  It appears the in vivo role of activin A in testis cord 
morphogenesis differs from its more classical functions during the development of other tubular 
structures.  The role of activin A during fetal testis development is actually most similar to its functions in 
morphogenesis of the teeth and epididymides. In the developing teeth, mesenchymal activin A promotes 
epithelial cell proliferation that allows for the progression of incisors and mandibular molars beyond the 
tooth bud stage [167, 173].  Similarly, the source of activin A in the developing Wolffian duct (embryonic 
precursor to the epididymis) is the mesenchyme, and this mesenchymal activin A acts upon the epithelium 
to promote proliferation and subsequent patterning [158].  
 Thus far, expression of activin A in organs of the male reproductive tract has been known to 
occur under the control of testicular androgens.  In the developing Wolffian duct, initial expression of 
mesenchymal activin A is androgen-independent but the expression of activin A at later developmental 
stages requires the presence of testosterone [158].  Androgens are similarly known to positively influence 
activin A expression levels in the adult prostate, although it is unclear whether androgens also regulate 
activin A production during prostate development [231].   The possibility of a similar relationship 
between androgens and activin A expression in the fetal testes certainly warrants further investigation.  
Fetal testis cord dysgenesis and/or reduced Sertoli cell proliferation has not been reported in mouse 
models lacking the ability to either produce or respond to androgen, suggesting androgens may not be 
essential for testicular activin A production [232-233].  In my Inhba cKO and Smad4 cKO mouse models, 
androgen production is sufficient at both fetal and adult stages to result in normal testis descent, 
anogenital distance, and development of the seminal vesicles.  Therefore, my data confirm that normal 
androgen production does not require the actions of fetal Leydig cell-derived activin A upon Sertoli cells.  
However, it remains to be determined whether production of activin A by the fetal Leydig cells requires 
the presence of androgens. 
 Interestingly, there is underlying evidence that activin A regulation of fetal testis cord 
expansion may be conserved across mammalian species.  Localization studies of activin pathway 
components in human fetal testes mirror the pattern observed in mice; specifically, activin A localizes to 
interstitial fetal Leydig cells whereas the Sertoli cell epithelium expresses activin receptors [159, 161, 
234].  In this chapter, I have demonstrated activin A protein has a stimulatory effect upon Sertoli cell 
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proliferation in cultured human fetal testes; however, the in vivo role of activin A during human testis 
development remains to elucidated.  A similar localization pattern to that of humans and mice has been 
observed in developing rat embryos, wherein Inhba mRNA localizes to the testis interstitium and activin 
receptor type 2B (Acvr2b) mRNA is detected within Sertoli cells [170].  Expression of the INHBA 
protein subunit has also been reported in the fetal Leydig cells of shiba goat, sheep, and equine embryos 
[235-237].  In humans, it has been hypothesized that adult testicular dysfunction, ranging from poor 
semen quality to testicular cancers, may arise due to altered development of the testes during fetal life 
[192].  Thus, the further study of the testicular activin A pathway in mice and other animal models may 
provide valuable insight into the developmental origins of human male reproductive disorders.   
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Figure 2.1:  Immunolocalization of INHBA, the subunit of activin A protein, in murine fetal 
testes.  (A) Double immunofluorescent staining for INHBA protein (green) and DAPI nuclear 
dye (red) in an E14.5 control testis section.  Image was taken at 10X magnification.  Scale bar 
= 250µm.  (B) Double immunofluorescent staining for INHBA protein (green) and DAPI 
nuclear dye (red) in an E19.5 control testis section.  Image was taken at 20X magnification.  
Scale bar = 100µm.  White dashed lines in (A) indicate the boundaries of the testis cords. 
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2.6:  FIGURES 
Control 
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Figure 2.2:  Testis morphology in control, Inhba knockout, and Smad4 knockout 
mouse embryos.  (A-F) Hematoxylin- and eosin-stained sagittal testis sections from 
E19.5 control (A), Inhba-/- (B), Inhba SF1-cre conditional KO (cKO) (C), Inhba fetal 
Leydig cell (FLC) cKO (D), Smad4 Sertoli cKO (E), and Smad4 FLC cKO (F) mice.  
Images were taken at 4X magnification.  Scale bar = 250µm.  Yellow arrowheads 
indicate straight lengths of testis cord emerging from the rete testis (rt). 
rt rt 
rt 
rt 
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Control 
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Figure 2.3:  Testis cord histology in control, Inhba knockout, and Smad4 knockout 
mouse embryos.  (A-F) H&E-stained histological sections from E19.5 control (A), 
Inhba-/- (B), Inhba SF1-cre cKO (C), Inhba FLC cKO (D), and Smad4 Sertoli cell 
cKO (E) testes.  Images were taken at 40X magnification.  Scale bar = 100µm.  Black 
arrows indicate Sertoli cells aberrantly located within the testis cord lumen. 
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Figure 2.5:  Effect of activin A signaling on Sertoli cell proliferation in murine fetal 
testes.  (A-E) Double immunofluorescent staining for the proliferation marker Ki67 
(green) and DAPI nuclear dye (red) in E19.5 control (A), Inhba-/- (B), Inhba SF1-cre 
cKO (C), Inhba FLC cKO (D), and Smad4 Sertoli cell cKO (E) testes.  Images were 
taken at 40X magnification.  Scale bar = 100µm.  tc = testis cord.  (F) Percentage of 
Ki67-positive Sertoli cells in E19.5 testes from the aforementioned strains.  p<0.0001 
for (a) versus (b) or (a) versus (c); p<0.01 for (b) versus (c).  n=3 for Inhba-/-, Inhba 
SF1-cre cKO, and Smad4 Sertoli cKO; n=7 for control and Inhba FLC cKO. 
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Figure 2.6:  Effect of activin A protein on Sertoli cell proliferation in human fetal 
testes.  (A-C) Double immunofluorescent staining for Ki67 (green) and DAPI nuclear 
dye (red) in 14-19 week gestational age human testes either collected at time=0 (A), 
cultured for 24 hours (B, untreated control), or cultured for 24 hours in media 
containing 100 ng/mL recombinant human activin A protein (C).  Images were taken 
at 40X magnification.  Scale bar = 100µm.  White dashed line indicates outline of 
testis cords.  Arrows indicate proliferating Sertoli cell nuclei.  (D) Percentage of Ki67-
positive Sertoli cells in human control fetal testes (time=0), untreated cultured control 
testes, and fetal testes cultured with recombinant human activin A protein.  Asterisk 
represents statistical difference from the untreated control (p<0.005, n=5). 
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Figure 2.7:  Model for the role of the activin A pathway during murine fetal testis 
development.  After testis cord organization, interstitial fetal Leydig cells produce 
activin A protein.  This fetal Leydig cell-derived activin A signals to Sertoli cells, 
promoting the epithelial proliferation necessary for testis cord expansion and coiling. 
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CHAPTER 3:  FETAL DISRUPTION OF THE MURINE TESTICULAR ACTIVIN A 
SIGNALING PATHWAY LEADS TO ADULT TESTICULAR DYSGENESIS 
 
 
3.1:  ABSTRACT 
 In Chapter 2, I presented evidence of the critical role fetal Leydig cell-derived activin A plays 
during fetal testis cord development.  Genetic disruption of the testicular activin A pathway resulted in 
impairment of testis cord coiling and elongation during fetal life.  While these studies revealed novel 
aspects of testis morphogenesis, they did not address whether alteration of fetal testis cord expansion 
might have functional consequences in the adult animal.  To determine if fetal disruption of the activin A 
pathway could manifest as testicular dysfunction in adulthood, I analyzed adult conditional knockout 
(cKO) and strain-specific control males at 8-16 weeks of age.  The activin A cKO mouse strains used in 
this study included Inhba SF1-cre cKO males, which lack Inhba expression in Sertoli and fetal Leydig 
cell precursors, and Inhba fetal Leydig cell (FLC) cKO males, which lack Inhba expression specifically in 
fetal Leydig cells.  I also analyzed testes from two Smad4 cKO lines – Smad4 Sertoli cKO mice, wherein 
Smad4 is deleted in Sertoli cells, and Smad4 FLC cKO mice wherein Smad4 is deleted in fetal Leydig 
cells.  My goal in comparing these four different mouse models was to tease out the requirement for 
Inhba and/or Smad4 expression in the two most critical somatic cells types of the testis; namely, the 
Sertoli and Leydig cells.    
Whereas adult Smad4 FLC cKO mice did not differ from controls, I found significant reductions 
in testis size and daily sperm production in Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO 
males.  Histological analysis of Inhba cKO and Smad4 Sertoli cKO testes revealed a general enlargement 
of seminiferous tubule cross-sections reminiscent of my observations of increased testis cord diameter in 
these strains during fetal life.  Testes from 8-16 week old adult Inhba SF1-cre cKO, Inhba FLC cKO, and 
Smad4 Sertoli cKO contained focal dysgenic tubules characterized by loss of spermatogenic cells, mixed 
stages of spermatogenesis, meiotic abnormalities, and vacuolization of Sertoli cells.  To investigate 
whether this testicular dysgenesis worsened with aging I also analyzed testis histology and function in 7-
12 month old Inhba SF1-cre cKO, Inhba FLC cKO, Smad4 Sertoli cKO, and control mice.  Testis size 
and daily sperm production remained lower in aged Inhba cKO and Smad4 Sertoli cKO mice compared to 
strain-specific controls.  While focal dysgenic tubules were evident in young adult cKO males, larger 
regions of dysgenesis were observed in aged Inhba SF1-cre cKO and Inhba FLC cKO testes.  Interstitial 
Leydig cell hyperplasia was also widespread in aged Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 
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Sertoli cKO testes.  Interestingly, androgen-sensitive endpoints such as anogenital distance and seminal 
vesicle weight did not differ between cKO and control males at either age, indicating androgen production 
was not dramatically altered by loss of testicular activin A signaling.  The similarities among Inhba SF1-
cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO mice from fetal development through adulthood point 
to disruption of the testicular activin A pathway during embryonic life as the source of testicular 
dysgenesis in all three mouse models.  In addition, Inhba cKO and Smad4 Sertoli cKO mice could prove 
valuable models in which to study aspects of human androgen-sufficient idiopathic oligozoospermia. 
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3.2:  INTRODUCTION 
The relationship between embryonic testis morphogenesis and adult testicular function is an area 
of great interest to reproductive and developmental biologists alike.  Nearly a decade ago, the hypothesis 
was put forth that adult testicular dysfunctions, such as impaired spermatogenesis, originate due to 
miscues during fetal testis development [238].  With regard to the human population, the hypothesis that 
changes in fetal testis morphogenesis might lead to low sperm count and reduced fertility in adulthood 
has proven controversial; however, an increasing body of epidemiological evidence suggests the 
incidence of human male reproductive disorders is on the rise in many developed countries.  Declining 
sperm counts and reduced semen quality have been reported in the United States and across much of 
Europe over the last several decades [239-244].  Understandably, a direct link between altered fetal testis 
development and reduced semen quality in adulthood has been difficult to establish in the human 
population.   
Given the limitations of studying human testis development, investigation of the relationship 
between fetal testis dysgenesis and adult testicular malfunctions has relied upon the use of animal models.  
Historically, one of the preferred animal models in which to study the fetal origins of testicular dysgenesis 
has been the phthalate-treated rat [245].  In the rat, in utero exposure to phthalates induces 
cryptorchidism, hypospadias, reduced Sertoli cell proliferation, and focal testis cord dysgenesis, 
conditions which can result in abnormal testicular function in adulthood [246-249].  However, many of 
the phenotypes observed in the phthalate-exposed rat model are related to decrease androgen production 
and/or signaling during both fetal and perinatal life [246-247, 249].  Although low androgen levels can 
occur in human males, clinic idiopathic oligozoospermia in men is generally not associated with 
decreased serum or local testosterone levels [250-254].  Therefore, while the phthalate-treated rat model 
provides insight into the roles of androgen during embryonic and postnatal development, it is not an ideal 
model in which to study the presumably more common situation of androgen-sufficient testicular 
dysfunction.  
In Chapter 2, I presented data confirming the essential actions of fetal Leydig cell-derived activin 
A upon Sertoli cell proliferation during murine fetal testis morphogenesis.  By comparing various 
knockout mouse models, I demonstrated that disruption of the activin A pathway resulted in decreased 
fetal Sertoli cell proliferation and thus underdeveloped testis cords by the time of birth.  Interestingly, 
although activin A is a product of the fetal Leydig cells its expression is apparently androgen-independent 
since testosterone production was not suppressed in testes from newborn Inhba
-/-
 mice, which lack 
expression of activin A in all tissues [158].  In addition, androgen-sensitive developmental parameters 
such as testicular descent were not altered in Inhba
-/-
, Inhba cKO, and Smad4 cKO embryos lacking the 
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normal activin A testicular pathway (Chapter 2).  Given the presence of androgen-sufficient testicular 
dysgenesis in my mouse models with disrupted testicular activin A signaling, I reasoned that Inhba cKO 
and Smad4 cKO mice might serve as useful models in which to study androgen-independent aspects of 
testicular dysgenesis.  The neonatal lethality of Inhba
-/-
 mice prevented the analysis of this genotype 
during adult development; however, the similarities between Inhba
-/-
, Inhba SF1-cre cKO, Inhba FLC 
cKO, and Smad4 Sertoli cKO testes during fetal life suggested these cKO models would likely serve as 
suitable replacements for Inhba
-/-
 males with regard to adult analysis [201].  In this chapter, I sought to 
investigate whether the fetal defects present in Inhba cKO and Smad4 cKO mouse testes would persist 
into adult life.  I hypothesized the testis cord dysgenesis present at birth in my cKO mouse models would 
fail to resolve during postnatal development and would thus lead to testicular dysfunction in adulthood.  
To test this hypothesis, I analyzed testicular function and histology in young adult (8-16 weeks) and aged 
adult (7-12 months) Inhba cKO and Smad4 cKO male mice as well as their strain-specific controls.   
 
 
3.3:  MATERIALS AND METHODS 
3.3.1:  Generation of global and conditional knockout mice 
 Please refer to Chapter 2.3.1 for information regarding the generation, genotyping, and breeding 
of the global and conditional knockout mice used in this research.  All procedures described were 
reviewed and approved by the Institutional Animal Care and Use Committee, and were performed in 
accordance with the Guiding Principles for the Care and Use of Laboratory Animals. 
3.3.2:  Histology of adult murine testes 
 Adult testes were fixed overnight (no more than 15 hours) at room temperature in Bouins fixative 
(Sigma, St. Louis, MO).  Penetration of fixative was aided by puncturing the testis tunica several times 
with a needle prior to fixation.  After fixation, testes were washed three times for 15 minutes each in 70% 
ethanol with shaking.  Samples were then stored in 70% ethanol at room temperature.  For histological 
processing, testes were dehydrated through an ethanol gradient followed by immersion in Histo-Clear  
(National Diagnostics, Atlanta, GA).  Testes were then embedded in paraffin wax and sectioned at 5 µm 
thick.  Sections were stained for 3 minutes with either Richard-Allan hematoxylin (Thermo Fisher 
Scientific, Waltham, MA) or Surgipath hematoxylin (Surgipath Medical Industries, Richmond, IL) 
followed by a 30 second counterstain with Surgipath eosin.  Slides were mounted with Permount 
mounting medium (Fisher Scientific, Pittsburgh, PA) diluted 50% with xylene. 
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3.3.3:  Evaluation of daily sperm production 
 Determination of daily sperm production (DSP) followed the methods of Joyce et al. (1993) 
with modifications [255].  Left testes were dissected out, weighed, and the tunica albuginea was removed.  
Testis weight following tunica removal was recorded, and the testis placed into a polypropylene Falcon 
tube containing 4 mL PBS with 0.05% Triton X-100 detergent.  Testes were homogenized for 30 seconds 
using a Polytron homogenizer that was rinsed in distilled water between samples.  Testis homogenate was 
vortexed briefly and 10 #L of homogenate was pipetted onto each chamber of a hemocytomter (20 #L 
total).  The number of intact spermatid heads (those from stages II-VIII, which survive homogenization) 
was counted in five 4x4 squares per chamber (10 squares total).  Cell counts from the two chambers were 
averaged and then multiplied by five to yield total spermatid cell counts.  Since developing spermatids 
spend 4.84 days in stages II-VIII, the number of spermatids per gram of testis weight was divided by 4.84 
to calculate daily sperm production. 
 
3.3.4:  Computer-assisted sperm analysis 
 On the day adult males were to be dissected, I prepared fresh dmKRBT (pH 7.3) medium to be 
used for sperm analysis.  Medium was prepared according to the following protocol:  
 
Ingredient Volume/amount 
NaCL (2M) 3 mL 
KCl (1M) 100 #L 
CaCl2 (1M) 100 #L 
NaHCO3 0.042 g 
MgSO4 (1M) 60 #L 
NaH2PO4 (1M) 18 #L 
Dextrose 0.05 g 
Sodium pyruvate 0.006 g 
TAPSO 0.324 g 
Sucrose 0.316 g 
BSA 0.3 g 
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 Ingredients were mixed in 25 mL of nanopure water and pH adjusted to 7.3.  Volume was 
brought up to 50 mL and filter-sterilized.  Medium was allowed to warm in a 37°C incubator for 1-2 
hours prior to computer-assisted sperm analysis (CASA). 
 To assess the quantity of epididymal sperm, the left cauda epididymis of young adult (8-16 week 
old) or aged adult (27-62 weeks of age) mice was removed within 2 minutes of carbon dioxide 
asphyxiation.  Cauda epididymides were weighed, then immediately placed into a 10 mm polystyrene 
tissue culture dish (Grenier Bio-One Cellstar, Monroe, North Carolina) containing 1 mL of dmKRBT (pH 
7.3).  Cauda epididymides were finely minced with surgical scissors and the dish was placed into a 37°C 
incubator for five minutes to allow sperm to swim out.  After five minutes had lapsed, 100 #L of medium 
was transferred from the culture dish to a 1.5 mL Eppendorf tube containing 900 #L of fresh dmKRBT 
(thus making a 1:10 dilution).  After vortexing briefly to mix, 15 #L of diluted medium + sperm was 
placed onto a glass cannula for CASA using the integrated visual optical system (IVOS) motility analyzer 
(Hamilton-Thorne Research, Beverly, MA).  The operational settings of the IVOS were the standard 
mouse parameters as recommended by the manufacturer.  For each sample, six scans were analyzed.     
 
3.3.5:  Hormone analysis 
 For measurement of plasma follicle-stimulating hormone (FSH) levels, blood was collected via 
postmortem cardiac puncture.  A 27G needle, attached to a 1.0 mL syringe and rinsed with 0.5M EDTA, 
was utilized for blood collection.  Following postmortem cardiac puncture, the needle was removed to 
prevent shearing and blood was transferred into a 1.5 mL Eppendorf tube containing 10 #L of 0.5M 
EDTA.  Tubes were then centrifuged at 300 rpm (no more than 1000g) for 15 minutes at 4°C.  Plasma 
was removed to a new 1.5 mL Eppendorf tube, labeled appropriately, and stored at -80°C. 
 FSH levels were analyzed via radioimmunoassay (RIA) by research specialist Sam Marion in 
the laboratory of Dr. Patricia Hoyer at the University of Arizona.  RIA was performed according to 
instructions with kits from the National Hormone and Pituitary Distribution Program.  The sensitivity of 
the assay was 1.0 ng/mL FSH.  The results of all RIA assays were calculated by four-parameter logistic 
analysis using AssayZap (BioSoft).  Plasma FSH levels were measured in three separate assays and intra-
assay coefficients of variation (CV) were as follows:  8.69% for 8-16 week old Inhba SF1-cre cKO, 
Smad4 Sertoli cKO, Smad4 FLC cKO, and strain-specific control mice (Sf1
cre/+
;Inhba
+/fl
, 
Amh
cre/+
;Smad4
+/fl
, and Amhr2
cre/+
;Smad4
+/fl
 respectively); 1.92% for 8-16 week old Inhba FLC cKO and 
strain-specific control (Amhr2
cre/+
;Inhba
+/fl
) samples; and 1.22% for all aged cKO and strain-specific 
control samples. 
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3.3.6:  Breeding studies 
 To determine their general fertility, individual 15-19 week old Inhba FLC cKO and control 
(Amhr2
cre/+
;Inhba
+/fl
) males were housed with a single C57BL6 female mouse for a period of six months.  
Females were monitored for pregnancy and the number of pups born per litter, as well as the time interval 
(in days) between litters was recorded. 
 To evaluate their ability to sire litters, individual 20-25 week old control (Smad4
fl/-
) or Smad4 
Sertoli cKO (Amh
cre/+
;Smad4
fl/-
) male mice were housed overnight with a female CD-1 mouse in proestrus 
or estrus (as determined via vaginal smear).  Females were removed the next morning and the presence or 
absence of a vaginal plug recorded.  Females were monitored for pregnancy and the number of pups born 
per litter was recorded.   
  
3.3.7:  Statistical analysis 
 Statistical differences were determined via two-tailed t-test comparisons. 
 
 
3.4:  RESULTS 
3.4.1:  Body size and masculinization are not altered in young adult Inhba cKO and Smad4 cKO male 
mice 
 As presented in Chapter 2, murine conditional knockout models lacking expression of Inhba, the 
gene encoding activin A, in either the SF1-positive cell population (Inhba SF1-cre cKO) or in the fetal 
Leydig cells (Inhba FLC cKO) exhibited a failure of testis cord elongation and coiling prior to birth.  
Similar underdevelopment of the testis cords was observed in a mouse model lacking expression of 
Smad4, a critical regulator of canonical TGF! superfamily signaling, within the Sertoli cells (Smad4 
Sertoli cKO).  The similarities in testis cord dysgenesis present in both Inhba FLC cKO and Smad4 
Sertoli cKO embryos implicated the Sertoli cell epithelium as a target of fetal Leydig cell-derived activin 
A.  Interestingly, no obvious phenotypic changes were observed in mice lacking expression of Smad4 
within the fetal Leydig cells (Smad4 FLC cKO), suggesting this gene is not critical for normal fetal 
Leydig cell function.  To investigate whether the aforementioned alterations of either Inhba or Smad4 
during fetal testis development could influence adult testicular function in my mouse models, I analyzed 
young adult cKO and strain-specific control males at 8-16 weeks of age. 
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 Given the influence genetic background can have on body size and other growth parameters, I 
compared each cKO mouse model to an appropriate strain-specific control, e.g. Sf1
cre/+
;Inhba
+/fl
 for Inhba 
SF1-cre cKO, Amhr2
cre/+
;Inhba
+/fl
 for Inhba FLC cKO, Amhr2
cre/+
;Smad4
+/fl
 for Smad4 FLC cKO, and 
Amh
cre/+
; Smad4
+/fl
 for the Smad4 Sertoli cKO strain.  I observed no statistical differences in body weight 
between Inhba SF1-cre cKO, Inhba FLC cKO, Smad4 FLC cKO, or Smad4 Sertoli cKO male mice and 
their strain-specific controls (Table 3.1).  This result confirmed that disruption of Inhba or Smad4 within 
the testes did not lead to overall growth retardation.  Importantly, since SF1-cre is theoretically expressed 
within the adrenal cortex, anterior pituitary, spleen and ventromedial hypothalamus as well as the gonads 
my observations of normal survival and growth patterns in Inhba SF1-cre cKO indicates Inhba expression 
within SF1-positive cell populations is not critical for the function of these other organs or for general 
survival [206].  In addition to body weight, anogenital distance and seminal vesicle weight also did not 
differ between my four cKO mouse models and their strain-specific controls (Table 3.1).  Since both 
anogenital distance and seminal vesicle weight are androgen-sensitive endpoints, this result indicated 
androgen production was likely adequate during both fetal and adult life in my cKO models.  Although I 
did not measure testosterone in cKO embryos, my analysis of testosterone production in newborn global 
Inhba
-/-
 revealed it was not decreased compared to Inhba
+/+
 or Inhba
+/-
 controls [158].  With regard to 
adult animals, seminal vesicle weight is regarded as an exquisitely sensitive measurement of androgen 
adequacy, as insufficient testosterone synthesis results in rapid involution of these accessory sex organs 
[256-258].  The maintenance of seminal vesicle weight comparable to that of controls in Inhba SF1-cre 
cKO, Inhba FLC cKO, Smad4 FLC cKO, and Smad4 Sertoli cKO mice suggests androgen production is 
not significantly reduced in these models. 
 
3.4.2:  Testis size is significantly decreased in young adult Inhba SF1-cre cKO, Inhba FLC cKO, and 
Smad4 Sertoli cKO mice but not in Smad4 FLC cKO males 
 Although body weight did not differ between cKOs and controls, testes of 8-16 week old young 
adult males were smaller in the absence of fetal Leydig cell expression of Inhba or Sertoli cell expression 
of Smad4 (Fig. 3.1).  Testis weight was significantly reduced in Inhba SF1-cre cKO mice (Fig. 3.1A) 
(33.45 ± 9.30 mg, n=10) and Smad4 Sertoli cKO mice (Fig. 3.1D) (65.93 ± 8.21 mg, n=7) compared to 
strain-specific controls (87.04 ± 10.59 mg, n=9 for Inhba SF1-cre control mice; 128.28 ± 8.05 mg, n=10 
for Smad4 Sertoli control mice; p<0.0001).  A significant reduction in testis weight was also observed in 
Inhba FLC cKO mice (Fig. 3.1B) (67.90 ± 22.04 mg, n=5 for cKO; 98.13 ± 6.81 mg, n=4 for control; 
p=0.035).  Interestingly, testis weight did not statistically differ between Smad4 FLC cKO young adults 
(Fig. 3.1C) (134.63 ± 19.77 mg, n=7) compared to controls (133.66 ± 18.37 mg, n=7).  These data are 
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summarized in Table 3.2.  My results indicate disruption of Inhba expression within either the SF1-
positive testicular somatic cells or specifically in the fetal Leydig cells leads to a decrease in testis weight 
without an associated decrease in body weight.  Similarly, disruption of Smad4 expression within fetal 
Sertoli cells results in reduced testis size.  However, loss of Smad4 expression within fetal Leydig cells 
does not affect testis weight at 8-16 weeks of age. 
 
3.4.3:  Efficiency of sperm production is reduced in Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 
Sertoli cKO mice but not in Smad4 FLC cKO males 
 I next analyzed daily sperm production (DSP) in 8-16 week old cKO and control males to 
determine whether fetal disruption of the testicular activin A pathway led to changes in sperm output in 
adulthood.  Since I observed a significant decrease in testis size in three of my four cKO models, I 
anticipated DSP per individual testis would also be reduced most of my cKO strains.  I chose to evaluate 
the efficiency of sperm output by calculating DSP per milligram of testis weight (Fig. 3.2).  By 
determining the DSP per unit of testis weight, I could reason that any reduction in DSP in my cKO 
models would be due to an underlying inefficiency of spermatogenesis rather than simply smaller testis 
size.  DSP was analyzed by homogenizing individual testes and counting the remaining homogenization-
resistant elongated spermatid heads.  I found DSP per milligram of testis weight to be similarly decreased 
in Inhba SF1-cre cKO males (Fig. 3.2A) (46,098.55 ± 11,874.94 sperm, n=9) and Inhba FLC cKO males 
(Fig. 3.2B) (36,659.43 ± 9,844.24 sperm, n=5) compared to their strain-specific controls (62,072.22 ± 
4,652.38 sperm, n=9 for Inhba SF1-cre control, p=0.002; 58,237.81 ± 7,842.43 sperm, n=4 for Inhba FLC 
control, p=0.015).  The DSP per milligram of testis weight was also significantly reduced in Smad4 
Sertoli cKO mice (Fig. 3.2D) (33,640.38 ± 8,653.54 sperm, n=7) compared to controls (57,793.84 ± 
7,212.93 sperm, n=9, p<0.0001).  As was the case with testis size, DSP per milligram of testis weight did 
not differ between Smad4 FLC cKO males (Fig. 3.2C) (60,804.86 ± 7.077.31 sperm, n=7) and controls 
(57,410.51 ± 6,243.29 sperm, n=7).  These data are summarized in Table 3.2. 
 In addition to determination of DSP, I also analyzed cauda epididymal sperm concentration (Fig. 
3.3).  Although both methods provide information on sperm quantity, DSP is indicative of the number of 
sperm heads produced whereas cauda epididymal sperm concentration reflects the amount of sperm that 
are released from the seminiferous tubules, reach the cauda epididymis, and are stored in that location.  I 
observed a significant decrease in sperm concentration in Inhba SF1-cre cKO mice (Fig. 3.3A) (5.256 ± 
3.015 million sperm, n=9) compared to controls (14.333 ± 4.320 million sperm, n=9, p<0.0001).  In 
contrast, sperm concentration in Inhba FLC cKO (Fig.  3.3B) (9.040 ± 3.084 million sperm, n=5), Smad4 
48 
FLC cKO (Fig. 3.3C) (22.186 ± 6.089 million sperm, n=7), and Smad4 Sertoli cKO (Fig. 3.3D) (13.586 ± 
4.216 million sperm, n=7) male mice did not significantly differ from that of strain-specific controls 
(12.700 ± 1.885 million sperm, n=4 for Inhba FLC control, p=0.077; 17.157 ± 2.669 million sperm, n=7 
for Smad4 FLC control; 15.733 ± 4.772 million sperm, n=9 for Smad4 Sertoli control).  These data are 
summarized in Table 3.2. 
 Taken together, my analysis of sperm output indicates that actual sperm production is reduced in 
the testes of young adult Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO mice.  Since 
determination of DSP is dependent upon the number of sperm heads present, sperm that are stuck within 
the seminiferous epithelium (fail to be released into the lumen) or are in the early stages of phagocytosis 
would still be counted using this method of analysis.  The observation of tubules within my cKO testes 
exhibiting failures of spermatid release could have artificially inflated my DSP calculations.  Surprisingly, 
this reduction in sperm production is only reflected in the cauda epididymal sperm concentration of Inhba 
SF1-cre cKO males.  
 
3.4.4:  Decreased sperm output in young adult Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli 
cKO mice is not due to decreased follicle-stimulating hormone (FSH) levels 
In rodents as well as humans, pituitary-derived follicle-stimulating hormone (FSH) is an 
important regulator of both Sertoli cell proliferation and spermatogenesis [227, 259-263].  Although FSH 
is not required for fetal or neonatal Sertoli cell proliferation in the mouse, it is involved in the 
establishment of final Sertoli cell numbers around 15-20 days postpartum [227].  Evidence of the 
importance of FSH for sperm production comes from classical experiments in which exogenous FSH 
supplementation was able to maintain spermatogenesis in hypophysectomized rats [259].  A more 
recently-developed technique, microarray analysis, has identified more than 300 genes that are regulated 
by FSH in cultured rat Sertoli cells [264].  In addition, the most commonly observed hormonal change in 
men with low sperm production is an elevation of follicle-stimulating hormone (FSH) levels; in fact, FSH 
levels are a common diagnostic tool in evaluation of human male subfertility/infertility [250, 252, 254, 
261, 265-266]. 
My observations of quantitatively reduced sperm production in several of my cKO mouse models 
prompted me to question whether this low sperm output could result from insufficient FSH levels.  To 
address this concern, plasma FSH levels in 8-16 week old Inhba cKO males, Smad4 cKO males, and 
controls were measured via radioimmunoassay courtesy of Sam Marion and Dr. Patricia Hoyer at the 
University of Arizona (Fig. 3.4).  As opposed to a decrease in FSH, plasma FSH levels were significantly 
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increased in Inhba SF1-cre cKO (Fig. 3.4A) (33.41 ± 8.44 ng/mL, n=9) and Smad4 Sertoli cKO (Fig. 
3.4D) (27.11 ± 4.87 ng/mL, n=7) males compared to their strain-specific controls (23.13 ± 4.59 ng/mL, 
n=9 for Inhba SF1-cre control, p=0.006; 16.58 ± 5.98 ng/mL, n=10 for Smad4 Sertoli control, p=0.0016).  
Plasma FSH levels did not significantly differ between Inhba FLC cKO (Fig. 3.4B) (34.83 ± 5.83 ng/mL, 
n=5) or Smad4 FLC cKO (Fig. 3.4C) (17.44 ± 8.35 ng/mL, n=6) males and their associated controls 
(31.44 ± 6.23 ng/mL, n=3 for Inhba FLC control; 17.37 ± 6.60 ng/mL, n=5 for Smad4 FLC control).  
These data are summarized in Table 3.2.  Thus, reduced sperm production in young adult Inhba SF1-cre 
cKO, Inhba FLC cKO, and Smad4 Sertoli cKO mice was not secondary to decreased FSH levels. 
 
3.4.5:  Despite reduced daily sperm production, young adult Inhba FLC cKO and Smad4 Sertoli cKO 
male mice are able to sire pups 
 In contrast to human males, male mice produce many times more sperm than required for 
fertilization.  It has been estimated that reductions in fertility are not apparent in the male mouse until 
sperm production falls below 10% of normal values [267].  Coupled with the fact that mice are a 
polyovular species, the extremely low threshold for fertility in male mice renders breeding studies a tool 
of limited usefulness.  However, given my observations of reduced daily sperm production, I performed 
breeding studies using Inhba FLC cKO, Smad4 Sertoli cKO, and control mice to evaluate whether these 
males were able to successfully sire pups (Table 3.3).  To assess the siring ability of Inhba FLC cKO and 
strain-specific control males, individual 15-19 week old male mice were housed with a single C75BL6 
female for a span of six months.  I monitored the females for pregnancy and recorded the number of pups 
born per litter as well as the number of days that passed between litters.  In control males, the average 
litter size was 9.89 ± 1.57 pups (n=2 males) compared to 8.77 ± 1.68 pups in the Inhba FLC cKO males 
(n=4 males) (Table 3.3A).  The average number of days between litters in control males was 42 ± 24.7 
days, whereas the average time interval in Inhba FLC cKO males was 29 ± 6.1 days (Table 3.3A).  
Although the small number of mice included in the control group precluded proper statistical analysis, 
there was not an apparent difference in the average litter size or average time interval between litters in 
Inhba FLC cKO and control males.  However, this breeding study confirmed that 15-19 week old Inhba 
FLC cKO males are capable of siring pups. 
 One major downfall of the aforementioned breeding study was the failure to account for issues 
related to female subfertility.  Since each male was housed with a single female for an extended period of 
time, it was impossible to distinguish whether changes in litter size or the number of days between litters 
were due to problems with male fertility, female fertility, or both.  Therefore, I took a different approach 
to test the siring ability of Smad4 Sertoli cKO and Smad4
fl/-
 control mice.  Male mice of 20-25 weeks of 
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age were housed overnight with a series of CD-1 strain females determined to be receptive (in either 
proestrus or estrus) by analysis of vaginal smears.  The next morning, females were checked for the 
presence of copulatory vaginal plugs.  Plugged females were monitored for pregnancy and the number of 
pups born per litter was recorded.  In planning this study, my goal was to provide each male with an 
optimal situation for successful mating (a receptive female) as well as multiple females in order to 
minimize any female-related effects on pregnancy rate or litter size.  The three Smad4 Sertoli cKO males 
included in this study plugged a total of 10 females, of which seven were pregnant (Table 3.3B).  This 
result was identical to my observations of 10 total plugs and seven pregnancies in the four Smad4
fl/-
 
control mice in this study.  The average litter size in the seven litters sired by control males was 13.57 ± 
3.82 pups (range of 10-20 pups) compared to 13.14 ± 5.01 pups (range of 3-18 pups) in Smad4 Sertoli 
cKO males.  Thus, pregnancy rate and litter size did not differ between Smad4 Sertoli cKO and control 
mice.  This study did confirm the ability of Smad4 Sertoli cKO males to sire litters despite decreased 
daily sperm production.   
 
3.4.6: Young adult Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO male mice have 
alterations in seminiferous tubule histology 
Reduced sperm production in the presence of normal or elevated FSH levels in Inhba SF1-cre 
cKO, Inhba FLC cKO, and Smad4 Sertoli cKO males pointed to changes in testis function as the primary 
source of this phenomenon.  In order to evaluate what alterations may have occurred, I analyzed testis 
histology in 8-16 week old young adult cKO mice and their strain-specific controls (Fig. 3.5).  Viewed at 
low (10X) magnification, testes from control males contained numerous round or oval seminiferous 
tubule cross-sections in various stages of spermatogenesis (Fig. 3.5A).  In contrast, testes from Inhba 
SF1-cre cKO (Fig. 3.5B), Inhba FLC cKO (Fig. 3.5C), and Smad4 Sertoli cKO (Fig. 3.5E) males 
contained elongated seminiferous tubule cross-sections as well as oval sections similar to those observed 
in controls.  This enlarged seminiferous tubule diameter in Inhba SF1-cre cKO, Inhba FLC cKO, and 
Smad4 Sertoli cKO testes was reminiscent of the testis cord phenotype observed during fetal development 
in these mouse strains (Chapter 2).  Thus, while some degree of tubule coiling occurred postnatally in 
these mouse models, it was not sufficient to result in completely normal testis histology by adulthood.  As 
was the case with the fetal testis cords, adult seminiferous tubule histology in Smad4 FLC cKO mice (Fig. 
3.5D) was comparable to that of control mice.  Higher magnification (20X) further confirmed the 
similarities in seminiferous tubule size and arrangement between Smad4 FLC cKO (Fig. 3.6B) and 
control (Fig. 3.6A) male mice.  In Inhba SF1-cre cKO (Fig. 3.6C), Inhba FLC cKO (Fig. 3.6D), and 
Smad4 Sertoli cKO (Fig. 3.6E) testes, higher magnification confirmed the presence of numerous tubules 
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that, while enlarged in diameter, undergo normal spermatogenesis.  However, focal dysgenic tubules 
could be observed scattered among normally-functioning tubules in Inhba SF1-cre cKO (Fig. 3.6F), 
Inhba FLC cKO (Fig. 3.6G), and Smad4 Sertoli cKO testes, a phenomenon not observed in either control 
(Fig. 3.6A) or Smad4 FLC cKO (Fig. 3.6B) testes.  Areas of apparent Leydig cell hyperplasia were also 
evident in some sections of Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO testes 
(arrowhead in Fig. 3.6H).  In addition, failures of spermiation, meiotic aberrations, mixed-stage tubules, 
and loss of spermatogonial stem cells were observed in some tubules of Inhba SF1-cre cKO, Inhba FLC 
cKO, and Smad4 Sertoli cKO young adult testes but not in Smad4 FLC cKO or control testes.  Taken 
together, these results suggest the decrease in DSP per milligram of testis weight in Inhba SF1-cre, Inhba 
FLC cKO, and Smad4 Sertoli cKO mice may be due to the increase in seminiferous tubule diameter (thus 
reducing seminiferous epithelium surface area) coupled with reduced or absent sperm output in focal 
dysgenic tubules. 
 
3.4.7:  Body size and masculinization endpoints remain similar to controls in aged adult Inhba cKO and 
Smad4 cKO male mice 
 The analysis of 8-16 week old young adult Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 
Sertoli cKO mice indicated the fetal testis dysgenesis present in these cKO mouse models persisted into 
adulthood, manifesting as reduced sperm production and abnormal testicular histology.  I next sought to 
determine whether the functional and histological deficits present in these mouse models as young adults 
might lead to further degeneration of the testes with advanced age.  I therefore analyzed Inhba SF1-cre 
cKO, Inhba FLC cKO, Smad4 Sertoli cKO, and strain-specific control mice at 7-12 months of age.  
Mirroring my findings in young adult males, there were no significant differences in body weight, 
anogenital distance, or seminal vesicle weight between my cKO mouse models and their associated 
controls (Table 3.4). As mentioned in 3.4.1, the observation of normal seminal vesicle weight in Inhba 
SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO indicated androgen production was not 
suppressed in the absence of testicular activin A signaling.  Unfortunately, one unavoidable issue in 
allowing mice to grow out to one year of age is premature death due to unexplained causes.  Although I 
had initially saved enough Smad4 Sertoli cKO and control males to allow for an adequate sample size for 
statistical analysis, by the time of collection I had only three control and two cKO males remaining.  
Thus, all statistical comparisons presented regarding these mice represent, at best, potential trends.   
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3.4.8:  Reductions in testis size persist in 7-12 month old Inhba cKO and Smad4 cKO male mice 
 Despite the similarities in body weight between cKO and control mice, testis size remained 
visibly smaller in Inhba SF1-cre cKO (Fig. 3.7A), Inhba FLC cKO (Fig. 3.7B), and Smad4 Sertoli cKO 
(Fig. 3.7C) males compared to controls.  This discrepancy in testis size was generally reflected in 
measurements of testis weight (Fig. 3.8).  Testis weight in both Inhba SF1-cre cKO (Fig. 3.8A) (44.54 ± 
4.11 mg) and Inhba FLC cKO (Fig. 3.8B) (88.50 ± 18.36 mg) male mice was significantly decreased 
compared to their strain-specific controls (100.51 ± 5.07 mg, n=4 for Inhba SF1-cre control, p<0.0001; 
124.31 ± 15.99 mg, n=8 for Inhba FLC control, p=0.0002).  As mentioned previously, the small sample 
size for Smad4 Sertoli cKO mice precluded proper statistical analyses; the comparison between Smad4 
Sertoli cKO and control mice was further complicated by the large discrepancy in testis weight between 
the two cKO males analyzed.  Average testis weight in one Smad4 Sertoli cKO was 113.4 mg, 
comparable to that of control males (127.87 ± 16.20 mg, n=3), whereas it was only 63.8 mg in the second 
cKO male.  Thus average testis weight for the two Smad4 Sertoli cKO males (Fig. 3.8C) was 88.55 ± 
35.07 mg (p=0.173 compared to controls).  Without a larger sample size, I cannot conclude whether testis 
size would indeed be decreased in aged Smad4 Sertoli cKO males, as was the case in young adults (Fig. 
3.1D).  Average testis weights for cKO and control strains are summarized in Table 3.4.  In comparing 
average testis weight in young adult (8-16 weeks) and aged adult (7-12 months) males, a significant 
increase in testis weight was observed in aged Inhba SF1-cre control, Inhba SF1-cre cKO, Inhba FLC 
control, and Inhba FLC cKO males compared to young males of identical genotype (Tables 3.6 and 3.7) 
(p$0.06).  This age-related increase in testis size was not observed in Smad4 Sertoli control or cKO mice 
(Table 3.8). 
 
3.4.9:  Daily sperm production, but not cauda epididymal sperm concentration, is significantly decreased 
in aged Inhba cKO and Smad4 cKO male mice        
 I next analyzed DSP in 7-12 month old Inhba cKO, Smad4 cKO, and control mice to evaluate 
whether the decreased sperm production present in young adult cKO males persisted into advanced age.  I 
found DSP per milligram of testis weight to be nearly significantly reduced in Inhba SF1-cre cKO (Fig. 
3.9A) (24,758.21 ± 7,248.81 sperm, n=5), and highly significantly reduced in Inhba FLC cKO (Fig. 3.9B) 
(26,412.98 ± 7,556.16 sperm, n=12) male mice compared to their strain-specific controls (46,726.42 ± 
22,662.64 sperm, n=4 for Inhba SF1-cre control, p=0.077; 49,997.97 ± 6,368.24 sperm, n=8 for Inhba 
FLC control, p<0.0001).  DSP per milligram testis weight would also likely be significant in Smad4 
Sertoli cKO mice (Fig. 3.9C) (25,003.69 ± 3,008.20 sperm, n=2) compared to controls (49,241.76 ± 
4,319.12 sperm, n=3, p=0.007) were the sample size larger (Fig. 3.9C). 
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 To determine whether decreases in DSP would translate into reductions in epididymal sperm 
output, I measured cauda epididymal sperm concentration in aged cKO and control males (Fig. 3.10).  
Sperm concentration was lower in Inhba SF1-cre cKO males (Fig. 3.10A) (8.840 ± 4.413 million sperm, 
n=5) than strain-specific controls (18.175 ± 16.024 million sperm, n=4, p=0.247), although not 
significantly so.  The extremely large standard deviation for sperm concentration in Inhba SF1-cre cKO 
was the result of a single male mouse with a cauda epididymal sperm concentration of 42.2 million 
sperm.  The average sperm concentration for the other three aged Inhba SF1-cre control males analyzed 
was only 10.17 ± 0.60 million sperm.  Despite the unusually high sperm concentration in the 
aforementioned Inhba SF1-cre cKO mouse, he did not significantly differ from other strain-specific 
control males with regard to any other parameters and I thus did not have good cause to omit him from 
the study..  I did observe a nearly-significant decrease in sperm concentration in Inhba FLC cKO (Fig. 
3.10B) (13.369 ± 8.182 million sperm, n=13) and Smad4 Sertoli cKO (Fig. 3.10C) (14.250 ± 5.728 
million sperm, n=2) mice compared to controls (19.663 ± 4.387 million sperm, n=8 for Inhba FLC 
control, p=0.061; 24.867 ± 4.225, n=3 for Smad4 Sertoli control, p=0.093).  Thus, cauda epididymal 
sperm concentration followed a non-significant decreasing trend in all three cKO mouse strains. 
 In comparing sperm output among age groups, DSP per milligram of testis weight was 
significantly or nearly-significantly decreased in 7-12 month old Inhba SF1-cre cKO, Inhba FLC cKO, 
and all control genotypes compared to males of the same genotypes at 8-16 weeks of age (Tables 3.6-3.8).  
A decrease in average DSP per milligram testis weight was also observed in aged Smad4 Sertoli cKO 
(25.00 ± 3.01 million sperm, n=2) compared to young adult males of the same genotype (33.64 ± 8.65, 
n=7) but it was not statistically significant (p=0.225).  With regard to cauda epididymal sperm 
concentration, nearly-significant differences between young and aged mice were only observed in Inhba 
FLC control and Smad4 Sertoli control mice.  In both instances, average sperm concentration was 
increased in aged males (19.66 ± 4.39 million sperm, n=8 for Inhba FLC control; 24.87 ± 4.23 million 
sperm, n=3 for Smad4 Sertoli control) compared to young males (12.70 ± 1.89 million sperm, n=4 for 
Inhba FLC control, p=0.014; 15.73 ± 4.77 million sperm, n=9, p=0.015).  Therefore, an age-related 
decline in DSP occurs in both control and cKO mice, whereas an age-related increase in cauda 
epididymal sperm concentration was detected in some control genotypes.  In general, the decline in DSP 
in aged control males was negligible.  Average DSP per milligram of testis weight was observed to 
decline roughly 25% in aged Inhba SF1-cre control males compared to young males of the same 
genotype, but this was most likely due to the extremely large standard deviation and small sample size 
(n=4). Taken together, these data indicate DSP in aged Inhba cKO and Smad4 cKO males is significantly 
decreased compared to age-matched controls (summarized in Table 3.5).  However, the relationship 
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between increasing age and decreasing cauda epididymal sperm concentration in cKO and control mice is 
substantially less clear. 
 
3.4.10:  Decreased DSP in Inhba cKO and Smad4 cKO mice does not result from insufficient FSH levels 
 In young adult Inhba cKO and Smad4 cKO males, DSP was reduced despite the presence of 
adequate FSH levels.  To evaluate whether a similar situation was occurring in aged cKO males, plasma 
FSH levels were measured via RIA (Fig. 3.11).  Plasma FSH levels did not significantly differ between 
Inhba SF1-cre cKO (Fig. 3.11A) (44.75 ± 9.21 ng/mL, n=5) and Smad4 Sertoli cKO (Fig. 3.11C) (33.57 
± 3.62 ng/mL, n=2) males compared to controls (37.33 ± 3.25 ng/mL, n=4 for Inhba SF1-cre control; 
31.14 ± 4.18 ng/mL, n=3 for Smad4 Sertoli cKO control).  FSH levels were significantly elevated in 
Inhba FLC cKO (Fig. 3.11B) (40.44 ± 9.97 ng/mL, n=13) mice compared to controls (28.76 ± 6.74 
ng/mL, n=8, p=0.009).  These data confirm FSH levels in Inhba cKO and Smad4 cKO are not suppressed 
and therefore are unlikely to be the source of decreased DSP in these mouse models. 
 Plasma FSH levels were generally similar between young adult and aged males will the exception 
of Inhba SF1-cre control, Inhba SF1-cre cKO, and Smad4 Sertoli control mice (Tables 3.7-3.9).  In these 
three genotypes, plasma FSH levels were significantly increased in 7-12 month old males when compared 
to 8-16 week old mice (Tables 3.7 and 3.9).  Specifically, average plasma FSH in aged Inhba SF1-cre 
males was 37.33 ± 3.25 ng/mL (n=4) compared to 23.13 ± 4.59 ng/mL (n=9) in young males (p=0.0002).  
Average plasma FSH in Inhba SF1-cre cKO mice was 44.75 ± 9.21 ng/mL (n=5), which was significantly 
higher than in young adult males (33.41 ± 8.44 ng/mL, n=9, p=0.038).  Aged Smad4 Sertoli control males 
also had significantly elevated average plasma FSH levels (31.14 ± 4.18 ng/mL, n=3) compared to young 
adults (16.58 ± 5.98 ng/mL, n=10, p=0.003).  The FSH levels I observed in control mice were comparable 
to some published reports of FSH concentration in normal postpubertal male mice [268-270].  Taken 
together, these data indicate plasma FSH levels are not reduced in Inhba cKO and Smad4 cKO mouse 
models at either age analyzed.  In addition, average FSH levels are increased in advanced age in Inhba 
SF1-cre control, Inhba SF1-cre cKO, and Smad4 Sertoli control mice.  Serum FSH levels are reported to 
increase with age in several species, including humans and horses, but there are limited data to suggest a 
similar age-related increase may occur in mice [271-273].  The failure to observe a consistent increase in 
FSH levels with advanced age in this study suggests elevated FSH levels may not be a hallmark of aging 
in mice. 
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3.4.11:  Histological analysis of testes from 7-12 month old Inhba cKO and Smad4 cKO males reveals 
abnormal seminiferous tubules and Leydig cell hyperplasia 
 Testes from 8-16 week old Inhba cKO and Smad4 cKO mice displayed several histological 
abnormalities including increased seminiferous tubule diameter, focal dysgenic tubules, meiotic 
aberrations, mixed-stage tubules, and signs of Leydig cell hyperplasia within the testis interstitium.  I 
therefore performed histological analysis of testes from 7 -12 month old cKO and control mice to see 
whether testicular dysgenesis had resolved or worsened with advanced age (Fig. 3.12).  At low 
magnification (10X), control testes (Fig. 3.12A) contained round and oval seminiferous tubule cross-
sections, similar to my observations in 8-16 week old control testes (Fig. 3.5A).  Histological sections of 
Inhba SF1-cre cKO (Fig. 3.12B), Inhba FLC cKO (Fig. 3.12C), and Sertoli Smad4 cKO (Fig 3.12D) 
testes revealed long, looping tubule cross-sections with occasional round or oval tubules scattered in 
between.  In addition, testes of Inhba SF1-cre cKO and Inhba FLC cKO males contained dysgenic 
tubules characterized by sloughing of spermatogenic cells into the tubule lumen (Fig. 3.12E), 
vacuolization of Sertoli cells (Fig. 3.12F), and disruption of the seminiferous epithelium (Fig. 3.12F).  A 
similar severity of tubule dysgenesis was not observed in aged Smad4 Sertoli cKO testes; however, the 
small sample size (one testis each from two different cKO males) prevented me from drawing concrete 
conclusions regarding histology of aged cKO males of this strain.  Areas of interstitial Leydig cell 
hyperplasia were observed throughout sections of Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 cKO 
testes (yellow asterisks in Fig. 3.12B-G). 
Higher magnification images (20X) showed regions of normal spermatogenesis in aged Inhba 
SF1-cre cKO (Fig. 3.13B), Inhba FLC cKO (Fig. 3.13C), and Smad4 Sertoli cKO (Fig. 3.13D) testes; 
however, tubule diameter was clearly larger than was observed in controls (Fig. 3.13A).  In addition to 
spermatogenically active tubules, testes from cKO mice contained dysgenic tubules, characterized by 
vacuolization and germ cell loss, as well as hyperplasia of the interstitial Leydig cells (yellow asterisks in 
Fig. 3.13E-G).  Dysgenic tubules likely on their way to becoming Sertoli cell-only are depicted in Inhba 
SF1-cre cKO (Fig. 3.13E) and Inhba FLC cKO (Fig. 3.13F) testes; in Fig. 3.13G, a yellow arrowhead 
highlights an abnormal cluster of what appear to be spermatogenic cell nuclei in a section from an aged 
Smad4 Sertoli cKO. 
 Histological analysis of Inhba cKO and Smad4 cKO aged adult testes confirmed that enlarged 
seminiferous tubule diameter and length present at fetal and young adult stages do not resolve by 7-12 
months of age.  As at 8-16 weeks of age, the majority of tubules in aged Inhba cKO and Smad4 cKO 
testes are undergoing grossly normal spermatogenesis.  In young adult Inhba SF1-cre cKO, Inhba FLC 
cKO, and Smad4 Sertoli cKO males, areas of dysgenesis are focal and typically consist of one or two 
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adjacent seminiferous tubule cross-sections.  In contrast, dysgenic regions in aged Inhba SF1-cre cKO 
and Inhba FLC cKO testes tend to involve multiple tubules.  The types of spermatogenic defects 
observed, including meiotic abnormalities, mixed-stage tubules, sloughing of cells into the tubule lumen, 
and failures of spermiation, did not seem to differ between young and aged cKO males.  Thus, the 
seminiferous tubule dysgenesis present at 7-12 months of age was more widespread but otherwise 
qualitatively similar to my observations in 8-16 week old young adult Inhba SF1-cre cKO and Inhba FLC 
cKO mice.  In the case of Smad4 Sertoli cell cKO males, the testicular abnormalities I observed in 8-16 
week old males were similar to those I found in Inhba cKO males of the same age.  The testis phenotype 
in the two aged Smad4 Sertoli cKO male mice I analyzed was comparatively milder than I observed in 
aged Inhba cKO males; however, the small sample size for the Smad4 Sertoli cKO strain does not allow 
me to definitively conclude that the focal dysgenic tubules present in 8-16 week old Smad4 Sertoli cKO 
resolve in old age.  Another obvious difference between young and aged adult cKO males related to 
Leydig cell hyperplasia within the testis interstitium.  Although there were some regions of apparent 
Leydig cell hyperplasia in young adult Inhba cKO and Smad4 cKO males, this phenomenon was evident 
throughout the interstitial compartment in aged mice. 
 
 
3.5:  DISCUSSION 
3.5.1:  Fetal testis dysgenesis persists into adulthood in Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 
Sertoli cKO male mice 
  As discussed in Chapter 2, disruption of activin A signaling from fetal Leydig cells to Sertoli 
cells during testis morphogenesis results in decreased Sertoli cell proliferation and thus failures in testis 
cord expansion.  Although testicular dysgenesis was evident in Inhba
-/-
, Inhba SF1-cre cKO, Inhba FLC 
cKO, and Smad4 Sertoli cKO embryos even before birth, whether postnatal development of the testes 
would proceed normally was an area of great interest to me.  Since postnatal proliferation of Sertoli cells 
is largely regulated by FSH, it was possible that Sertoli cells of Inhba cKO and Smad4 Sertoli cKO mice 
could proliferate at an increased rate postnatally, thus overcoming the fetal setbacks in Sertoli cell number 
[227].  Instead, underdevelopment of the testis cords was not completely resolved by postnatal growth as 
evidenced by continuation of seminiferous tubule elongation and enlargement in both young and aged 
adult cKO males.  In addition to their unusual seminiferous tubule size, young adult Inhba cKO and 
Smad4 cKO mice presented with decreased testis size, reduced sperm production, and focal dysgenic 
tubules.  These characteristics persisted into advanced age in cKO males, with regional dysgenesis of 
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seminiferous tubules and widespread Leydig cell hyperplasia.  Further evidence the decreased sperm 
production I observed in Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO may have its roots 
in fetal development comes from my data regarding Sertoli cell proliferation in newborn cKO testes 
(presented in Chapter 2).  Since spermatid numbers in adult rodents are dependent upon Sertoli cell 
number, my observation of reduced Sertoli cell proliferation at birth suggests Sertoli cell numbers, and 
thus the potential for sperm production, are decreased in Inhba cKO and Smad4 Sertoli cKO males 
compared to controls [274].  In addition, the enlargement of seminiferous tubule diameter in Inhba cKO 
and Smad4 Sertoli cKO testes would presumably further reduce sperm production compared to controls 
by decreasing the overall seminiferous epithelium surface area.  Based on these results, I conclude the 
fetal dysgenesis induced by disruption of the testicular activin A signaling pathway does persist into 
adulthood, impacting both testicular histology and function.  Additionally, the continuing similarities 
between Inhba cKO and Smad4 Sertoli cKO male mice from fetal stages through adulthood suggests 
activin A is the major TGF! superfamily ligand acting canonically upon the Sertoli cells throughout life. 
 It is important to note that in the Inhba cKO and Smad4 cKO mouse models presented here, 
activin A and SMAD4 are permanently removed from their respective cell populations during fetal testis 
development.  Therefore, while these models provide the opportunity to track the effects of fetal loss of 
testicular activin A signaling throughout life, I was not able to study the specific role of testicular activin 
A during critical timepoints between fetal life and adulthood.  Currently, testicular activin A is not 
thought to have a direct impact on spermatogenesis in rodents.  Although activin is essential for the 
production of FSH by the pituitary gland, the activin that stimulates FSH production comes from the 
pituitary gonadotrophs rather than the testes [154].  In addition, testicular activin A protein levels are 
reported to be much lower in the testes of sexually mature mice compared to newborn mice, suggesting 
activin A may not be a critical regulator of adult testicular function [275, 276].  In adult human testes, 
immunohistochemical studies have implicated Leydig cells as a source of activin A protein and the 
spermatogonia and Sertoli cells as presumptive targets of activins based upon their expression of activin 
receptors [277-278].  While the potential exists for activin A signaling in adult human testes, whether the 
activin A pathway is required for spermatogenesis remains unknown.  Although my analysis has focused 
upon the role of activin A in the somatic cells, activin A has also been implicated in the postnatal 
proliferation and subsequent maturation of murine germ cells during the early postnatal period [275-276].  
The low levels of circulating activin A observed after cessation of germ cell proliferation suggest activin 
A may not play an ongoing signaling role in the testes past fetal and early postnatal life [275].  While the 
precise relationship between circulating and testicular activin A levels has not been established in the 
mouse, serum activin A levels during postnatal development in the rat are typically several-fold higher 
than local testicular levels [279].  Additionally, castration is not known to significantly impact serum 
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activin A levels, indicating the contribution of testicular activin A to circulating levels may be extremely 
small [280].  Indeed, spermatogenesis was able to progress normally in many tubules from Inhba SF1-cre 
cKO and Inhba FLC cKO mice, indicating activin A may not be essential for the progression of 
spermatogenesis.  However, I cannot at this time rule out the potential contribution of activin A from cell 
types not targeted for Inhba deletion in my cKO mouse models.  
 In contrast to the Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO models, I did 
not observe evidence of testicular dysgenesis in fetal Smad4 FLC cKO mice (Chapter 2).  The normal 
appearance of Smad4 FLC cKO testes at birth continued into adulthood.  At 12-16 weeks of age Smad4 
FLC cKO males did not differ from controls with regard to body weight, anogenital distance, seminal 
vesicle weight, testis weight, daily sperm production, sperm concentration, of plasma FSH levels.  In 
addition, I did not detect any differences in testis histology between Smad4 FLC cKO and control male 
mice.  I therefore concluded that expression of Smad4 within the fetal and adult Leydig cells (which also 
express Amhr2 and would therefore lack Smad4 in this mouse model) is not critical for normal testis 
development or function [217].  Given the importance of SMAD4 for canonical TGF! superfamily 
signaling, I was surprised to observe no apparent requirement for Smad4 in the Leydig cells at any stage 
of life.  However, an immunohistochemical time course study of SMAD4 expression in the rat detected 
SMAD4 expression exclusively within the cytoplasm of Leydig cells between 3-90 days of age [281].  
Since transcriptionally active SMAD4 would be anticipated to accumulate in the nucleus, the detection of 
SMAD4 solely in the Leydig cell cytoplasm suggests these cells are not canonically responding to any 
potential TGF! ligands.  Thus, the apparent lack of function of SMAD4 in the Leydig cells of the rat 
mirrors observations in my Smad4 FLC cKO mouse model. 
 
3.5.2:  Disruption of testicular activin A signaling during fetal development creates new murine models of 
testicular dysgenesis 
 In this study, I have presented mouse models that recapitulate what is thought to be the most 
common presentation of testicular dysgenesis in the human population – low sperm count in normally-
masculinized males [238].  I have found Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO 
mice to present with decreased sperm production, abnormal testicular histology and normal-to-elevated 
FSH levels in adulthood.  Interestingly, these cKO mice are normally masculinized as evidenced by the 
proper development of all androgen-sensitive endpoints (Tables 3.1 and 3.4); therefore, the low sperm 
count, elevated FSH levels, and testicular dysgenesis present in these models are not likely to result from 
insufficient androgen production.  Common age-related histological changes in human testes include 
reduced numbers of Sertoli and spermatogenic cells, areas of arrested spermatogenesis and fibrosis, 
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Sertoli cell vacuolization, and multinucleation of spermatogenic cells [282-286].  While I found similar 
histological changes in adult Inhba cKO and Smad4 cKO mice, I did not observe other alterations 
sometimes associated with aging in humans such as decreased seminiferous tubule diameter and 
thickening of the peritubular myoid cell/basal membrane layer surrounding tubules [287-288].   
 Although Inhba cKO and Smad4 Sertoli cKO males display several characteristics common to 
human cases of idiopathic infertility, significant differences in testicular aging exist between man and 
mouse.  In humans, maximum testicular volume has been observed around 25 years of age, with a slight 
but significant decline in testis volume around 80 years of age [289-290].  Interestingly, a direct 
association between testosterone levels and testis size was only observed in aged men, suggesting the 
reduction in testicular volume is not related to decreasing testosterone levels [289, 291].  In contrast to the 
available human data, I did not observe a decline in testis weight with aging in any of my cKO or control 
mouse strains.  Although I did not measure testosterone levels in aged mice in this study, maintenance of 
seminal vesicle weight in all control and cKO males suggests testosterone levels are grossly normal even 
into advanced age.  In humans, there is a well-documented aging-related decline in testosterone 
production; however, there can be a great deal of individual variation [292-299].  It has been suggested 
that approximately 30% of men over the age of 60 years have low serum testosterone levels although 
testosterone production rarely declines to a level that prevents spermatogenesis [300].  As with 
testosterone production, spermatogenic changes in aging human males are variable; however, the majority 
of studies support decreases in semen volume, sperm morphology, and sperm motility while an age-
related decrease in sperm concentration is more tenuous [301-311].  In Inhba cKO and Smad4 Sertoli 
cKO males, I observed a trend of decreasing daily sperm production between young and aged adults; 
however, semen volume, sperm morphology, and sperm motility were not analyzed in these animals.  
Despite some differences in testicular aging between humans and mice, the overall physiological and 
histological similarities between Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO male mice 
and men with idiopathic oligozoospermia suggest these knockout mice could serve as a useful model for 
the study of androgen-sufficient oligozoospermia.  
 
 
 
 
 
 
Table 3.1:  Body weight, anogenital distance, and seminal vesicle weight in 8-16 
week old Inhba SF1-cre cKO, Inhba FLC cKO, Smad4 FLC cKO, and Smad4 Sertoli 
cKO males and their strain-specific controls.  For the given parameters, no statistical 
significance was observed between cKO and strain-specific control mice (p>0.01). 
Genotype n 
Body weight 
(g) 
Anogenital 
distance (mm) 
Seminal 
vesicle weight 
(mg) 
Inhba SF1-cre control 9 29.74 ± 3.35 15.15 ± 1.03 270.26 ± 48.60 
Inhba SF1-cre cKO 10 26.71 ± 1.51 14.99 ± 0.81 258.44 ± 43.67 
Inhba FLC control 4 26.42 ± 0.88 15.03 ± 0.39 206.08 ± 27.34 
Inhba FLC cKO 5 26.06 ± 2.27 14.43 ± 0.80 211.98 ± 23.03 
Smad4 FLC control 7 33.24 ± 5.32 16.05 ± 0.55 356.79 ± 61.95 
Smad4 FLC cKO 7 29.62 ± 4.41 15.49 ± 0.65 344.47 ± 44.50 
Smad4 Sertoli control 10 27.93 ± 2.07 15.27 ± 0.75 307.54 ± 38.46 
Smad4 Sertoli cKO 7 30.33 ± 5.56 15.06 ± 0.71 355.37 ± 95.95 
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Table 3.2:  Testis weight, daily sperm production (DSP), cauda epididymal sperm 
concentration, and plasma FSH levels in 8-16 week old Inhba SF1-cre cKO, Inhba 
FLC cKO, Smad4 FLC cKO, and Smad4 Sertoli cKO males and their strain-specific 
controls.  
Average testis 
weight (mg) 
Average DSP/mg 
testis weight 
(thousands) 
Average sperm 
concentration 
(millions) 
Average plasma 
FSH (ng/mL) 
Inhba SF1-cre 
control 
87.04 ± 10.59 
n=9 
range: 65.1-101.2 
62.07 ± 4.65 
n=9 
range: 54.3-69.2 
14.33 ± 4.32 
n=9 
range: 8.3-21.8 
23.13 ± 4.59 
n=9 
range: 16.5-28.7 
Inhba SF1-cre 
cKO 
33.45 ± 9.60 
n=10 
range: 17.9-48.8 
46.10 ± 11.87 
n=10 
range: 15.7-31.5 
5.26 ± 3.02 
n=9 
range: 2.3-12.3 
33.41 ± 8.44 
n=9 
range: 20.6-44.7 
p-value  
(control vs. cKO) 
p<0.0001 p=0.002 p<0.0001 p=0.006 
Inhba FLC 
control 
98.13 ± 6.81 
n=4 
range: 91.6-107.7 
58.24 ± 7.84 
n=4 
range: 47.8-64.2 
12.70 ± 1.89 
n=4 
range: 11-15.3 
31.44 ± 6.23 
n=3 
range: 27.2-38.6 
Inhba FLC cKO 
67.90 ± 22.04 
n=5 
range: 37.6-96.2 
38.66 ± 9.84 
n=5 
range: 23.7-47.6 
9.04 ± 3.08 
n=5 
range: 6.1-14.2 
34.83 ± 5.83 
n=5 
range: 27.0-40.79  
p-value  
(control vs. cKO) 
p=0.035 p=0.015 p=0.077 p=0.467 
Smad4 FLC 
control 
133.66 ± 18.37 
n=7 
range: 95.9-149.3 
57.41 ± 6.24 
n=7 
Range: 47.8-65.9 
17.16 ± 2.67 
n=7 
range: 12.8-21.2 
17.37 ± 6.60 
n=5 
range: 13.3-28.6 
Smad4 FLC cKO 
134.63 ± 19.77 
n=7 
range: 107.4-164.2 
60.80 ± 7.08 
n=7 
range: 48.0-70.7 
22.19 ± 6.09 
n=7 
range: 13.8-32.6 
17.44 ± 8.35 
n=6 
range: 6.4-27.3 
p-value  
(control vs. cKO) 
p=0.926 p=0.360 p=0.070 p=0.988 
Smad4 Sertoli 
control 
128.28 ± 8.05 
n=10 
range: 114.5-137.5 
57.79 ± 7.21 
n=8 
range: 47.7-67.9 
15.73 ± 4.77 
n=9 
range: 5.9-21.5 
16.58 ± 5.98 
n=10 
range: 8.8-27.0 
Smad4 Sertoli 
cKO 
65.93 ± 8.21 
n=7 
range: 52.3-75.1 
33.64 ± 8.65 
n=7 
range: 23.0-45.2 
13.59 ± 4.22 
n=7 
range: 9.3-22.5 
27.11 ± 4.87 
n=7 
range: 20.7-34.4 
p-value  
(control vs. cKO) 
p<0.0001 p<0.0001 p=0.034 p=0.002 
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Table 3.3:  Breeding studies in adult Inhba FLC cKO, Smad4 Sertoli cell cKO, and 
strain-specific control males.  (A) Average litter size and between-litter interval in 
Inhba FLC cKO and control male mice.  Individual 15-19 week old males were 
housed with a single C57BL6 female for a period of six months; litter size and time 
interval were recorded.  No statistical differences were observed between control and 
Inhba FLC cKO mice for the parameters tested; however, the small sample size (n=2) 
for the control males should be noted.  (B) Number of plugs, number of pregnancies, 
average litter size, and litter size range in Smad4 Sertoli cKO and strain-specific 
control mice.  Individual 20-25 week old males were given a series of female CD-1 
mice in proestrus or estrus.  Plugged females were monitored for pregnancy and the 
number of pups born per litter was recorded.  No statistical differences were observed 
between control and Smad4 Sertoli cKO mice for the parameters tested.   
Total # 
of 
plugs 
Total # 
pregnant 
Average litter 
size            
(n=7 litters) 
Litter 
size 
range 
Control 
(n=4)  10 7 
13.57 ± 3.82 
pups 
10-20 
pups 
Smad4 
Sertoli cKO 
(n=3) 
10 7 
13.14 ± 5.01 
pups 
3-18 
pups 
Average litter size 
Average interval 
between litters 
Control 
(n=2)  
9.89 ± 1.57 pups 42 ± 24.7 days 
Inhba FLC cKO 
(n=4) 
8.77 ± 1.68 pups 29 ± 6.1 days 
A 
B 
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Table 3.4:  Body weight, anogenital distance, and seminal vesicle weight in aged 
(7-12 months) Inhba SF1-cre cKO, Inhba FLC cKO, and Smad4 Sertoli cKO males 
and their strain-specific controls.  For the given parameters, no statistical significance 
was observed between cKO and strain-specific control mice (p>0.01). 
Genotype n 
Body weight 
(g) 
Anogenital 
distance (mm) 
Seminal 
vesicle weight 
(mg) 
Inhba SF1-cre control 4 45.17 ± 6.19 19.42 ± 2.19 467.30 ± 105.67 
Inhba SF1-cre cKO 5 41.75 ± 8.57 17.97 ± 1.22 550.64 ± 224.21 
Inhba FLC control 8 42.90 ± 8.59 17.86 ± 1.06 632.54 ± 382.11 
Inhba FLC cKO 13 41.02 ± 9.57 17.73 ± 1.20 547.75 ± 89.34 
Smad4 Sertoli control 3 45.08 ± 4.47 18.57 ± 0.77 636.27 ± 42.25 
Smad4 Sertoli cKO 2 40.00 ± 0.14 17.16 ± 0.33 496.05 ± 34.86 
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Average testis 
weight (mg) 
Average DSP/mg 
testis weight 
(thousands) 
Average sperm 
concentration 
(millions) 
Average plasma 
FSH (ng/mL) 
Inhba SF1-cre 
control 
100.51 ± 5.07 
n=4 
range: 95.5-107.6 
46.73 ± 22.66 
n=4 
range: 22.5-76.8 
18.18 ± 16.02 
n=4 
range: 9.6-42.2 
37.33 ± 3.25 
n=4 
range: 33.6-41.5 
Inhba SF1-cre 
cKO 
44.54 ± 4.11 
n=5 
range: 38.4-49.8 
24.76 ± 7.25 
n=5 
range: 15.7-31.5 
8.84 ± 4.41 
n=5 
range: 5.3-15.8 
44.75 ± 9.21 
n=5 
range: 33.7-55.0 
p-value  
(control vs. cKO) 
p<0.0001 p=0.077 p<0.247 p=0.172 
Inhba FLC 
control 
124.31 ± 15.99 
n=8 
range: 103.7-146.8 
50.00 ± 6.37 
n=8 
range: 41.1-60.0 
19.66 ± 4.39 
n=8 
range: 15.4-26.3 
28.76 ± 6.74 
n=8 
range: 19.6-37.0 
Inhba FLC cKO 
88.50 ± 18.36 
n=13 
range: 43.6-107.3 
26.41 ± 7.56 
n=12 
range: 16.2-44.5 
13.37 ± 8.18 
n=13 
range: 0-27.1 
40.44 ± 9.97 
n=13 
range: 27.3-65.2  
p-value  
(control vs. cKO) 
p=0.0002 p<0.0001 p=0.061 p=0.009 
Smad4 Sertoli 
control 
127.87 ± 16.20 
n=3 
range: 111.8-144.2 
49.24 ± 4.32 
n=3 
range: 46.4-54.2 
24.87 ± 4.23 
n=3 
range: 19.6-25.4 
29.35 ± 6.30 
n=3 
range: 26.5-34.6 
Smad4 Sertoli 
cKO 
88.55 ± 35.07 
n=2 
range: 63.8-113.4 
25.00 ± 3.01 
n=2 
range: 22.9-27.1 
14.25 ± 5.73 
n=2 
range: 10.2-18.3 
33.57 ± 3.62 
n=2 
range: 31.0-36.1 
p-value  
(control vs. cKO) 
p=0.173* p=0.007* p=0.093* p=0.554* 
Table 3.5:  Testis weight, daily sperm production (DSP), cauda epididymal sperm 
concentration, and plasma FSH levels in aged (7-12 months) Inhba SF1-cre cKO, 
Inhba FLC cKO, and Smad4 Sertoli cKO males and their strain-specific controls.  
Asterisk indicates insufficient sample size for proper statistical analysis; thus values 
are included to provide evidence of a potential trend. 
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Average testis 
weight (mg) 
Average DSP/
mg testis weight 
(thousands) 
Average sperm 
concentration 
(millions) 
Average plasma 
FSH (ng/mL) 
Inhba SF1-cre control  
(12-16 weeks) 
87.04 ± 10.59 
n=9 
62.07 ± 4.65 
n=9 
14.33 ± 4.32 
n=9 
23.13 ± 4.59 
n=9 
Inhba SF1-cre control 
(41 weeks) 
100.51 ± 5.07 
n=4 
46.73 ± 22.66 
n=4 
18.18 ± 16.02 
n=4 
37.33 ± 3.25 
n=4 
p-value  
(young vs. aged) 
p=0.036 p=0.065 p=0.499 p=0.0002 
Inhba SF1-cre cKO 
(12-16 weeks) 
33.45 ± 9.60 
n=10 
46.10 ± 11.87 
n=10 
5.26 ± 3.02 
n=9 
33.41 ± 8.44 
n=9 
Inhba SF1-cre cKO 
(41 weeks) 
44.54 ± 4.11 
n=5 
24.76 ± 7.25 
n=5 
8.84 ± 4.41 
n=5 
44.75 ± 9.21 
n=5  
p-value  
(young vs. aged) 
p=0.030 p=0.003 p=0.124 p=0.038 
Table 3.6:  Comparison of testis weight, daily sperm production (DSP), cauda 
epididymal sperm concentration, and plasma FSH levels in young adult (12-16 weeks) 
and aged adult (41 weeks) Inhba SF1-cre control and cKO male mice. P-values 
represent young versus aged for each genotype. 
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Average testis 
weight (mg) 
Average DSP/
mg testis weight 
(thousands) 
Average sperm 
concentration 
(millions) 
Average plasma 
FSH (ng/mL) 
Inhba FLC control  
(8 weeks) 
98.13 ± 6.81 
n=4 
58.24 ± 7.84 
n=4 
12.70 ± 1.89 
n=4 
31.44 ± 6.23 
n=3 
Inhba FLC control 
(27-51 weeks) 
124.31 ± 15.99 
n=8 
50.00 ± 6.37 
n=8 
19.66 ± 4.39 
n=8 
28.76 ± 6.74 
n=8 
p-value  
(young vs. aged) 
p=0.012 p=0.078 p=0.014 p=0.565 
Inhba FLC cKO 
(8 weeks) 
67.90 ± 22.04 
n=5 
38.66 ± 9.84 
n=5 
13.59 ± 4.22 
n=7 
27.11 ± 4.87 
n=7 
Inhba FLC cKO 
(27-51 weeks) 
88.50 ± 18.36 
n=13 
26.41 ± 7.56 
n=12 
14.25 ± 5.73 
n=2 
33.57 ± 3.62 
n=2 
p-value  
(young vs. aged) 
p=0.060 p=0.014 p=0.858 p=0.131* 
Table 3.7:  Comparison of testis weight, daily sperm production (DSP), cauda 
epididymal sperm concentration, and plasma FSH levels in young adult (8 weeks) and 
aged adult (27-51 weeks) Inhba FLC control and cKO male mice. P-values represent 
young versus aged for each genotype. 
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Table 3.8:  Comparison of testis weight, daily sperm production (DSP), cauda 
epididymal sperm concentration, and plasma FSH levels in young adult (12-14 weeks) 
and aged adult (35-44 weeks) Smad4 Sertoli control and cKO male mice. P-values 
represent young versus aged for each genotype. Asterisk indicates insufficient sample 
size for proper statistical analysis; thus values are included to provide evidence of a 
potential trend. 
Average testis 
weight (mg) 
Average DSP/
mg testis weight 
(thousands) 
Average sperm 
concentration 
(millions) 
Average plasma 
FSH (ng/mL) 
Smad4 Sertoli control  
(12-14 weeks) 
128.28 ± 8.05 
n=10 
57.79 ± 7.21 
n=8 
15.73 ± 4.77 
n=9 
16.58 ± 5.98 
n=10 
Smad4 Sertoli control 
(35-44 weeks) 
127.87 ± 16.20 
n=3 
49.24 ± 4.32 
n=3 
24.87 ± 4.23 
n=3 
31.14 ± 4.18 
n=3 
p-value  
(young vs. aged) 
p=0.956 p=0.091 p=0.015 p=0.003 
Smad4 Sertoli cKO 
(12-14 weeks) 
65.93 ± 8.21 
n=7 
33.64 ± 8.65 
n=7 
9.04 ± 3.08 
n=5 
34.83 ± 5.83 
n=5 
Smad4 Sertoli cKO 
(35-44 weeks) 
88.55 ± 35.07 
n=2 
25.00 ± 3.01 
n=2 
13.37 ± 8.18 
n=2 
40.44 ± 9.97 
n=2 
p-value  
(young vs. aged) 
p=0.107* p=0.225* p=0.273* p=0.259* 
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Figure 3.1:  Testis weight in 8-16 week old control, Inhba cKO, and Smad4 cKO male 
mice.  (A-D) Average testis weight (in milligrams) of young adult Inhba SF1-cre cKO 
(A), Inhba FLC cKO (B), Smad4 FLC cKO (C), and Smad4 Sertoli cell cKO (D) 
males as well as strain-specific controls.  Single asterisk indicates p<0.0001; double 
asterisk indicates p<0.05. 
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Figure 3.2:  Daily sperm production in 8-16 week old control, Inhba cKO, and Smad4 
cKO male mice.  (A-D) Daily sperm production (DSP) per milligram of testis weight 
in young adult Inhba SF1-cre cKO (A), Inhba FLC cKO (B), Smad4 FLC cKO (C), 
and Smad4 Sertoli cell cKO (D) males as well as strain-specific controls.  Single 
asterisk indicates p<0.0001; double asterisk indicates p!0.015. 
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Figure 3.3:  Sperm concentration in 8-16 week old control, Inhba cKO, and Smad4 
cKO male mice.  (A-D) Average cauda epididymal sperm concentration (in millions) 
in young adult Inhba SF1-cre cKO (A), Inhba FLC cKO (B), Smad4 FLC cKO (C), 
and Smad4 Sertoli cell cKO (D) males as well as strain-specific controls. M = 
millions.  Asterisk indicates p<0.0001. 
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Figure 3.4:  Plasma follicle-stimulating hormone (FSH) levels in 8-16 week old 
control, Inhba cKO, and Smad4 cKO male mice.  (A-D) Average plasma FSH 
concentration (ng/mL) in young adult Inhba SF1-cre cKO (A), Inhba FLC cKO (B), 
Smad4 FLC cKO (C), and Smad4 Sertoli cell cKO (D) males as well as strain-specific 
controls.  Asterisk indicates p<0.01. 
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Figure 3.5:  Seminiferous tubule histology in 8-16 week old control, Inhba cKO, and 
Smad4 cKO male mice.  (A-E) H&E-stained histological sections from young adult 
control (A), Inhba SF1-cre cKO (B), Inhba FLC cKO (C), Smad4 FLC cKO (D), and 
Smad4 Sertoli cell cKO (E) testes shown at 10X magnification.  Scale bar = 250µm.   
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Figure 3.6:  Spermatogenesis in 8-16 week old control, Inhba cKO, and Smad4 cKO 
male mice.  (A-E) High magnification (20X) H&E-stained histological sections from 
control (A), Inhba SF1-cre cKO (B), Inhba FLC cKO (C), Smad4 FLC cKO (D), and 
Smad4 Sertoli cell cKO (E) testes reveal areas of normal spermatogenesis.  Focal 
areas of aberrant spermatogenesis are also present in Inhba SF1-cre cKO (F), Inhba 
FLC cKO (G), and Smad4 Sertoli cell cKO (H) testes.  Asterisks indicate dysgenic 
tubules.  Arrowhead indicates area of Leydig cell hyperplasia.  Scale bar = 100µm.   
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Figure 3.7:  Testis size in aged (7-12 months) Inhba cKO and Smad4 cKO mice.  (A-
C) Images of testes from Inhba SF1-cre cKO (A), Inhba FLC cKO (B), Smad4 Sertoli 
cKO (C) males and their strain-specific controls.   
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Figure 3.8:  Testis weight in 7-12 month old control, Inhba cKO, and Smad4 cKO 
male mice.  (A-C) Average testis weight (in milligrams) of aged adult Inhba SF1-cre 
cKO (A), Inhba FLC cKO (B), and Smad4 Sertoli cell cKO (C) males as well as 
strain-specific controls.  Single asterisk indicates p<0.0001; double asterisk indicates 
p<0.0005. 
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Figure 3.9:  Daily sperm production in 7-12 month old control, Inhba cKO, and 
Smad4 cKO male mice.  (A-C) Daily sperm production per milligram of testis weight 
in aged adult Inhba SF1-cre cKO (A), Inhba FLC cKO (B), and Smad4 Sertoli cell 
cKO (C) males as well as strain-specific controls.  Single asterisk indicates p<0.0001; 
double asterisk indicates p<0.008; triple asterisk indicates p<0.08. 
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Figure 3.10:  Sperm concentration in 7-12 month old control, Inhba cKO, and Smad4 
cKO male mice.  (A-c) Average cauda epididymal sperm count in aged adult Inhba 
SF1-cre cKO (A), Inhba FLC cKO (B), and Smad4 Sertoli cell cKO (C) males as well 
as strain-specific controls. 
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Figure 3.11:  Plasma follicle-stimulating hormone (FSH) levels in 7-12 month old 
control, Inhba cKO, and Smad4 cKO male mice.  (A-C) Average FSH concentration 
(ng/mL) in aged adult Inhba SF1-cre cKO (A), Inhba FLC cKO (B), and Smad4 
Sertoli cell cKO (C) males as well as strain-specific controls.  Asterisk indicates 
p<0.01. 
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Figure 3.12:  Seminiferous tubule histology in aged (7-12 month old) control, Inhba 
cKO, and Smad4 cKO male mice.  (A-G) H&E-stained histological sections from 
young adult control (A), Inhba SF1-cre cKO (B,E), Inhba FLC cKO (C,F), and Smad4 
Sertoli cell cKO (D,G) testes shown at 10X magnification.  Asterisks indicate Leydig 
cell hyperplasia.  Arrows indicate severely dysgenic tubules.  Arrowhead indicates 
abnormal cluster of cells within tubule lumen.  Scale bar = 250µm.   
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Figure 3.13:  Spermatogenesis in aged (7-12 month old) control, Inhba cKO, and 
Smad4 cKO male mice.  (A-D) High magnification (20X) H&E-stained histological 
sections from control (A), Inhba SF1-cre cKO (B), Inhba FLC cKO (C), Smad4 
Sertoli cell cKO (D) testes reveal areas of normal spermatogenesis.  Focal areas of 
aberrant spermatogenesis are also present in Inhba SF1-cre cKO (E), Inhba FLC cKO 
(F), and Smad4 Sertoli cell cKO (G) testes.  Asterisks indicate Leydig cell hyperplasia.  
Arrowhead indicates abnormal cluster of cells within tubule lumen.  Scale bar = 
100µm.   
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CHAPTER 4:  TARGETED DELETION OF SMAD4 IN THE STEROIDOGENIC FACTOR 1-
POSITIVE SOMATIC CELLS RESULTS IN FETAL TESTIS CORD DYSGENESIS THAT 
GIVES RISE TO TESTICULAR TUMORS IN ADULTHOOD 
 
 
4.1:  ABSTRACT 
 The testicular activin A pathway is critical for normal murine testicular development, as fetal 
disruption of activin A signaling results in reduced testis size, low sperm count, and testicular dysgenesis 
in adulthood.  Using genetic mouse models, I was able to pinpoint fetal Leydig cells as the primary source 
of testicular activin A.  Identification of the Sertoli cells as the direct targets of fetal Leydig cell-derived 
activin A was achieved using conditional knockout (cKO) mouse models lacking expression of Smad4, 
the central downstream component of canonical transforming growth factor ! (TGF!) superfamily 
signaling, in various cell types within the fetal testes.  Whereas no changes in testis development were 
observed in mice lacking Smad4 expression in the fetal Leydig cells, disruption of Smad4 in Sertoli cells 
recapitulated the testis dysgenesis present in activin A conditional knockout mice during both fetal and 
adult life.  In addition to these Smad4 cKO models, I also produced a mouse model in which Smad4 
expression was disrupted within steroidogenic factor 1- (Sf1-) positive somatic cell precursors early in 
testis development.  By studying testes from these Smad4 SF1-cre cKO mice, I sought to determine the 
role of canonical TGF! superfamily signaling in early Sertoli and fetal Leydig cell differentiation and 
development.  Given the importance of SMAD4 for transduction of canonical signals from a wide variety 
of ligands including activins, TGF!s, bone morphogenetic proteins (BMPs), anti-Müllerian hormone 
(AMH), and growth differentiation factors (GDFs), I hypothesized this early deletion of Smad4 in SF1-
positive somatic cell precursors would result in severe testicular dysgenesis and possibly even gonadal 
agenesis.  Analysis of embryonic Smad4 SF1-cre cKO testes revealed enlargement of testis cord diameter 
and severe defects in testis cord expansion.  These defects were reminiscent of but qualitatively more 
severe than what I observed in Inhba
-/-
, Inhba SF1-cre cKO, Inhba FLC cKO, or Smad4 Sertoli cKO 
mice.  Newborn Smad4 SF1-cre cKO testes also tended to be misshapen and contain visible hemorrhages.  
Young adult (12-16 weeks of age) Smad4 SF1-cre cKO mice had smaller testes but no significant 
differences in sperm production compared to controls.  Histological analysis of young adult testes 
revealed areas of grossly normal spermatogenesis as well as regions of dysgenic tubules characterized by 
vacuolization, loss of spermatogenic cells, and multinucleated spermatogenic cells.  Seminiferous tubule 
diameter in Smad4 SF1-cre cKO males was enlarged compared to controls, similar to observations in my 
Inhba cKO and Smad4 Sertoli cKO models.  Interestingly, Smad4 SF1-cre cKO testes tended to contain 
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extremely large blood vessels compared to controls; in addition, the seminiferous tubules immediately 
adjacent to the blood vessels tended to be highly dysgenic.  Interstitial cells in dysgenic regions appeared 
disorganized and areas of Leydig cell hyperplasia were evident in Smad4 SF1-cre cKO males.  Taken 
together, the testicular dysgenesis I observed in Smad4 SF1-cre cKO males at 12-16 weeks of age was 
generally more pervasive and severe than in Inhba cKO or Smad4 Sertoli cKO males of similar age.  I 
therefore chose to analyze Smad4 SF1-cre cKO males in advanced age (56-62 weeks) to see whether 
degeneration of the seminiferous tubules would become more severe over time.  Surprisingly, testes from 
aged Smad4 SF1-cre cKO males contained red, yellow, and white tumors on their surface.  Upon 
sectioning, I found the tumors to be large regions of partially-resolved hemorrhage encapsulated in 
fibrous tissue.  Very little tissue identifiable as seminiferous tubules remained in aged Smad4 SF1-cre 
cKO testes, and the tubules that persisted were devoid of spermatogenic cells.  Not surprisingly, Smad4 
SF1-cre testes did not produce any sperm as determined via daily sperm production (DSP) and cauda 
epididymal sperm concentration analyses.  Leydig cell adenomas occupied the majority of interstitial 
space between degenerated tubules.  In addition, blood vessels in Smad4 SF1-cre cKO testes displayed a 
rounding and disorganization of the endothelium, suggesting blood vessel leakiness may have been a 
contributing factor in hemorrhage development.  Thus, the testicular dysgenesis present at 12-16 weeks 
becomes dramatically more severe in 56-62 week old Smad4 SF1-cre cKO males.  Further 
characterization of this model might provide novel insights into the role of blood vessels during testis 
development and function. 
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4.2:  INTRODUCTION 
In Chapter 2, I presented novel evidence that fetal Leydig cell-derived activin A is a critical 
regulator of Sertoli cell proliferation during murine testis morphogenesis.  In the absence of activin A 
signaling, the fetal testis cords fail to undergo convolution and expansion as a result of insufficient Sertoli 
cell proliferation.  Disruption of Smad4, the central component of TGF! superfamily signaling, in Sertoli 
cells recapitulated the fetal testis cord dysgenesis present in mouse models lacking fetal Leydig cell 
production of activin A, thus confirming the Sertoli cells are direct targets of activin A protein.  The fetal 
Leydig cells themselves do not appear to be a target of the canonical signaling of activin A or any other 
TGF! superfamily ligand as deletion of Smad4 in the fetal Leydig cells did not alter testicular histology 
or function at any timepoint analyzed.  The transforming growth factor ! (TGF!) superfamily of growth 
factors regulate a host of cellular processes throughout both fetal and adult life, ranging from axis 
formation, tissue patterning, gastrulation and specification of left-right asymmetry to the modulation of 
diseases ranging from pulmonary arterial hypertension to hereditary hemorrhagic telangiectasia (HHT) to 
cancer [312-315].  Thus far, two different canonical SMAD pathways have been identified which can be 
activated by TGF! superfamily ligands.  The identity of the ligand determines which SMAD pathway is 
utilized by the target cell; specifically, activins and TGF!s activate SMAD2 and SMAD3 receptor 
SMADS, whereas bone morphogenetic proteins (BMPs) activate SMADs 1, 5, and 8 [316].  In canonical 
TGF! superfamily signaling, SMAD4 serves as the central component of the pathway, binding to either 
set of receptor SMADs, escorting the receptor SMADs into the nucleus, and eliciting changes in gene 
transcription [212].  Since SMAD4 is the central regulator of canonical TGF! superfamily signaling, I 
hypothesized that disruption of Smad4 expression early in Sertoli and fetal Leydig cell development 
might lead to severe testicular dysgenesis and possibly complete degeneration of the gonads.  
Furthermore, I postulated that given the potential for crosstalk between the two cell populations, 
concurrent loss of Smad4 expression in Sertoli and fetal Leydig cells might uncover a role for Smad4 
during fetal Leydig cell development that could not be ascertained from study of the Smad4 FLC cKO 
mouse model alone. 
 
 
4.3:  MATERIALS AND METHODS 
4.3.1:  Generation of Sf1
cre/+
;Smad4
fl/-
 conditional knockout (cKO) mice 
To produce Sf1
cre/+
;Smad4
fl/-
 cKO mice, Smad4
+/-
 mice (derived as described in Chapter 1.3.1) were bred 
to Sf1
cre/+
 transgenic mice [206].  The resulting Sf1
cre/+
’Smad4
+/-
 males were then mated to Smad4
fl/fl
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females [208].  Timed matings were produced by housing female mice with males overnight and checking 
for vaginal plugs the next morning (E0.5 = noon of the day when a vaginal plug was found).  Fetal tissue 
was collected from E12.5-E19.5. For fetal and adult analyses, no differences were observed between 
Sf1
cre/+
;Smad4
+/fl
 and Smad4
fl/-
 control genotypes so both were included as controls.  Genotyping of 
Sf1
cre/+
;Smad4
+/fl
 control and Sf1
cre/+
;Smad4
fl/-
 cKO mice embryos was performed using the procedures 
described in Chapter 2.3.1.  For animals intended for adult analysis, male pups were genotyped via tail or 
ear tissue biopsy at 10-12 days of age and genotyping carried out following the protocols detailed in 
Chapter 2.3.1.  For adult mice, a postmortem tail biopsy was collected and genotyping procedures 
repeated to confirm pre-weaning genotyping results.  All procedures described were reviewed and 
approved by the Institutional Animal Care and Use Committee, and were performed in accordance with 
the Guiding Principles for the Care and Use of Laboratory Animals. 
 
4.3.2:  Immunohistochemistry and histology of murine testes 
 Immunohistochemistry and histology of fetal testes was performed as described in Chapter 2.3.2 
and Chapter 2.3.3.  Histological processing of adult testes was carried out as detailed in Chapter 3.3.2. 
 
4.3.3.  Histology of adult murine epididymides 
 Adult epididymides were fixed overnight for not more than 15 hours in 4% paraformaldehyde in 
PBS at 4°C (see Chapter 2.3.2 for reagent details).  After fixation, epididymides were washed three times 
for 15 minutes each in PBS with shaking at room temperature.  Samples were then stored in PBS at 4°C.  
For histological processing, epididymides were dehydrated through an ethanol gradient followed by 
immersion in Histo-Clear  (National Diagnostics, Atlanta, GA).  Epididymides were then embedded in 
paraffin wax and sectioned at 5 µm thick.  Sections were stained for 3 minutes with Richard-Allan 
hematoxylin (Thermo Fisher Scientific, Waltham, MA) and 30 seconds with Surgipath eosin (Surgipath 
Medical Industries, Richmond, IL).  Slides were mounted with Permount mounting medium (Fisher 
Scientific, Pittsburgh, PA) diluted 50% with xylene. 
 
4.3.4:  Computer-assisted sperm analysis (CASA)  
 CASA was performed as described in Chapter 3.3.3. 
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4.3.5:  Evaluation of daily sperm production (DSP) 
 Determination of DSP was conducted as detailed in Chapter 3.3.4. 
 
4.3.6:  Hormone analysis 
 Measurement of plasma follicle-stimulating hormone (FSH) was carried out as described in 
Chapter 3.3.6.  The intra-assay coefficient of variation (CV) for the FSH radioimmunoassay (RIA) was 
1.22%. 
 
4.3.7:  Statistical analysis 
 Statistical differences were determined via two-tailed t-test comparisons. 
 
 
4.4:  RESULTS 
4.4.1:  Inactivation of Smad4 in SF1-positive somatic cells of murine fetal testes results in 
underdevelopment of the testis cords 
  To investigate the requirement for Smad4 in somatic cells of the fetal testis, I utilized the 
Smad4
fl/fl
 and Sf1
cre/+
 mouse lines described in Chapters 2 and 3 to produce a conditional knockout mouse 
line in which Smad4 is removed specifically from cells expressing SF1 (hereafter referred to as Smad4 
SF1-cre cKO) [206, 208].  Within the fetal testes, SF1 is initially expressed by somatic cell precursors 
and following testis differentiation can be found within Sertoli and fetal Leydig cells [318-319].  In 
addition to its expression in the testes, the Sf1/Cre transgene is also found in the adrenal cortex, anterior 
pituitary, spleen, and the ventromedial hypothalamus [206]. 
 Upon initial collection of newborn (E19.5) Smad4 SF1-cre cKO pups, I was struck by the unusual 
appearance of their testes (Fig. 4.1).  Whereas light microscopy of control testes revealed a “honeycomb” 
pattern indicative of normal testis cord coiling (Fig. 4.1A), testis cords in Smad4 SF1-cre cKO testes had 
amore of a “striped” appearance suggestive of reduced testis cord coiling (Fig. 4.1B-D).  Even more 
intriguing than the apparent underdevelopment of the testis cords was the observation of large red 
hemorrhagic patches in approximately 80% of newborn Smad4 SF1-cre cKO testes (arrowheads in Fig. 
4.1C-1D).  In addition, Smad4 SF1-cre cKO testes often deviated from the typical oval shape, exhibiting 
dented areas (arrow in Fig. 4.1C) or pointed poles (arrow in Fig. 4.1D).  Histological analysis of E19.5 
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Smad4 SF1-cre cKO testes (Fig. 4.2F) revealed fewer, but larger, testis cord cross-sections compared to 
control testes (Fig. 4.2E).  To determine the timing of the onset of testis cord dysgenesis, I performed a 
time course analysis of testis cord loop development by staining transverse testis sections with an 
antibody specific to laminin.  The laminin staining outlined the boundaries of the testis cords and allowed 
me to visually determine the shape of the testis cords.  I did not observe appreciable differences between 
control (Fig. 4.2A) and cKO (Fig. 4.2B) testes at E15.5, the timepoint I previously established as 
immediately prior to the onset of testis cord coiling (Chapter 2).  In both control and Smad4 SF1-cre cKO 
embryos, testis cords had a roughly circular appearance indicating coiling had not yet begun.  By the time 
of birth (E19.5), the testis cords of control testes had undergone elongation and coiling, revealing many 
small oval and circular testis cord cross-sections (Fig. 4.1C).  In contrast, Smad4 SF1-cre cKO testes 
showed severe underdevelopment of the testis cords, with very little discernible coiling or convolution 
(Fig. 4.1D).  The testis cord phenotype in Smad4 SF1-cre cKO embryos was reminiscent of those I 
observed in my mouse models with either disruption of fetal Leydig cell expression of activin A (Inhba
-/-
, 
Inhba SF1-cre cKO, Inhba FLC cKO) or Sertoli cell expression of Smad4 (data presented in Chapter 2).  
However, the severity of testis cord dysgenesis in Smad4 SF1-cre cKO appeared more severe than in my 
other models with altered testicular activin A signaling. 
 
4.4.2: Smad4 SF1-cre cKO male mice have reductions in testis size and function in adulthood 
 Given the severe lack of testis cord coiling, presence of hemorrhagic regions, and abnormal shape 
of Smad4 SF1-cre cKO fetal testes I was curious whether these deficits would resolve or worsen during 
postnatal development.  Fortunately, despite inactivation of Smad4 expression in a host of SF1-positive 
tissues including the adrenal cortex, anterior pituitary, spleen, and ventromedial hypothalamus, Smad4 
SF1-cre cKO were viable and appeared generally healthy.  I analyzed Smad4 SF1-cre cKO and strain-
specific control mice as young adults (12-16 weeks of age) as well as in advanced age (56-62 weeks).  At 
both ages, body weight did not significantly differ between control (young = 31.58 ± 5.39 grams, n=6; 
aged = 48.60 ± 8.98 grams, n=6) and Smad4 SF1-cre cKO males (young = 29.62 ± 3.40 grams, n=5; aged 
= 49.70 ± 6.08 grams, n=4) (Table 4.1).  Anogenital distance was not different between young control and 
Smad4 SF1-cre cKO males (15.89 ± 1.03 mm for control, n=6; 15.91 ± 0.30 mm for cKO, n=5); however, 
anogenital distance was significantly increased in aged Smad4 SF1-cre cKO males (20.01 ± 0.71 mm, 
n=4) compared to aged controls (17.60 ± 1.18 mm, n=6, p=0.007) (Table 4.1).  As with body weight, 
seminal vesicle weight did not significantly differ in young cKO males (300.14 ± 31.59 mg, n=5) 
compared to controls (304.05 ± 77.33 mg, n=6).  Differences in seminal vesicle weight were also not 
observed in aged Smad4 SF1-cre cKO mice (1045.58 ± 814.78 mg, n=4) versus controls (1603.77 ± 
87 
943.01 mg, n=6) (Table 4.1).  The presence of normal anogenital distance and seminal vesicle weight in 
adult Smad4 SF1-cre cKO indicated androgen production was adequate to allow for normal development 
of these highly androgen-sensitive endpoints [256-258, 320]. 
 I measured testis weight and observed a highly significant reduction in average testis weight in 
12-16 week old Smad4 SF1-cre cKO males (22.65 ± 9.32 mg, n=5) compared to controls (84.58 ± 24.00 
mg, n=6, p<0.0001) (Fig. 4.3A).  Testis weight remained significantly reduced in 56-62 week old Smad4 
SF1-cre cKO mice (27.11 ± 18.56 mg, n=4) compared to age-matched control males (102.44 ± 17.70 mg, 
n=6, p<0.0001) (Fig. 4.3B).  I next evaluated daily sperm production (DSP) by counting the number of 
homogenate-resistant elongated spermatid heads in testis homogenate.  To account for the dramatic 
difference in testis size between Smad4 SF1-cre cKO and control males, I determined DSP per milligram 
of testis weight rather than per testis.  DSP per milligram of testis weight did not significantly differ 
between 12-16 week old control (35,222.66 ± 16,153.88 sperm, n=6) and Smad4 SF1-cre cKO mice 
(19,078.14 ± 21,075.58 sperm, n=5) (Fig. 4.4A).  Surprisingly, I could not detect any sperm in testis 
homogenate from 56-62 week old Smad4 SF1-cre cKO males (Fig. 4.4B); therefore, DSP per milligram 
testis weight was significantly higher in control mice (58,885.17 ± 21,266.62 sperm, n=6) compared to 
cKO males (0.00 ± 0.00 sperm, n=3, p<0.0001).  I observed similar trends in cauda epididymal sperm 
concentration; specifically, sperm concentration in young Smad4 SF1-cre cKO mice (6.47 ± 4.57 million 
sperm, n=3) did not statistically differ from that of controls (10.47 ± 6.78 million sperm, n=6) (Fig. 4.5A).  
However, I could not detect any sperm within the cauda epididymides of aged Smad4 SF1-cre cKO males 
(n=3).  As would be expected, cauda epididymal sperm concentration was significantly higher in control 
males (13.55 ± 4.34 million sperm, n=6, p<0.0001) based upon the complete absence of sperm in cKO 
males (Fig. 4.5B). 
 Intrigued by the lack of sperm in aged Smad4 SF1-cre cKO testes, I next analyzed plasma 
follicle-stimulating hormone (FSH) levels in cKO and control mice since FSH is an important regulator of 
spermatogenesis [227, 259-262].  FSH levels were measured via radioimmunoassay by Sam Marion and 
Dr. Patricia Hoyer at the University of Arizona (Fig. 4.6).  At 12-16 weeks of age, plasma FSH levels did 
not significantly differ between Smad4 SF1-cre cKO mice (20.13 ± 9.51 ng/mL, n=4) and age-matched 
control males (29.35 ± 6.30 ng/mL, n=7, p=0.099).  A significant reduction in plasma FSH levels was, 
however, evident in 56-62 week old Smad4 SF1-cre cKO males (16.48 ± 1.44 ng/mL, n=4) compared to 
controls (24.42 ± 5.13 ng/mL, n=7, p=0.016). 
 In comparing data from young and aged Smad4 SF1-cre cKO males, there were no significant 
differences in average testis weight (22.65 ± 9.32 mg, n=5 for young males; 27.11 ± 18.56 mg, n=4 for 
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aged males; p=0.650), average DSP per milligram testis weight (19,078.14 ± 21,075.58 sperm, n=5 for 
young males; 0.00 ± 0.00 sperm, n=3 for aged males; p=0.180), average sperm concentration (6.47 ± 4.57 
million sperm, n=3 for young males; 0.00 ± 0.00 million sperm, n=3 for aged males; p=0.071), or average 
plasma FSH levels (20.13 ± 9.51 ng/mL, n=4 for young males; 16.48 ± 1.44 ng/mL, n=4 for aged males; 
p=0.477) between the two age groups (Table 4.2).  Similarly, average values were similar in 12-16 week 
old and 56-62 week old control males with regard to testis weight (84.58 ± 24.00 mg, n=6 for young 
males; 102.44 ± 17.70 mg, n=6 for aged males; p=0.181), DSP per milligram testis weight (35,222.66 ± 
16,153.88 sperm, n=6 for young males; 58,885.17 ± 21,266.62 sperm, n=6 for aged males; p=0.055), 
cauda epididymal sperm concentration (10.47 ± 6.78 million sperm, n=6 for young males; 13.55 ± 4.34 
million sperm, n=6 for aged males; p=0.370), and plasma FSH levels (29.35 ± 6.30 ng/mL, n=7 for young 
males; 24.42 ± 5.13 ng/mL, n=7 for aged males; p=0.158) (Table 4.2).  Thus, from a statistical standpoint 
there were no discernible age-related changes in testicular size or function in control and Smad4 SF1-cre 
cKO mice.  However, the complete absence of sperm in testes of aged Smad4 SF1-cre cKO contradicted 
this result. 
 
4.4.3: Smad4 SF1-cre cKO males exhibit progressive degeneration of normal testicular structure 
 Although plasma FSH levels were significantly lower in aged Smad4 SF1-cre cKO males 
compared to age-matched controls, it seemed unlikely to be the main reason for the lack of sperm 
production in aged cKO mice.  To better understand the complete absence of sperm output in aged Smad4 
SF1-cre cKO, I decided to evaluate testis histology in cKO and control males.  Prior to histological 
analysis, I examined testes from young and aged adult Smad4 SF1-cre cKO and control testes under light 
microscopy (Fig. 4.7).  At 12-16 weeks of age, Smad4 SF1-cre cKO testes were appreciably smaller than 
control testes but appeared otherwise externally normal (Fig. 4.7A).  I did not observe any signs of the 
hemorrhagic patches that were visible in newborn Smad4 SF1-cre cKO testes (Fig. 4.1).  In viewing testes 
from 56-62 week old males, it was immediately apparent that Smad4 SF1-cre cKO were highly abnormal 
by this age (Fig. 4.7B-F).  Out of four aged Smad4 SF1-cre cKO males, seven of the eight testes I 
collected had lumpy red, white, or yellow growths visible on their surface (Fig. 4.7C-F).  The single cKO 
testis that did not contain these tumors was extremely small but had a highly-vascularized surface (see 
blood vessels visible on testis in Fig. 4.7B).  Interestingly, despite the dramatic reduction in testis size 
compared to controls, Smad4 SF1-cre cKO epididymides were roughly the same size as those of control 
males (Fig. 4.7B).  Despite the tumor-like growths adding substantial mass to 56-62 week old Smad4 
SF1-cre cKO testes, they remained obviously smaller than control testes (Fig. 4.7C). 
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 Histological analysis of 12-16 week old Smad4 SF1-cre cKO testes revealed the presence of two 
main regions within the testes showing very different histology (Fig. 4.8).  In areas of Smad4 SF1-cre 
cKO testes still undergoing spermatogenesis, seminiferous tubule diameter was obviously enlarged (Fig. 
4.8B-C) compared to control testes at the same magnification (Fig. 4.8A).  However, Smad4 SF1-cre cKO 
testes also contained areas of dysgenic tubules that were no longer carrying out spermatogenesis (Fig. 
4.8D-E).  Under higher magnification, I was able to locate tubules undergoing some degree of 
spermatogenesis (Fig. 4.9B-C) as well as a variety of abnormal tubules characterized by vacuolization 
(Fig. 4.9C, 4.9E-F, 4.9H), loss of spermatogenic cells (Fig. 9C, 9E-H), and multinucleated spermatogenic 
cells (Fig. 4.9G), defects not observed in age-matched controls (Fig. 4.9A, 4.9D).  The cKO images 
shown in Fig. 4.9B-C, 4.9E-F, and 4.9G-H represent testes from three different individual animals.  In 
addition to the tubular defects, the interstitium surrounding the dysgenic areas in Smad4 SF1-cre cKO 
testes appeared disorganized and contained hyperplastic Leydig cells (Fig. 4.9C, 4.9E, 4.9G-H).  Another 
notable feature of 12-16 week old Smad4 SF1-cre cKO testes was the presence of unusually large blood 
vessels (Fig. 4.10).  Compared to the blood vessels found among the seminiferous tubules in control 
males (Fig. 4.10A, 4.10C), blood vessels in Smad4 SF1-cre cKO testes were often several times larger in 
diameter and tended to be surrounded by dysgenic tubules (Fig. 4.10B, 4.10D). 
 In addition to my analysis of testis histology in young adult Smad4 SF1-cre cKO and control 
males, I also evaluated epididymal histology in 10 week old males of both genotypes (Fig. 4.11).  In 
control males, numerous sperm could be seen in epithelial cross-sections of the entire epididymis – caput 
(Fig. 4.11A), corpus (Fig. 4.11C), and cauda (Fig. 4.11E) – as well as in the vas deferens (Fig. 4.11G).  In 
epididymides from Smad4 SF1-cre cKO male mice, far fewer sperm are evident in the caput epididymis 
(Fig. 4.11B) and sperm become much more scarce through the corpus (Fig. 4.11D) and cauda (Fig. 4.11F) 
regions.  In fact, the luminal contents of the cauda epididymis (Fig. 4.11F) and vas deferens (Fig. 4.11H) 
are largely devoid of sperm and appear to consist largely of eosinophilc cellular debris. 
 My histological analysis of 12-16 week old Smad4 SF1-cre cKO testes indicates regional 
degeneration of normal testicular architecture is already occurring in young adult cKO mice; however, 
light microscopic analysis of aged testes suggests dramatic alteration of testis tissue must occur by 56-62 
months of age (Fig. 4.7).  I thus examined histological sections from aged Smad4 SF1-cre cKO and 
control males (Fig. 4.12).  Interestingly, the lone tumor-free Smad4 SF1-cre cKO testis (Fig. 4.7B), 
arguably the most “normal” testis from the aged cKO males, was found to contain widespread tubule 
dysgenesis and complete interstitial disorganization (Fig. 4.12A).  Among Smad4 SF1-cre cKO testes 
with outwardly visible tumor-like growths, histology was generally quite similar; specifically, these testes 
consisted of a large, encapsulated hemorrhagic region with a thin crescent of degenerated seminiferous 
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tubules at the periphery (Fig. 4.12B-E).  The hemorrhagic areas were determined not to be acute due to 
the extensive fibrosis surrounding the regions as well as signs of revascularization (arrows in Fig. 4.12B-
E)..  I next looked at seminiferous tubule histology in Smad4 SF1-cre cKO and control aged testes (Fig. 
4.13).  Despite being over one year of age, the testes of control males contained spermatogenically-active 
tubules displaying normal histology (Fig. 4.13A).  In contrast, spermatogenesis was completely absent 
from tubules of Smad4 SF1-cre cKO testes (Fig. 4.13B-C, 4.13D-E).  In the single testis that did not 
contain visible tumors, Sertoli cells and virtually all remaining germ cells were sloughed off into the 
seminiferous tubule lumen (Fig. 4.13B-C).  In addition to widespread vacuolization of the Sertoli cell 
epithelium, eosinophilic fluid was apparent within the interstitial compartment as well as within 
individual seminiferous tubule cross-sections (Fig. 4.13B-C).  In Smad4 SF1-cre cKO testes containing 
tumors, the residual seminiferous tubule tissue was completely degenerated (Fig. 4.13D-E).  
Spermatogenic cells were almost completely absent, and the remaining Sertoli cells were clumped within 
the luminal areas of the seminiferous tubules (Fig. 4.13D).  In some cases, areas that may have once been 
occupied by seminiferous tubules were instead filled with an overgrowth of somatic cells, most likely 
Leydig cells (Fig. 4.13E, Fig. 4.14F).  Higher magnification views of seminiferous tubules in Smad4 SF1-
cre cKO and control testes further confirmed the lack of spermatogenic cells in aged cKO testes (Fig. 
4.14B-C, 4.14E-F).  The interstitial regions of Smad4 SF1-cre cKO testes were visibly disorganized as 
well compared to controls (Fig. 4.14A, 4.14D). 
 To better understand the testicular pathology in my Smad4 SF1-cre cKO testes, I consulted with 
Dr. Susan Ball-Kell, a DVM/PhD pathologist at the University of Illinois at Urbana-Champaign College 
of Veterinary Medicine Veterinary Diagnostic Laboratory.  Dr. Ball-Kell thought it is likely that the 
seminiferous tubule dysgenesis and the presence of large hemorrhagic regions in cKO testes resulted from 
separate phenomena occurring during testicular aging.  Since seminiferous tubule degeneration is already 
occurring at 12-16 weeks of age in Smad4 SF1-cre cKO testes, with no obvious signs of blood seepage at 
this stage, she proposed it was likely that tubule dysgenesis precedes blood leakage.  However, the 
presence of hemorrhagic areas in fetal Smad4 SF1-cre cKO testes and of dramatically enlarged testicular 
blood vessels in 12-16 week old cKO testes supports an ongoing problem with the testis vasculature.  She 
therefore closely examined blood vessels in control and Smad4 SF1-cre cKO aged testes (Fig. 4.15).  In 
control testes, the endothelial cells comprising the vessel walls laid in a smooth, flat pattern around the 
vessel (Fig. 4.15A, 4.15C).  In addition, seminiferous tubules were often found in close proximity to the 
testicular blood vessels.  In examining blood vessels in the single non-tumorous aged testis, we noticed 
the cells comprising the vessel walls were rounded and disorganized, suggesting the vessel could 
potentially be leaky (Fig. 4.15B, 4.15C).  While this abnormal appearance of the vessel walls was also 
observed in blood vessels within Smad4 SF1-cre cKO testes containing hemorrhagic tumors, the lone 
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non-tumor testis had an additional interesting feature.  The peripheral blood vessels in the non-tumor 
testis had been surrounded by a network of loose connective tissue that served to keep them separate from 
the main testis “body” containing the seminiferous tubules (Fig. 4.15B, 4.15D; compare to Fig. 4.15A, 
4.15C where the blood vessel is in close contact with seminiferous tubules).  Dr. Ball-Kell reasoned this 
“cordoning off” of the potentially leaky blood vessels might explain why this single testis did not develop 
the hemorrhagic damage observed in the other 7 Smad4 SF1-cre cKO testes. 
 In addition to the hemorrhagic lesions, degeneration of the seminiferous tubules, and increase in 
blood vessel leakiness, what little identifiable testicular tissue remained in 56-62 week old Smad4 SF1-cre 
cKO often consisted of Leydig cell hyperplasia and Leydig cells adenomas (Fig. 4.16).  Both low (Fig. 
4.16A-B) and high magnification images (Fig. 4.16C-D) reveal areas of Smad4 SF1-cre cKO testes 
consisting almost exclusively of Leydig cells.  Leydig cells in Smad4 SF1-cre cKO testes were observed 
to be clustering up and forming basement membranes around themselves, thus forming Leydig cell 
adenomas.  In addition, occasional multinucleated Leydig cells could be observed, suggesting 
transformation and/or dedifferentiation of some Leydig cells may be occurring in Smad4 SF1-cre cKO 
testes (arrowheads in Fig. 4.16C-D).  Although multinucleated Leydig cells are present at low levels in 
aged human testes, there is little data regarding their occurrence in rodents [321-323]. 
 By far the most unusual finding in aged Smad4 SF1-cre cKO mice was the identification of a 
teratoma in one of the 5 Smad4 SF1-cre cKO testes analyzed (Fig. 4.17).  At low magnification, the 
teratoma is visible as blue, hematoxylin-enriched regions near the center of one of the hemorrhagic 
lesions (Fig. 4.17A).  Higher magnifications of various histological sections confirm the teratoma is 
located within the fibrous capsule of the hemorrhage, compartmentally distinct from the remaining 
testicular tissue (Fig. 4.17B-D).  Under high magnification, osteoblasts and chrondrocytes are visible 
within the abnormal region, confirming it is either a teratoma or the result of abnormal activation of a 
mesenchymal stem cell (Fig. 4.17E-F) [324-327].  Considering I only observed this phenomenon in one 
out of 5 testes analyzed for histology (the remainder were used for daily sperm production analysis), it is 
difficult to interpret the significance of this finding.  It is possible that I may have observed teratomas in 
other aged Smad4 SF1-cre cKO males if I had allowed more time to pass prior to collecting them.  It is 
also possible that the presence of a teratoma in this individual testis was a one-time development that 
would be difficult to replicate. 
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4.5:  DISCUSSION 
4.5.1:  Smad4 SF1-cre cKO mice develop fetal testis dysgenesis that progresses to cessation of 
spermatogenesis as well as tumorigenesis in adulthood 
 Testes from Smad4 SF1-cre cKO male mice differed substantially from control testes at all 
stages analyzed.  At newborn stage, Smad4 SF1-cre cKO testes were often misshapen and had visible 
hemorrhages (Fig. 4.1).  Analysis of testis cord loop development revealed a severe retardation of testis 
cord coiling and elongation (Fig. 4.2).  This underdevelopment of the fetal testis cords gave way to 
significantly reduced testis size and a trend of decreasing sperm production in young adult cKO males 
compared to controls (Fig. 4.3-4.5).  Even at 12-16 weeks, signs of cessation of spermatogenesis as well 
as disorganization/hyperplasia of the interstitial compartment are visible in Smad4 SF1-cre cKO testes; 
however, there are still tubules undergoing normal spermatogenesis at this age (Fig. 4.8).  By one year of 
age, the gonads of male Smad4 SF1-cre cKO mice are barely recognizable as testes due to the assortment 
of visible tumors (Fig. 4.7).  Histological analysis of cKO testes revealed an unusual and perplexing 
hemorrhagic disorder in which the majority of the testis is occupied by chronic hemorrhaged tissue 
surrounded by a fibrous capsule (Fig. 4.12).  The relatively small number of residual seminiferous tubules 
that are still visible in aged Smad4 SF1-cre cKO testes are completely lacking spermatogenic cells; in 
addition, the Sertoli cells of many of these tubules have detached from the basement membrane and are 
clumped within the tubule lumen (Fig. 4.14).  Not surprisingly, aged cKO mice do not produce any 
sperm.  Androgen production in these highly dysgenic Smad4 SF1-cre cKO testes is sufficient to maintain 
androgen-sensitive organs such as the seminal vesicles, likely due to the extensive Leydig cell hyperplasia 
in these cKO testes (Fig. 4.16).  I observed Leydig cell adenomas in 100% of Smad4 SF1-cre cKO males 
at 13-16 months of age; in contrast, the spontaneous incidence of Leydig cell adenomas in mice greater 
than 18 months of age is reported at 0.7-1.2% depending upon the background strain [328-329]. 
  
4.5.2:  Smad4 SF1-cre cKO mice exhibit more severe testicular dysgenesis than other Smad4 cKO mice at 
all ages analyzed 
 In Chapters 2 and 3, I presented data from my fetal and adult studies of various Inhba and 
Smad4 conditional knockout mice.  In general, I found strong similarities in both fetal and adult testicular 
phenotypes in mice lacking Inhba  expression in the fetal Leydig cell and Sertoli cells simultaneously 
(Inhba SF1-cre cKO), lacking Inhba expression in the fetal Leydig cells only (Inhba FLC cKO), or 
lacking Smad4 expression in the Sertoli cells only (Smad4 Sertoli cKO).  In all three mouse models, 
decreased fetal Sertoli cell proliferation resulted in failures of testis cord coiling and expansion 
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(summarized in Table 4.3).  This coiling deficit could not be completely overcome by postnatal Sertoli 
cell proliferation and thus manifested as increased seminiferous tubule diameter in adulthood.  In both 
Inhba cKO males as well as Smad4 Sertoli cKO males, testis size and sperm production were reduced in 
adulthood while plasma FSH tended to be elevated.  While the phenotypes I observed in Inhba cKO and 
Smad4 Sertoli cKO mice was not entirely identical, the nature and extent of testicular dysgenesis was 
similar enough over a variety of timepoints to allow me to conclude that disruption of fetal Leydig cell-
derived activin A signaling upon fetal Sertoli cells has lifelong consequences in my mouse models. 
 During embryogenesis, the testis defects present in Smad4 SF1-cre cKO males are reminiscent 
of, but more severe, than those of Inhba cKO or Smad4 Sertoli cKO mice.  Specifically, the 
underdevelopment of the fetal testis cords observed in Smad4 SF1-cre cKO is on the more severe end of 
what I typically observed in my other cKO models of testicular dysgenesis.  In addition, I did not find 
blatantly misshapen testes or large hemorrhagic patches in newborn Inhba SF1-cre cKO, Inhba FLC cKO, 
or Smad4 Sertoli cKO testes.  With regard to analysis of young adult cKO males, Smad4 SF1-cre cKO 
had the smallest testes of any of my mouse models.  They were also the only model with a tendency 
towards decreased, rather than increased, plasma FSH levels.  In terms of testicular histology, enlarged 
seminiferous tubule diameter and seemingly hyperplastic interstitial regions were characteristic of Inhba 
SF1-cre cKO, Inhba FLC cKO, Smad4 Sertoli cKO, and Smad4 SF1-cre cKO testes.  However, whereas 
the first three models mentioned had focal dysgenic tubules, dysgenesis was widespread in Smad4 SF1-
cre cKO testes (Fig. 4.8).  In addition, the testis interstitium of Smad4 SF1-cre cKO  mice appeared more 
disorganized and histologically abnormal than I observed in Inhba cKO or Smad4 Sertoli cKO testes.  
The overall testicular dysgenesis in young adult Smad4 SF1-cre cKO was also more severe than the 
defects found in aged testes from my other cKO strains.  Clearly, the complete degeneration of 
seminiferous tubule tissue and development of tumor-like hemorrhages in aged Smad4 SF1-cre cKO 
testes differs substantially from the focal loss of spermatogenesis I observe in aged Inhba SF1-cre cKO, 
Inhba FLC cKO, and Smad4 Sertoli cKO testes. 
 Although I cannot conclusively determine why the testicular dysgenesis phenotype was more 
severe in Smad4 SF1-cre cKO male mice than in my other models with disrupted testicular activin A 
signaling, there are a few probable scenarios.  The three main differences among my various cKO mouse 
models are 1) the gene whose expression is deleted, 2) the cell type in which the gene is inactivated, and 
3) the timing of deletion of said gene.  With regard to the first difference, it is somewhat easier to 
understand why Inhba SF1-cre cKO or Inhba FLC cKO mice have a less severe phenotype than Smad4 
SF1-cre cKO mice when one consider that deletion of Inhba is only eliminating at worst activin A and 
inhibin A protein production.  In contrast, loss of Smad4 expression theoretically precludes a cell from 
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responding canonically to any TGF! superfamily ligand.  The second major difference among my cKO 
mouse models is the specific cell type in which the gene of interest is inactivated.  For example, I created 
mouse models in which Smad4 was inactivated in the Sertoli cells only, the Leydig cells only, or in both 
Sertoli and Leydig cells (Smad4 SF1-cre cKO).  It is plausible the more severe phenotype in Smad4 SF1-
cre cKO arose due to disruption of SMAD4 in two of the most critical somatic cell populations of the 
testes.  However, loss of Smad4 expression in Sertoli cells alone produces a less severe testicular 
dysgenesis phenotype whereas disruption of Smad4 in the fetal Leydig cells did not result in any 
discernible deviations from normal testis development or function.  Therefore, unless loss of Smad4 in 
both cells disrupts some sort of TGF! superfamily crosstalk between these two cell populations it seems 
unlikely that inactivation of Smad4 in both Sertoli and Leydig cells is the root cause of testicular 
degeneration in Smad4 SF1-cre cKO mice.  Further support that SMAD4 is not critical for adult Leydig 
cell function in general comes from immunolocalization studies in the rat that observed SMAD4 within 
the cytoplasm, but not the nucleus, at a range of postnatal ages analyzed [281].  This pattern suggests that 
while adult Leydig cells do express SMAD4 it does not appear to enter the nucleus and regulate gene 
transcription.  One intriguing hypothesis related to the type of cells in which Smad4 is removed is that 
perhaps the severe phenotype in Smad4 SF1-cre cKO males is due to the loss of SMAD4 in some 
unidentified SF1-positive cell population other than the Sertoli and Leydig cells.  Furthermore, if these 
putative cells were associated with the vasculature it might explain the hemorrhagic events in fetal and 
aged adult life in Smad4 SF1-cre cKO testes. 
 My final proposed explanation, and the hypothesis I favor, is that differences in phenotypic 
severity between Smad4 Sertoli cKO and Smad4 SF1-cre cKO are due to differences in the timing of 
Smad4 removal.  In both models, Smad4 is inactivated within Sertoli cells; however, since SF1 is already 
expressed within Sertoli cell precursors prior to sex determination the removal of Smad4 occurs quite 
early in testis development in Smad4 SF1-cre cKO embryos.  SF1 transcripts can be detected as early as 
E9 in the mouse urogenital ridge, suggesting efficient deletion of the Smad4 gene in Smad4 SF1-cre cKO 
mice can most likely be achieved by the onset of sex determination around E10.5 [317].  In contrast, 
expression of anti-Müllerian hormone (Amh), the gene whose promoter drives Cre recombinase 
expression in my Smad4 Sertoli cKO mouse model, is not detected until mouse fetal testes until E12.5, or 
after Sertoli cell differentiation [209, 330].  Although the absolute time difference in Smad4 ablation is 
likely only 2-3 days, the Sertoli cell precursors undergo a tremendous transformation in that short amount 
of time.  Therefore, I predict that it is the earlier removal of Smad4 within Sertoli cells, rather than the 
loss of Smad4 in both Sertoli and Leydig cells, that results in the increased severity of testicular 
dysgenesis in Smad4 SF1-cre cKO mice compared to my other mouse models. 
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4.5.3:  The presence of hemorrhages in fetal and aged Smad4 SF1-cre cKO testes confirms the importance 
of proper vasculature for testicular development and fertility 
 Some of the most striking and mysterious features of Smad4 SF1-cre cKO testes are the  
hemorrhagic regions visible in newborn cKO testes and the large, encapsulated hemorrhage-tumors 
present in aged adults.  Although the etiology of these vascular defects remains to be elucidated, there are 
a few conclusions that can be drawn from my observations in Smad4 SF1-cre cKO mice.  Proper 
establishment of a vasculature network early in fetal testis development is known to be critical for normal 
testis morphogenesis.  For example, endothelial cell migration and coelomic vessel formation are 
disrupted in mice lacking expression of platelet-derived growth factor " (Pdgfr!), leading to abnormal 
testis cord morphogenesis [85].  Given the aforementioned disruption of Smad4 right around the time of 
sex determination in Smad4 SF1-cre cKO males, it is possible that loss of Smad4 in Sertoli and fetal 
Leydig precursor cells somehow impacts vasculature development, thus leading to the hemorrhages and 
perhaps even oddly-shaped testes I observed at the time of birth.  However, the disruption of vasculature 
function would have to be mild enough so as not to disrupt testis cord formation to the extent that occurs 
in Pdgfra
-/-
 testes [85].  Abnormal blood accumulation within the fetal testis interstitium has been reported 
in a mouse model lacking expression of Fkhl18, a member of the forkhead (Fox) transcription factor 
family [331].  This blood leakage appears to occur as a result of gaps between endothelial cells within 
testicular blood vessels [331].  Interestingly, Fox family proteins are known to be downstream 
components of activins and other TGF! superfamily signal transduction pathways in other tissue contexts 
[332-334].  Fkhl18 expression was detected in both Sertoli cells and periendothelial cells, raising the 
possibility that Smad4 and Fkhl18 could both influence vasculature formation via their transcriptional 
effects within Sertoli cells [331].  Blood leakage has also been observed in the fetal testes of mice lacking 
the endothelial gap junction proteins connexin37 and connexin40 [335]. 
 The unusual hemorrhagic tumors I observed in aged Smad4 SF1-cre cKO testes have been 
difficult to classify due to the rarity of similar pathologies in animals or humans.  The most similar 
vascular events observed in humans appear to be localized testicular infarctions that, although rare, are 
known to accompany specific blood-related disease states such as sickle cell anemia, polycythemia, and 
hypersensitivity angiitis [336-337].  However, a few cases of localized testicular infarctions in the 
absence of underlying disease have been reported [338-339].  In my Smad4 SF1-cre cKO mouse model, 
hemorrhaged areas become encapsulated by a thick layer of fibrotic tissue and show signs of 
revascularization (Fig. 4.12).  I was unable to locate any case reports of similar fibrosis or 
revascularization of infarcted/hemorrhaged areas in the testes of mice, humans, or any other animals.  
Therefore, it appears possible the attempted resolution of hemorrhagic tumors in Smad4 SF1-cre cKO 
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may represent a previously unreported process in the testis.  One of the most intriguing aspects of the 
hemorrhagic tendencies observed in Smad4 SF1-cre cKO fetal and aged adult testis is the fact that I did 
not observe any obvious hemorrhages in 12-16 week old testes.  Although unusually large blood vessels 
were present in the testes of young adult Smad4 SF1-cre cKO males, I did not detect any residual 
hemorrhagic regions persisting from fetal stage (Fig. 4.10).  However, while the majority of newborn 
Smad4 SF1-cre cKO testes displayed large hemorrhages, they were not present in every testis so it is 
possible, though unlikely, that the cKO males I analyzed at 12-16 weeks all happened to be from that 
small (20%) hemorrhage-free  portion of the population.  Further study of Smad4 SF1-cre cKO testes 
from embryogenesis through adulthood might reveal novel aspects of testicular vasculogenesis and 
vascular maintenance. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1:  Body weight, anogenital distance, and seminal vesicle weight in young 
adult (12-16 weeks) and aged adult (56-62 weeks) Smad4 SF1-cre cKO and control 
male mice.  With the exception of anogenital distance in the aged group, cKO and 
strain-specific control mice did not statistically differ for the parameters measured 
(p>0.01).  Anogenital distance was significantly increased in the aged cKO group 
compared to aged controls (indicated by asterisk; p=0.007). 
Genotype Age n 
Body weight 
(g) 
Anogenital 
distance (mm) 
Seminal vesicle 
weight (mg) 
Smad4 SF1-cre control 12-16 weeks 6 31.58 ± 5.39 15.89 ± 1.03 304.05 ± 77.33 
Smad4 SF1-cre cKO 12-16 weeks 5 29.62 ± 3.40 15.91 ± 0.30 300.14 ± 31.59 
Smad4 SF1-cre control 56-62 weeks 6 48.60 ± 8.98 17.60 ± 1.18 1603.77 ± 943.01 
Smad4 SF1-cre cKO 56-62 weeks 4 49.70 ± 6.08 20.01* ± 0.71 1045.58 ± 814.78 
4.6:  FIGURES AND TABLES 
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Table 4.2:  Comparison of testis weight, daily sperm production (DSP), cauda 
epididymal sperm concentration, and plasma FSH levels in young adult (12-16 weeks) 
and aged adult (41 weeks) control and Smad4 SF1-cre cKO male mice. P-values 
represent young versus aged for each genotype.   
Average testis 
weight (mg) 
Average DSP/
mg testis 
weight 
(thousands) 
Average sperm 
concentration 
(millions) 
Average plasma 
FSH (ng/mL) 
Smad4 SF1-cre control  
(12-16 weeks) 
84.58 ± 24.00 
n=6 
range: 65.1-101-2 
35.22 ± 16.15 
n=6 
range: 7.3-49.7 
10.47 ± 6.78 
n=6 
range: 3.4-19.0 
29.35 ± 6.30 
n=7 
range: 20.5-34.8 
Smad4 SF1-cre control 
(56-62 weeks) 
102.44 ± 17.70 
n=6 
range: 77.5-124.6 
53.99 ± 26.78 
n=6 
range: 27.9-79.1 
13.55 ± 4.34 
n=6 
range: 7.5-18.5 
24.42 ± 5.13 
n=7 
range: 16.6-32.7 
p-value  
(young vs. aged) 
p=0.184 p=0.055 p=0.370 p=0.158 
Smad4 SF1-cre cKO 
(12-16 weeks) 
22.65 ± 9.32 
n=5 
range: 17.9-48.8 
19.08 ± 21.08 
n=5 
range: 0.0-52.4 
6.47 ± 4.57 
n=3 
range: 1.5-10.5 
20.13 ± 9.51 
n=4 
range: 11.6-33.2 
Smad4 SF1-cre cKO 
(56-62 weeks) 
27.11 ± 18.56 
n=4 
range: 11.7-52.3 
0.00 ± 0.00 
n=3 
range: 0.0-0.0 
0.00 ± 0.00 
n=3 
range: 0.0-0.0 
16.48 ± 1.44 
n=4  
p-value  
(young vs. aged) 
p=0.650 p=0.180 p=0.071 p=0.477 
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Table 4.3:  Summary of major testicular phenotypes studied in Inhba-./-, Inhba SF1-
cre cKO, Inhba FLC cKO, Smad4 FLC cKO, Smad4 Sertoli cKO, and Smad4 SF1-cre 
cKO mouse strains during fetal and adult life.  N/A = not available (Inhba-/- mice 
could not be analyzed in adulthood due to perinatal lethality). 
Genotype 
Fetal development Adult 
Testis cord 
expansion? 
Sertoli cell 
proliferation? 
Other 
findings 
Testis 
size? 
Sperm 
production? 
Phenotype in 
advanced 
age? 
Inhba-/- Impaired Reduced 
Die 
perinatally 
N/A N/A N/A 
Inhba SF1-
cre cKO 
Impaired Reduced Reduced Reduced 
Similar to 
young adults 
Inhba FLC 
cKO 
Impaired Reduced Reduced Reduced 
Similar to 
young adults 
Smad4 FLC 
cKO 
Normal 
Not analyzed; 
presumably 
normal 
Normal Normal 
Not analyzed, 
presumably 
normal 
Smad4 
Sertoli cKO 
Impaired Reduced Reduced Reduced 
Similar to 
young adults 
Smad4 SF1-
cre cKO 
Impaired 
Not analyzed, 
presumably 
reduced 
Hemorrhages Reduced Reduced 
Hemorrhagic 
tumors, 
degenerated 
seminiferous 
tubules 
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Figure 4.1:  Testis appearance in newborn (E19.5) control and Smad4 SF1-cre cKO 
mice.  (A-B)  Low magnification images of control (A) and Smad4 SF1-cre cKO (B) 
newborn testes with epididymides attached.  (C-D)  Higher magnification images of 
Smad4 SF1-cre cKO newborn testes with epididymides removed.  Testes display 
abnormal testis shape, stunted testis cord coiling, and large hemorrhagic areas.  E = 
epididymis.  Arrows indicate areas of abnormal testis shape.  Arrowheads indicate 
hemorrhagic regions. 
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Figure 4.2:  Morphogenesis of testis cords in control and Smad4 SF1-cre cKO mouse 
embryos.  (A-D) Developmental time course of testes from control (A,C) and cKO 
(B,D) embryos.   Scale bar = 100µm.  White arrows indicate underdeveloped testis 
cords.  (E-F) H&E-stained sagittal testis sections from E19.5 control (E) and cKO (F) 
embryos.  Scale bar = 250µm.  
E F 
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Figure 4.3:  Testis weight in control and Smad4 SF1-cre cKO male mice.  (A-B) 
Average testis weight (in milligrams) of 12-16 week old young adult (A) and 56-62 
week old aged adult (B) Smad4 SF1-cre cKO and control males.  Asterisk indicates 
p<0.0001. 
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Figure 4.4:  Daily sperm production in control and Smad4 SF1-cre cKO male mice.  
(A-B) Daily sperm production (DSP) per milligram of testis weight in 12-16 week old 
young adult (A) and 56-62 week old aged adult (B) Smad4 SF1-cre cKO and control 
males.  Asterisk indicates p<0.0001.  No sperm were detected in any of the aged cKO 
testes analyzed. 
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Figure 4.5:  Sperm concentration in control and Smad4 SF1-cre cKO male mice.  (A-
B) Average cauda epididymal sperm concentration (in millions) of 12-16 week old 
young adult (A) and 56-62 week old aged adult (B) Smad4 SF1-cre cKO and control 
males.  Asterisk indicates p<0.0001. No cauda epididymal sperm were detected in any 
of the aged cKO males analyzed. 
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Figure 4.6:  Plasma follicle-stimulating hormone (FSH) levels in control and Smad4 
SF1-cre cKO male mice.  (A-B) Average plasma FSH level (ng/mL) of 12-16 week 
old young adult (A) and 56-62 week old aged adult (B) Smad4 SF1-cre cKO and 
control males.  Asterisk indicates p<0.02.  
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Figure 4.7:  Testis appearance in control and aged Smad4 SF1-cre cKO male mice.  
(A) Images of testes from 12-16 week old young adult cKO and control mice.  (B)  
Images of testes from 56-62 week old cKO and control mice with epididymides 
attached.  (C) Images of testes from 56-62 week old cKO and control mice with 
epididymides removed.  (D-F) Images of representative testes from 56-62 week old 
cKO mice.  E = epididymis. 
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Figure 4.8:  Seminiferous tubule histology in 12-16 week old control and Smad4 SF1-
cre cKO male mice.  (A-E) H&E-stained histological sections from young adult 
control (A) and Smad4 SF1-cre cell cKO (B-E) testes shown at 10X magnification.  
(B-C) Images of regions of Smad4 SF1-cre testes undergoing spermatogenesis.  (D-E) 
Representative images of dysgenic regions of Smad4 SF1-cre testes largely absent of 
spermatogenesis.  Scale bar = 250µm.   
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Figure 4.9:  Spermatogenesis in 12-16 week old control and Smad4 SF1-cre cKO 
male mice.  (A-H) H&E-stained histological sections from young adult control (A,D) 
and Smad4 SF1-cre cell cKO (B-C, E-H) testes shown at 20X magnification.  (B-C) 
Images of regions of Smad4 SF1-cre testes still undergoing spermatogenesis.  (E-H) 
Representative images of dysgenic regions of Smad4 SF1-cre testes displaying Leydig 
cell hyperplasia and absence of normal spermatogenesis.  Asterisk indicate Leydig cell 
hyperplasia; arrowhead indicates abnormal cluster of spermatogenic cell nuclei within 
the tubule lumen.  Scale bar = 100µm.   
Smad4 SF1-cre cKO  
A B C 
E D F 
G H 
* 
* * 
* 
* 
108 
Control Smad4 SF1-cre cKO  
Figure 4.10:  Testicular blood vessels in 12-16 week old control and Smad4 SF1-cre 
cKO male mice.  (A-B) H&E-stained histological sections from young adult control 
(A) and Smad4 SF1-cre cKO (B) testes shown at 10X magnification.  Scale bar = 
250µm.  (C-D) Identical sections in control (C) and cKO (D) testes enlarged to 20X 
magnification.  Arrows indicate blood vessels.  Scale bar = 100µm.    
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Figure 4.11:  Epididymal histology in 10 week old control and Smad4 SF1-cre cKO 
mice.  (A-H) H&E-stained sections through the caput (A-B), corpus (C-D), and caudal 
(E-F) regions of the epididymis, as well as the vas deferens (G-H).  For each region, 
both control (A,D,E,G) and cKO (B,D,F,H) are pictured.  Scale bar = 25µm. 
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Figure 4.12:  Low-magnification images of dysgenic testes from 56-62 week old 
Smad4 SF1-cre cKO male mice.  (A-E) H&E-stained histological sections from aged 
adult Smad4 SF1-cre cKO testes shown at 4X magnification.  Arrows indicate large 
blood vessels within hemorrhagic regions.  Arrowheads indicate areas containing 
residual seminiferous tubules. 
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Figure 4.13:  Testis histology in 56-62 week old control and Smad4 SF1-cre cKO 
male mice.  (A-E) H&E-stained histological sections from aged adult control (A) and 
Smad4 SF1-cre cell cKO (B-E) testes shown at 10X magnification.  Scale bar = 
250µm.   
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Figure 4.14:  Seminiferous tubule histology in 56-62 week old control and Smad4 
SF1-cre cKO male mice.  (A-H) H&E-stained histological sections from aged adult 
control (A,D) and Smad4 SF1-cre cell cKO (B-C, E-F) testes shown at 20X 
magnification.  Scale bar = 100µm.   
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Figure 4.15:  Testicular blood vessels in 56-62week old control and Smad4 SF1-cre 
cKO male mice.  (A-B) H&E-stained histological sections from aged adult control 
(A,C) and Smad4 SF1-cre cKO (B,D) testes shown at 40X magnification.  Scale bar = 
50µm.    
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Figure 4.16:  Leydig cell hyperplasia in testes from 56-62 week old Smad4 SF1-cre 
cKO male mice.  (A-D) H&E-stained histological sections shown at 20X (A-B) and 
40X (C-D) magnification.  Scale bars = 100µm (20X) and 50µm (40X).  Arrowheads 
indicate multinucleated Leydig cells. 
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Figure 4.17:  Testicular teratoma containing chondrocytes and osteoblasts in a 56 
week old Smad4 SF1-cre cKO male mouse.  (A-D) H&E-stained histological sections 
shown at 4X (A-B), 10X (C), 20X (D), and 40X (E-F) magnification.  Arrowheads 
indicate location of teratoma in lower magnification images.  Scale bars = 500µm 
(4X), 250µm (10X), 100µm (20X), and 50µm (40X). 
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CHAPTER 5:  IN UTERO EXPOSURE TO ESTROGENIC COMPOUNDS MAY ALTER THE 
ACTIVIN A SIGNALING PATHWAY IN MURINE FETAL TESTES 
 
 
5.1:  ABSTRACT 
A trend of declining sperm counts in humans has been documented for the past several decades.  
Disruption of fetal testis development due to environmental toxicant exposure is one proposed cause of 
this disturbing trend.  In both humans and laboratory animals, in utero exposure to estrogenic compounds 
can result in testicular dysgenesis and impaired sperm production; however, the specific genetic pathways 
involved are unknown.  Using transgenic mouse models, I have identified Inhba as a critical factor for 
normal testis morphogenesis.  Disruption of the activin A pathway results in fetal testis dysgenesis 
leading to low sperm counts and abnormal testicular histology in adult mice.  The similarities between the 
testes of mice with disrupted activin A signaling and those of mice with fetal exposure to estrogenic 
toxicants suggested the activin A pathway could be a target of estrogenic compounds.  Interestingly, links 
between the activin A pathway and estrogen have been demonstrated in several murine tissues including 
the ovary; however, it is unknown whether this relationship also exists in the fetal testis.  I hypothesize 
that one mechanism behind estrogen-induced fetal testis dysgenesis in mice is disruption of the testicular 
activin A pathway.  To test this hypothesis, I orally dosed pregnant dams with the estrogenic compounds 
diethylstilbestrol (DES) and bisphenol A (BPA) from embryonic day 10.5 (E10.5) to E17.5.  I collected 
testes from the E19.0 pups and analyzed testicular histology as well as changes in gene expression of 
activin A pathway components.  I observed moderate to severe fetal testicular dysgenesis in most DES 
and BPA exposed testes.  Specifically, there was an apparent increase in the amount of visible interstitial 
space in testis cross-sections from DES- or BPA-treated testes.  In addition, straight lengths of testis cords 
could be seen emerging from the rete testis of many DES or BPA exposed testes, suggesting testis cord 
expansion may have been impaired by exposure to exogenous estrogens.  The similarities between the 
fetal testes of mice gestationally exposed to DES or BPA and the testes of  genetic mouse models with 
specific disruption of the testicular activin A pathway provided indirect evidence of an effect of 
estrogenic compounds upon the testicular activin A pathway.  To confirm an interaction between estrogen 
and activin signaling in the murine fetal testes, I am performing quantitative real-time PCR (qPCR) 
analysis to evaluate the expression of genes associated with the activin A pathway.  Since components of 
the activin A signaling pathway are also present in human fetal testes, this research may uncover potential 
mechanisms behind estrogen-induced changes during human testis development. 
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5.2:  INTRODUCTION 
 My studies of various global and conditional knockout mouse models demonstrated the 
importance of fetal testicular activin A signaling for both normal fetal testis morphogenesis and adult 
testicular function.  Given the novelty of my findings, I wondered whether activin A could be a relevant 
pathway for cases of testicular dysgenesis in humans as well.  Many genes identified as critical for mouse 
embryonic testis morphogenesis, for example, sex-determining region of the Y chromosome (Sry), have 
also been confirmed to have roles in human testis development [17, 46].  Although activins and inhibins 
have myriad roles in human testes, there are essentially no references to Inhba loss-of-function mutations 
in humans.  Since Inhba is critical for survival, as evidenced by the neonatal lethality of Inhba
-/-
 mice, it 
was not surprising that I could not uncover evidence of human INHBA mutations in the scientific 
literature [201].  Mutations in ACVRL1, the gene encoding activin receptor-like kinase 1 (ALK1) can 
cause a vascular disorder known as hereditary hemorrhagic telangiectasia (HHT); however, bone 
morphogenetic proteins (BMPs) rather than activins are the primary ligands for ALK1 [338-339].  Since 
comparison of my mouse models to human cases of INHBA mutation/inactivation was not possible, I next 
looked for signaling pathways known to influence activin expression and/or signaling.  Interestingly, 
interaction between estrogen signaling and the activin A pathway have been reported in a number of 
rodent tissues including the pituitary, uterus, and ovary [174-177, 342].  The relationship between activin 
and estrogens may be highly conserved, at least in the ovary, since Inhba expression was decreased in the 
ovaries of female hatchling alligators collected from a lake contaminated with estrogenic compounds 
[343].  Further evidence of the conserved crosstalk between activin A and estrogen comes from studies in 
cultured human breast cancer cells in which estrogen and activin were able to inhibit one another’s 
transcriptional activities [344].  The precise nature of the crosstalk between these two signals appears to 
differ based upon tissue context; for example, estrogen exposure was found to increase Inhba expression 
in the rat endometrium but decrease its expression in the murine ovary [174, 177].  The potential for 
interactions between the estrogen and activin A signaling pathways in murine fetal testes, however, has 
not been explored. 
 Numerous studies have demonstrated the detrimental effects of developmental exposure to 
estrogenic compounds on testis development and function in humans, laboratory species, and wildlife 
[200, 345-354].  Many of these studies have utilized the nonsteroidal synthetic estrogen diethylstilbestrol 
(DES) as a model compound in which to analyze estrogen signaling outcomes [355].  In the mouse, 
gestational or neonatal exposure to DES can produce a multitude of reproductive defects, including 
reproductive tract abnormalities, retention of Müllerian duct remnants, hypotrophic testes, 
cryptorchidism, low sperm production, and interstitial cell tumors [193, 200, 356-364].  Putative effects 
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of in utero exposure to DES in human males include testicular cancer, hypospadias, cryptorchidism, 
reduced sperm count, and impaired fertility [365].  In murine fetal testes, DES has been shown to signal 
via estrogen receptor " (ER", gene symbol Esr1), which is expressed specifically within the fetal Leydig 
cells [178, 366-367].  As discussed in Chapter 2, the fetal Leydig cells are also the major source of activin 
A in the developing testes, suggesting DES or other estrogenic compounds could signal directly to fetal 
Leydig cells via ER" to regulate activin A/Inhba expression.  I therefore hypothesized that in utero 
exposure to DES induces testicular dysgenesis at least in part by altering fetal Leydig cell expression of 
Inhba and thus interfering with the testicular activin A pathway. 
 In addition to studying DES, I also became interested in bisphenol A (BPA), a component of 
polycarbonate and polysulfone plastics first synthesized in 1891 [368].  BPA was first shown to have 
estrogenic effects over 70 years ago, and is now known to elicit effects via estrogen receptor in a variety 
of human and animal cells.  Some of these effects are observed at extremely low concentrations, including 
low picomolar through low nanomolar exposures of BPA [369-373].  Unlike DES, which is known to 
signal via ER" in murine fetal testes, the specific estrogen receptor/s activated by BPA are not fully 
characterized and are likely to differ based upon tissue context [178, 374].  BPA has been demonstrated to 
signal via ER" in the murine ovary and uterus, raising the possibility that a similar relationship might 
exist in the testes [375-376].  There is also evidence that BPA can function as a selective estrogen 
receptor modulator (SERM) and therefore does not always mimic the effects of estradiol or DES 
treatment [377-380].  In utero treatment with BPA has been shown to increase ER" expression in murine 
fetal prostatic cells as well as in the adult brain [381-382].  In contrast to DES, not much is known about 
the effects of gestational exposure to BPA on murine testis development as most of the studies on the 
reproductive effects of BPA in the mouse have focused upon the female [383-388].  Currently there exists 
a great deal of controversy regarding the physiological effects of low-dose bisphenol A and their potential 
ramifications for human and animal health.  I anticipate my study will provide much-needed insight into 
the putative influence of this compound on fetal testis development. 
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5.3:  MATERIALS AND METHODS 
5.3.1:  Mouse husbandry and tissue collection 
Outbred CD-1 mice bred in our resident mouse colony from stock purchased from Charles River 
Laboratories (Wilmington, MA) were used for all studies. I selected the CD-1 outbred mouse strain based 
upon its well-characterized sensitivity to estrogenic exposures [389-391].  Efforts were made to minimize 
exposure to potentially confounding estrogenic compounds such as BPA from caging materials and 
phytoestrogens in food [392-396].  All control and treated mice were single-housed in conventional non-
ventilated polycarbonate caging (which did unfortunately contain BPA) with glass water bottles and 
corncob bedding.  Mice were acclimated to conventional caging and NIH-31 low/moderate phytoestrogen 
food for one month prior to the start of the study.  Once mice were fully acclimated, timed matings were 
produced by housing female mice with males overnight and checking for vaginal plugs the next morning 
(E0.5 = noon of the day when a vaginal plug was found).  Plugged females were dosed (see section 5.3.2 
below) at 5:30 pm from E10.5 through E17.5 and fetal tissues were collected between E18.5 and E19.0 
(late afternoon/evening of E18.5).  All procedures described were reviewed and approved by the 
Institutional Animal Care and Use Committee, and were performed in accordance with the Guiding 
Principles for the Care and Use of Laboratory Animals. 
Pregnant dams were euthanized via carbon dioxide asphyxiation and blood was collected via 
postmortem cardiac puncture as described in Chapter 3.  Uteri were removed and pups dissected out 
individually.  Intrauterine position, body weight, and anogenital distance were recorded for each pup.  For 
male embryos, one testis was separated from its associated epididymis and the tissues were individually 
snap-frozen for quantitative real-time PCR analysis (qPCR).  The other testis was fixed, with epididymis 
attached, in either 4% paraformaldehyde or Bouins fixative as described in Chapter 2.  In addition to testis 
and epididymis, liver samples were collected from each male pup and snap-frozen for possible qPCR 
analysis. 
 
5.3.2:  Dosing of pregnant mice 
The treatment groups I selected for my study were 5 µg/kg/day DES, 0.05 µg/kg/day DES, 50 
µg/kg/day BPA, 0.5 µg/kg/day BPA, and a vehicle control.  DES and BPA stocks were made in 100% 
ethanol at a concentration that ensured ethanol vehicle would equal 0.0375% of the final oral dosing 
volume (well below the ethanol concentration known to be fetotoxic).  The experimental doses of BPA 
used in this study were selected based upon the current Environmental Protection Agency (EPA) human 
reference dose and Food and Drug Administration (FDA) acceptable daily intake dose [397].  
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Specifically, the highest dose of BPA utilized in this study (50 µg/kg/day) was 1,000-fold lower than the 
currently accepted EPA lowest observed adverse effect level (LOAEL) of 50 mg/kg/day [398].  The 
lowest BPA dose (0.5 µg/kg/day) in this study was 100,000-fold below this LOAEL [398]. I selected 0.05 
µg/kg/day of DES as an appropriate positive control for ER"-mediated changes in murine fetal testes 
based upon reports that BPA has a 100- to 1000-fold lower potency relative to DES [398-417].  To allow 
for more accurate analysis of data from my low-dose BPA and DES doses, I included a reference DES 
dose of 5 µg/kg/day.  This represents the highest recommended DES dose appropriate to serve as a 
positive control for “low-dose” BPA studies [398]. 
Since dams would be dosed from mid-to-late gestation, their weight was going to be increasing 
dramatically during the dosing period.  To simplify dosing, I prepared a range of DES and BPA stocks to 
account for these changes: 
 
Dam weight BPA stock (50 µg/kg) DES stock (5 µg/kg) 
35 grams 116.67 mg BPA/mL ethanol 11.67 mg DES/mL ethanol 
40 grams 133.33 mg BPA/mL ethanol 13.33 mg DES/mL ethanol 
45 grams 150 mg BPA/mL ethanol 15 mg DES/mL ethanol 
50 grams 166.67 mg BPA/mL ethanol 16.67 mg DES/mL ethanol 
55 grams 183.33 mg BPA/mL ethanol 18.33 mg DES/mL ethanol 
60 grams 200 mg BPA/mL ethanol 20 mg DES/mL ethanol 
65 grams 216.67 mg BPA/mL ethanol 21.67 mg DES/mL ethanol 
 
To produce 0.5 µg/kg BPA and 0.05 µg/kg DES stocks, the higher concentration stocks detailed 
above were diluted 100-fold.  For the final dosing solutions actually given to the mice, I then added 0.375 
µL of the appropriate stock solution per 1 mL of tocopherol-stripped corn oil vehicle (MD Biosciences, 
St. Paul, MN).  For the vehicle control, 0.375 µL of 100% ethanol was added per 1 mL of tocopherol-
stripped corn oil vehicle.  Dosing stocks (corn oil + ethanol stock) were made up in 10 mL volumes to 
minimize errors associated with pipetting extremely small volumes and were stored in BPA-free 
polypropylene conical tubes (Corning, Corning, NY).  A standard manual micropipette was used to 
deliver 40 µL of corn oil vehicle containing either ethanol vehicle,  5 µg/kg/day DES, 0.05 µg/kg/day 
DES, 50 µg/kg/day BPA, or 0.5 µg/kg/day BPA.  If a dam’s weight fell between two weight levels, I 
dosed with 20 µL each of the higher and lower solution; for example, a dam weighing 37.5 grams 
received 20 µL of the “35 gram” solution and 20 µL of the “40 gram” solution. To perform dosing via 
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oral pipetting, pregnant mice were weighed to ensure administration of proper dose, briefly restrained, 
and the appropriate treatment solution was gently pipetted into the mouth.  Mice were found to readily 
swallow the corn oil vehicle, making this a simple and minimally stressful method for oral exposure.  
Dosing continued from E10.5 through E17.5 and fetal tissues were collected between E18.5 and E19.0 
(late afternoon/evening of E18.5).  Since maternal blood and pup tissues were stored for potential future 
BPA analysis, the decision was made not to artificially inflate tissue BPA levels by administering a final 
dose at E18.5, shortly before animals were collected. 
 
 5.3.3:  Histology of murine fetal testes 
 Fetal testis histology was performed as described in Chapter 2.3.3.  
 
 5.3.4:  Quantitative real-time PCR (qPCR) 
 RNA was isolated from snap-frozen tissues using the Qiagen RNeasy mini kit (Qiagen, Valencia, 
CA) using the following slightly modified version of the manufacturer’s protocol (developed and verified 
by the laboratory of Dr. Jodi Flaws at the University of Illinois at Urbana-Champaign): 
1.  Homogenize individual testes in 600 µL of buffer RLT (included in kit) for 30-45 
seconds on ice.  Repeat 3 times with 30 seconds of rest in between.  Wash 
homogenizer after each tube. 
2.  Add 600 µL of 70% ethanol and pipette gently. 
3.  Apply 600 µL of testis homogenate + ethanol to an RNeasy mini spin column 
sitting in a 2 mL collection tube (provided in kit).  Centrifuge for 28 seconds at 
13,000 RPM.  Repeat with remaining 600 µL of homogenate + ethanol. 
4.  Apply 700 µL of RW1 buffer (included in kit) onto the column and centrifuge for 
28 seconds at 13,000 RPM. 
5.  Transfer the mini column into a new 2 mL collection tube. 
6.  Apply 500 µL of buffer RPE (provided in kit) onto the column and centrifuge for 
28 seconds at 13,000 RPM.  Discard contents of the collection tube. 
7.  Apply 500 µL of buffer RPE onto the column and centrifuge for 2 minutes at 
13,000 RPM. Discard contents of the collection tube. 
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8.  Centrifuge the mini column + collection tube for 1 minute at 13,000 RPM.  When 
finished, transfer the mini column to a new 1.5 mL collection Eppendorf tube 
provided in the RNeasy kit. 
9. Pipette 20 µL of RNase-free water directly onto the membrane and centrifuge for 1 
minute at 13,000 RPM.  Repeat once for a total of 40 µL of isolated total RNA. 
  
 Following RNA isolation, the concentration and purity of the collected RNA was analyzed via 
Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE).  RNA samples were stored at -80°C.  
To synthesize cDNA, I used 0.5 µg of RNA in a 20 µL reaction volume following directions included in 
the Qiagen Omniscript Reverse Transcriptase kit (Qiagen, Valencia, CA).  The reverse transcription (RT) 
reaction was performed by placing tubes containing RNA and the RT reaction mix in a 37°C water bath 
for 1 hour.    The resulting cDNA was stored at -20°C.  I performed quantitative real-time PCR (qPCR) 
using Bio-Rad SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA) in the following reaction (volumes 
given are for one sample): 
Volume of SsoFast 
EvaGreen Supermix 
Volume of primers                                 
(5 pmol mix of forward and reverse) 
Volume of 
molecular H20 
Volume of 
cDNA 
10.5 #L 1.26 #L 6.24 #L 2 #L 
 
The Bio-Rad CFX96 Real-Time PCR Detection System and associated Bio-Rad CFX Manager 
software were used to carry out qPCR and analyze the results (Bio-Rad, Hercules, CA).  The master 
protocol used for qPCR included an initial incubation at 95°C for 10 minutes, followed by denaturing at 
94°C for 10 seconds, annealing (annealing temperature for each primer is listed in the table below) for 10 
seconds, and extension at 72°C for 10 seconds, for a total of 50 cycles.  This was followed by 5 seconds 
at 65°C.  A melting curve was generated at 65°-89.4°C to monitor the generation of a single product.  A 
standard curve was generated from five serial dilutions of one of the samples, thus allowing analysis of 
the amount of cDNA in the exponential phase.  Primers used thus far, including those specific to ER" 
(Esr1),  Inhba, Insl3, and the housekeeping gene beta actin are detailed below: 
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5.3.5:  Statistical analysis 
 Statistical differences between two groups were determined via two-tailed t-test comparisons; 
ANOVA was used to compare three or more groups. 
 
 
5.4:  RESULTS 
5.4.1:  In utero exposure to DES or BPA does not negatively impact body weight or anogenital distance in 
E19.0 CD-1 pups 
The strain of mouse selected for low-dose BPA studies is an important decision as estrogen 
sensitivity can vary significantly among mouse strains [391].  The CD-1 outbred mouse strain has been 
recommended as an appropriate model for the investigation of low-dose BPA effects due to its well-
characterized sensitivity to estrogenic exposures [389-391, 398-403].  The experimental doses of BPA 
used in this study (50 µg/kg/day and 0.5 µg/kg/day) were selected to fall within the current 
Environmental Protection Agency (EPA) human reference dose and Food and Drug Administration 
(FDA) acceptable daily intake dose of 50 µg/kg/day [397].  Thus the highest dose of BPA I utilized for 
my studies (50 µg/kg/day) was 1,000-fold lower than the currently accepted EPA lowest observed adverse 
effect level (LOAEL) of 50 mg/kg/day [398].  My lowest BPA dose (0.5 µg/kg/day) was 100,000-fold 
below this LOAEL [398].  The careful selection of positive control compounds and doses is particularly 
critical when investigating low-dose effects of BPA, as appropriate positive controls are absolutely 
critical for proper interpretation of data [398, 404-408].  Since BPA has a 100-to-1000 fold lower potency 
Gene Sequences (5’-3’) 
Annealing 
temperature 
Melt 
temperature 
Band size Source 
Actb     
(beta actin) 
GGGCACAGTGTGGGTGAC 
CTGGCACCACACCTTCTAC 
55° C 86.0°C 238 bp [395] 
ER" 
ACCATTGACAAGAACCGGAGC
CTGAAGCACCCATTTCATT 
55°C  84.4°C  170 bp [175] 
Insl3 
TGGTCCTTGCTTACTGCGATCT 
CCTGGCTATGTCATTGCAACA 
60°C  77.5°C  Not reported [178] 
Inhba 
GATCATCACCTTTGCCGAGT 
TGGTCCTGGTTCTGTTAGCC 
56°C 83.5°C 143 bp [175] 
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relative to DES, I selected 0.05 µg/kg/day of DES as an appropriate positive control for ER"-mediated 
changes in murine fetal testes [398-417].  To allow for more accurate analysis of data from my low-dose 
BPA and DES doses, I also included a reference DES dose of 5 µg/kg/day, the highest recommended 
DES dose appropriate for “low-dose” BPA studies [398]. 
 For this study, pregnant CD-1 female mice were orally dosed from E10.5 to E17.5 with one of the 
following treatments – corn oil vehicle control, 5 µg/kg/day DES, 0.5 µg/kg/day DES, 50 µg/kg/day 
BPA, or 0.5 µg/kg/day BPA.  For each treatment, three pregnant females were dosed and thus three litters 
per treatment were collected at E19.0.  The average number of pups per litter did not statistically differ 
among treatments groups (Table 5.1).  I also did not detect statistical differences in average pup body 
weight (both sexes) or male pup body weight normalized to take into account litter size (Table 5.1).  
Anogenital distance (AGD) was normalized by the cube root of body weight as this has been shown to be 
an effective method to account for potential differences in AGD resulting from differences in pup size 
(Table 5.1) [418].  These data indicate treatment with low doses of DES or BPA did not result in 
detrimental changes in litter size, body weight of pups, or male pup AGD. 
 
5.4.2:  In utero exposure to either 5 µg/kg/day DES or 50 µg/kg/day BPA alters testis descent in E19.0 
CD-1 male pups 
 In mice as well as humans, exposure to DES can result in cryptorchidism due to downregulation 
of the insulin-like growth factor 3 (Insl3) gene [362-364].  As anticipated, testicular descent was visually 
normal in all male pups gestationally exposed to vehicle control, 0.05 µg/kg/day DES, or 0.5 µg/kg/day 
BPA (Table 5.2).  In these three treatment groups, testes were observed to descent to a point next to the 
bottom of the bladder.  Normal descent was also observed in 4 of 18 male pups exposed to 5 µg/kg/day 
DES and 6 of 19 male pups exposed to 50 µg/kg/day BPA.  However, a partial failure of testis descent 
was also observed in these two groups, as evidenced by descent of the testes only to the top of the 
bladder.  This “partial cryptorchidism” occurred in 13 of 18 male pups in the 5 µg/kg/day DES treatment 
group and 13 of 19 male pups exposed to 50 µg/kg/day BPA.  Full cryptorchidism in which the testes 
failed to descend below the bottom of the kidneys occurred in one pup out of 18 in the 5 µg/kg/day DES 
treatment group (Table 5.2).  This variation in penetrance of the cryptorchid phenotype is not entirely 
surprising since it is unlikely each pup is exposed to identical amounts of DES or BPA in utero.  My 
observation of normal testis descent in pups exposed to 0.05 µg/kg/day DES is in keeping with previous 
reports that in utero exposure of CD-1 pups to 0.25 µg/kg/day DES resulted in normal testis descent and 
only minimal inhibition of Insl3 expression [178].  However, it is important to note that constant exposure 
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in the aforementioned study was achieved via Alzet pump whereas all animals in my study were exposed 
via once-daily oral dosing [178]. 
 
5.4.3:  Testes of male pups gestationally exposed to DES or BPA range from normal to severely dysgenic 
 To determine whether in utero exposure to DES or BPA affected testis morphogenesis, I 
examined histological sections in 4-5 testes from each treatment group (Fig. 5.1).  I observed that 
individual testes tended to fall into one of three categories – normal, mildly dysgenic, and severely 
dysgenic.  In the case of normal testes, numerous small round or oval testis cord cross-sections filled the 
majority of the testis, and substantial expanses of interstitial tissue were rare.  Severely dysgenic testes 
displayed large regions of interstitial space uninterrupted by testis cords.  There appeared to be fewer 
testis cord cross-sections visible in severely dysgenic testes, and straight lengths of uncoiled testis cords 
could be seen emerging from the rete testis.  Mildly dysgenic testes fell in between the two extremes, 
exhibiting more visible interstitial area than normal testes but also more testis cord cross-sections than 
highly dysgenic testes.  Grossly normal testis cord development was observed in all vehicle control-
treated testes as well as a small number of individual testes from all treatment groups (Fig. 5.1A-5.1E; 
Table 5.3).  Varying degrees of testis cord dysgenesis were observed in the remainder of testes from pups 
exposed to DES or BPA (Fig. 5.1F-5.1M).  Less severely dysgenic testes showed a general increase in 
interstitial space and the appearance of elongated testis cord cross-sections (Fig. 5.1F-5.1I).  More 
severely dysgenic testes from 0.05 µg/kg/day DES, 5 µg/kg/day DES, 50 µg/kg/day BPA, and 0.5 
µg/kg/day BPA exposed pups displayed noticeably fewer testis cord cross-sections than controls (Fig. 
5.1J-5.1M).  Out of the four vehicle control testes analyzed thus far, all four exhibited normal testis 
histology (Table 5.3).  I examined five testes each from 5 µg/kg/day DES, 0.05 µg/kg/day DES, and 0.5 
µg/kg/day BPA and in all three treatment groups I observed one testis with normal testis cord appearance, 
two testes displaying mild testicular dysgenesis, and two testes displaying severe dysgenesis (Table 5.3).  
For the 50 µg/kg/day BPA treatment group, two of the four testes developed normally whereas one testis 
was mildly dysgenic and one testis was severely dysgenic (Table 5.3). 
 I next took a closer look at rete testis histology in dysgenic testes from my treated male pups (Fig. 
5.2).  One of the characteristic histological abnormalities I observed in my genetic mouse models of 
disrupted testicular activin A signaling was the appearance of elongated, “finger-like” lengths of testis 
cords emerging from the rete testis, presumably the result of reduced testis cord convolution (Chapter 2).  
In vehicle control testes, testis cords of normal diameter filled in the regions immediately adjacent to the 
rete testis epithelium, visually obscuring the transition from rete epithelium to regular coiled testis cord 
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epithelium (Fig. 5.2A, 5.2F).  Testes exposed to 5 µg/kg/day DES exhibited straight, “finger-like” 
projections from the rete testis that were visually similar to the deficits I observed in Inhba cKO and 
Smad4 cKO mice (Fig. 2.2B, 2.2G).  Similar disorganization of the rete testis was present in dysgenic 
testes from pups belonging to the 0.05 µg/kg/day DES (Fig. 5.2C, 5.2H), 50 µg/kg/day BPA (Fig. 5.2D, 
5.2I), and 0.5 µg/kg/day BPA (Fig. 5.2E, 5.2J) treatment groups.  In addition to underdevelopment of the 
testis cords, some testes from DES and BPA exposed pups contained unusually large blood vessels, a 
phenotype not observed in vehicle control-treated testes (arrows in Fig. 5.1B, 5.1G, 5.1D, 5.1I, 5.1J). 
 
5.4.4:  Exposure to low doses of BPA or DES can alter gene expression within murine fetal testes 
 The striking histological changes I observed in testes exposed to BPA or DES led me to question 
the mechanism behind this testicular dysgenesis.  The similar appearances of fetal testes in BPA/DES-
exposed pups and genetic mouse models with disrupted testicular activin A signaling prompted me to 
investigate whether the expression of genes relevant to the activin A pathway might be altered following 
estrogen exposure.  I also chose to look at estrogen receptor expression since activin is known to 
modulate estrogen receptor expression in other tissue contexts [175-177].  To confirm my DES positive 
control doses were sufficiently effective, I also sought to analyze the expression of  genes whose 
expression is known to be altered by DES treatment, such as Insl3 and steroidogenic acute regulatory 
protein (StAR) [178]. 
 Thus far, I have performed qPCR analysis of three different target genes -- ER" (Esr1), Inhba, 
and Insl3 (Fig. 5.3).  For gene expression analysis, testes from a minimum of five different pups 
(representing all three litters per treatment group) were individually analyzed and then averaged.  With 
regard to ER" (Fig. 5.3A), I observed a decrease in ER" expression in my 5 µg/kg/day DES, 0.05 
µg/kg/day DES, 50 µg/kg/day BPA, and 0.5 µg/kg/day BPA treatment groups compared to vehicle 
controls.  However, this decrease only reached statistical significance (p<0.05) in the 50 µg/kg/day BPA 
group.  Although I anticipated Inhba expression would be downregulated following estrogenic exposure, I 
actually observed a statistically-significant increase in Inhba expression compared to vehicle controls in 
the testes of mouse pups exposed to 5 µg/kg/day DES or 0.5 µg/kg/day BPA (Fig. 5.3B).  Likewise, I 
observed an increase in Insl3 expression in testes gestationally exposed to 0.05 µg/kg/day DES or 50 
µg/kg/day BPA.  My preliminary qPCR results indicate exposure to even extremely low doses of DES or 
BPA can elicit changes in gene expression; however, my data do not currently provide evidence of a link 
between the activin A signaling pathway and estrogen-induced fetal testis dysgenesis. 
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5.5:  DISCUSSION 
5.5.1:  Gestational exposure to 5 µg/kg/day DES or 50 µg/kg/day BPA, but not lower doses, can lead to 
partial impairment of testis descent 
 In mice, testicular descent occurs in two phases – the transabdominal phase, mediated by 
INSL3, and the inguinoscrotal phase, controlled by testicular androgens [96. 419-422].  In mice, 
transabdominal descent takes place between E15.5 and E17.5, making it possible the partial impairment 
of testis descent in some E19.0 male pups exposed to 5 µg/kg/day DES and 50 µg/kg/day BPA could be 
due to a delay in the timing of testis descent [423].  My observation of increased Insl3 expression at E19.0 
following in utero exposure to 50 µg/kg/day BPA or 0.05 µg/kg/day DES supports a possible 
compensatory upregulation of Insl3 late in gestation.  It is intriguing to note that while ~50% of male 
pups gestationally exposed to 50 µg/kg/day BPA showed partial impairment of testis descent, I did not 
observe any abnormally descended testes in the 0.05 µg/kg/day DES treatment group.  Thus, it is difficult 
to interpret the biological consequences of the change in Insl3 expression in these two treatment groups. 
  
 
5.5.2:  In utero exposure to DES or BPA can lead to testicular dysgenesis reminiscent of mouse models 
with disrupted testicular activin A signaling 
 In Chapter 2, I described my findings of underdeveloped testis cords in genetic mouse models 
lacking either fetal Leydig cell expression of activin A or Sertoli cell expression of Smad4.  In the 
absence of testicular activin A signaling, reductions in Sertoli cell proliferation led to a failure of testis 
cord expansion during embryogenesis.  The histological similarities between dysgenic testes of embryos 
exposed to DES or BPA and those with disrupted testicular activin A signaling suggests estrogen-induced 
testicular dysgenesis might result from alteration of the activin A pathway.  In both instances, 
abnormalities including a general decrease in testis cord cross-sections, an apparent increase in the 
amount of visible interstitial space, and the projection of elongated, straight segments of testis cord from 
the rete testis.  My observation of fetal testis dysgenesis in male mouse pups gestationally exposed to 
BPA or DES was somewhat surprising, as there are a number of in utero dosing studies performed in 
mice which have found no effect on development of the male reproductive system [424-426]. 
 To investigate the potential crosstalk between estrogen and activin signaling pathways in the 
etiology of fetal testis dysgenesis, I am performing quantitative real-time PCR (qPCR) analysis of genes 
related to both the estrogen and activin A pathways.  Thus far, I have investigated ER", Inhba, and Insl3 
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expression levels in my five treatment groups.  There was a trend of decreasing ER" expression in testes 
exposed to either DES or BPA; however, the large standard deviation in my control group prevented all 
but one of the treatment groups from achieving statistical significance.  ER" expression relative to beta 
actin was significantly decreased compared to vehicle control in testes from my 50 µg/kg/day BPA 
treatment dose, which is also the FDA acceptable daily intake value for humans [403].  I plan to increase 
my sample size for all treatment groups in order to clarify whether the trend of decreasing ER" 
expression in the presence of any DES or BPA dose is a true phenomenon.  Although I anticipated Inhba 
expression would be downregulated following exposure to estrogenic compounds, I actually observed an 
increase in Inhba expression in my 5 µg/kg/day DES and 0.5 µg/kg/day BPA groups.  It is possible that 
Inhba expression initially goes down following exposure to BPA/DES, but that by looking at the end of 
fetal development I am missing this downward trend.  It is also possible I am observing a compensatory 
upregulation of Inhba is some of my treatment groups. To address these concerns, future studies in our 
lab based off of the preliminary data I am presenting here will include analysis at earlier stages to 
investigate the acute effects of estrogen exposure upon Inhba expression.  Another possibility is that 
exposure to estrogenic compounds simply does not alter the activin A signaling pathway.  Since changes 
in activin A signaling do not necessarily have to occur at the level of the ligand, I will perform qPCR to 
look for changes in downstream components of the activin A pathway including activin receptors and 
SMADs. 
 In genetic mouse models with disrupted testicular activin A signaling, fetal underdevelopment 
of the testis cords is not resolved during postnatal growth and results in small testis size, reduced sperm 
production, and abnormal seminiferous tubule histology in adulthood.  Given their similarities during 
fetal development, it is possible the testes of DES- or BPA-treated mice would develop similar 
dysfunctions in adulthood.  However, unlike my genetic mouse models in which either Inhba or Smad4 is 
permanently removed from relevant cell types, there is a possibility that partial or even complete recovery 
of activin A signaling could occur in DES or BPA exposed testes once estrogen treatment is withdrawn 
(i.e. after birth).  Although some published reports did not find changes in testis size or function in 
adulthood following in utero exposure to BPA, other groups have observed effects of BPA exposure on 
male reproduction [398, 424-429].  Thus, it is possible the fetal testis dysgenesis induced by BPA 
exposure could be overcome during postnatal development.  Future studies in our laboratory may 
investigate whether recovery of fetal testis cord dysgenesis can occur during postnatal life in male pups 
gestationally exposed to DES or BPA.   
 
 
Table 5.1:  Average litter size, pup sex ratio,  pup body weight, and anogenital 
distance (AGD) in vehicle control, DES, and BPA treatment groups.  Asterisk 
indicates treatment group differs significantly from control group for given parameter 
(p<0.05). 
# of 
litters 
Average # of 
pups per 
litter 
Average pup 
body weight (g) 
normalized by 
litter size 
Average body 
weight – male 
pups (g) 
normalized by 
litter size 
Average male 
pup AGD (mm) 
normalized to 
cube root of 
body weight (g) 
Vehicle control 3 10.7 ± 4.5 1.53 ± 0.23 1.73 ± 0.81 2.00 ± 0.31 
5 µg/kg/day DES 3 8.0 ± 4.4 1.46 ± 0.15 1.52 ± 0.11 1.99 ± 0.43 
0.05 µg/kg/day 
DES 
3 10.7 ± 1.5 1.36 ± 0.17 1.42 ± 0.12 2.55* ± 0.19 
50 µg/kg/day BPA 3 13.3 ± 3.2 1.22 ± 0.27 1.22 ± 0.27 1.95 ± 0.51 
0.5 µg/kg/day BPA 3 12.3 ± 1.5 1.39 ± 0.13 1.45 ± 0.12 2.25 ± 0.38 
5.6:  FIGURES AND TABLES 
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Table 5.2:  Incidence and severity of cryptorchidism in male pups from control, DES, 
and BPA treatment groups.  Partial cryptorchidism was considered to have occurred 
when testes descended to the top of the bladder.  Failure of the testes to descend 
further than below the kidneys was considered full cryptorchidism. 
# of males with 
normal testis 
descent 
# of males with 
partial 
cryptorchidism 
# of males with 
full 
cryptorchidism 
Total # of males 
per treatment 
Vehicle control 19 0 0 19 
5 µg/kg/day DES 4 13 1 18 
0.05 µg/kg/day 
DES 
12 0 0 12 
50 µg/kg/day BPA 6 13 0 19 
0.5 µg/kg/day BPA 17 0 0 17 
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Table 5.3:  Incidence of testis cord dysgenesis in vehicle control, DES, and BPA 
treatment groups based upon histological analysis.  Values indicate the number of 
individual pups analyzed per treatment group; at least one pup was analyzed from 
each litter (n=3 litters per treatment group).  Examples of each category (“normal”, 
“mildly dysgenic”, “severely dysgenic” ) are pictured in Figure 5.1.   
Normal 
Mildly 
dysgenic 
Severely 
Dysgenic 
Total 
Vehicle control 4 0 0 4 
5 µg/kg/day DES 1 2 2 5 
0.05 µg/kg/day DES 1 2 2 5 
50 µg/kg/day BPA 2 1 1 4 
0.5 µg/kg/day BPA 1 2 2 5 
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Figure 5.3:  Quantitative real-time PCR analysis of gene expression in testes 
following in utero DES or BPA exposure. (A-C) Relative expression levels of ER! 
(A), Inhba (B), and Insl3 (C) compared to the housekeeping gene beta actin are 
shown.  For each gene, the vehicle control has been set to a value of 1.  For each 
treatment group, 5-11 testes (representing three litters) were used for analysis.  Error 
bars indicate standard deviation from the mean.  Asterisk indicates p<0.05 compared 
to vehicle control. 
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FUTURE DIRECTIONS 
 
My doctoral research has uncovered Inhba/activin A as the first fetal Leydig cell-derived factor 
required for normal development of the murine fetal testis cords.  This novel paracrine communication 
from fetal Leydig cells to Sertoli cells promotes fetal Sertoli cell proliferation, thus driving elongation and 
coiling of the testis cords.  I have also confirmed that fetal testis cord expansion sets the stage for normal 
testicular function in adulthood, as mouse models with disrupted testicular activin A signaling beginning 
in fetal life have undersized testes and reduced sperm production as adults.  Although I have characterized 
the major roles of the activin A pathway with regard to testis development and dysgenesis, there remain 
many unexplored aspects of this fascinating signaling pathway in male reproduction.  For example, 
identification of the signaling factor/s controlling initiation and maintenance of Inhba expression in the 
fetal Leydig cells may provide evidence of further paracrine interactions in the embryonic testes.  
Preliminary data from Dr. Ivraym Barsoum, a graduate of the Yao lab, suggested expression of Inhba 
might occur downstream of desert hedgehog (Dhh) signaling from the Sertoli cells.  By performing in 
vitro culture of fetal testes with a chemical inhibitor of hedgehog family signaling, he was able to abolish 
Inhba mRNA expression.  However, since Dhh is an important regulator of fetal Leydig cell 
differentiation it is difficult to determine whether the decrease in Inhba mRNA was a direct result of loss 
of DHH signaling (i.e. DHH is a direct regulator of Inhba expression) or whether this decrease was 
secondary to a gross reduction in the fetal Leydig cell population due to inhibition of DHH signaling 
[108-109, 111, 126].  Further investigation of the potential relationship between DHH signaling and 
Inhba expression could provide valuable insight into the specification and function of the fetal Leydig cell 
lineage.  
 Similarly, identification of genes downstream of activin A signaling is an important next step in 
improving our understanding of this signaling pathway.  Sertoli cells are likely the direct targets of fetal 
Leydig cell-derived activin A based upon the phenotypic similarities between mice lacking Sertoli cell 
expression of Smad4, a critical regulator of TGF! superfamily signaling, and mice lacking fetal Leydig 
cell expression of Inhba.  Ideally, fetal Sertoli cells from control and Inhba-null testes could be isolated 
via laser capture microdissection and differential gene expression analyzed via microarray [430].  Genes 
upregulated specifically within control Sertoli cells could be screened for the presence of activin response 
elements or Smad binding elements in their promoter regions [431-436].  Similarly, isolation and 
microarray analysis of fetal Leydig cells from control and Inhba
-/-
 testes might reveal changes in fetal 
Leydig cell gene expression and/or function in the absence of testicular activin A signaling.  For example, 
I observed a statistically significant increase in testosterone production (p<0.05) in newborn Inhba
-/-
 testes 
compared to wild-type testes, suggesting expression of genes related to steroidogenesis may be 
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upregulated in the absence of Inhba [158].  However, it is also possible the increased testosterone 
production is due to an increase in the number of fetal Leydig cells in Inhba
-/-
 testes.  Thus, an important 
next step in studying the role of testicular activin A signaling during fetal testis development is to perform 
stereological analysis of control, Inhba
-/-
, and the various conditional knockout mouse models presented 
herein.  Normal testis function in both embryonic and adult life requires complex interactions among a 
multitude of cell populations, including the Sertoli cells, germ cells, Leydig cells, peritubular myoid cells, 
and vasculature.  Therefore, acquiring relative cell counts at both fetal and adult stages could provide a 
great deal of information about the changes in testis morphology and function observed in mice with 
disrupted testicular activin A signaling. 
 In evaluating the link between fetal testis dysgenesis and adult testicular dysfunction in my 
various mouse models, I chose to analyze male mice in young adulthood (8-16 weeks) as well as in more 
advanced age (27-62 weeks).  While I learned a great deal from evaluating these timepoints, analysis of 
Inhba cKO and Smad4 cKO mouse models during early postnatal life might reveal important changes in 
Sertoli cell behavior during this critical time.  In mice, follicle-stimulating hormone (FSH) and androgen 
regulate Sertoli cell proliferation between birth and puberty [227].  The compromised Sertoli cell 
proliferation in Inhba cKO and Smad4 cKO during fetal development makes the neonatal/postnatal 
development of these cells particularly intriguing.  Careful analysis of early postnatal cKO testes could 
reveal compensatory increases in the rate of Sertoli cell proliferation; conversely, Sertoli cell proliferation 
rates may remain suppressed during postnatal development of Inhba cKO and Smad4 cKO testes.  
Characterization of Sertoli cell proliferation during this FSH-dependent proliferative phase should 
provide a better understanding of the direct causes of reduced testis size and low sperm production in 
Inhba cKO and Smad4 cKO adult mice. 
 Perhaps the most intriguing mouse model I developed during my doctoral research is the Smad4 
SF1-cre cKO model, which develops unusual hemorrhagic testicular tumors in advanced age.  Although I 
evaluated testis histology and function in fetal life, young adulthood, and advanced age, my 
characterization provided only an extremely basic understanding of the role of Smad4 in the SF1-positive 
somatic cells of the testis.  Detailed study of testis morphogenesis in Smad4 SF1-cre cKO embryos is 
critical to determining precisely how loss of Smad4 in the SF1-positive precursor cell populations results 
in abnormalities of the testicular vasculature during both fetal and adult life.  Reports of similar 
vasculature issues in testes are rare in the scientific literature, although deletion of the forkhead 
transcription factor Fkhl18 has been reported to result in the accumulation of blood within the fetal testis 
interstitium due to gaps in the endothelial cells of blood vessels [333].  The expression of Fkhl18 within 
Sertoli cells, coupled with a known role for activins and TGF! superfamily ligands in regulating other 
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forkhead transcription factors, raises the possibility this gene could play a role in the vascular defects 
apparent in Smad4 Sertoli cKO mice [334-336].  Ideally, further analysis of Smad4 Sertoli cKO mice 
would also include a time course of testis histology throughout adult life to pinpoint the ages at which 
seminiferous tubule degeneration, Leydig cell hyperplasia/adenoma formation, and hemorrhages occur.  
Although the usefulness of the Smad4 Sertoli cKO mouse as a model for any human or animal disease is 
currently in doubt, this mouse model may still be valuable to study the roles of testicular vasculature in 
fetal testis development, adulthood, and advanced age. 
 Investigation into the possible link between testicular activin A signaling and estrogen-induced 
fetal testis dysgenesis has proven to be one of the most challenging and intriguing aspects of my research 
project.  Thus far, I have found that in utero exposure to low doses of diethylstilbestrol (DES) or 
bisphenol A (BPA) can result in impairment of testis cord development.  The changes in testis cord 
histology due to estrogenic exposures are visually similar to my observations in Inhba
-/-
, Inhba cKO, and 
Smad4 Sertoli cKO mouse models.  My current work on this project is to perform quantitative real-time 
PCR (qPCR) to analyze changes in the expression of genes related to the activin A signaling pathway.  I 
am also investigating whether the expression of genes classically recognized as being sensitive to 
estrogenic exposures, such as insulin-like growth factor 3 (Insl3) and steroidogenic acute regulatory 
protein (StAR), is altered in the testes of mouse pups gestationally exposed to BPA or DES [178].  A 
major limitation of my current analysis is the fact that by analyzing the testes of near-term pups I am in 
many ways only observing the final outcome of in utero exposure to BPA or DES.  Therefore, future 
plans in our laboratory include following an identical dosing scheme but collecting pups at earlier 
timepoints to determine the acute effects of estrogenic exposure on testis development.  Ideally, a time 
course of gene expression throughout fetal development in control and treated testes could be established 
as a reference for other researchers.  In addition, further investigation into the potential role of the activin 
A signaling pathway in estrogen-induced testicular dysgenesis may include utilizing some of the cKO 
mouse models described in this dissertation for DES and BPA dosing studies. 
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APPENDIX A:  EVALUATION OF TESTIS CORD HISTOLOGY IN NEWBORN TESTES 
FROM MOUSE MODELS LACKING COMPONENTS OF ACTIVIN A SIGNALING  
 
 
A.1:  INTRODUCTION 
 In Chapter 2, I presented data supporting the fetal Leydig cells as the primary source of activin A 
in the embryonic testes.  Conditional knockout (cKO) embryos lacking expression of inhibin !A (Inhba) 
in the fetal Leydig cells displayed defects in testis cord expansion and Sertoli cell proliferation generally 
similar to defects observed in Inhba
-/-
 embryos (Fig. 2.2).  Although this genetic evidence supported the 
fetal Leydig cells as the major source of activin A, other interstitial cells may also express Inhba.  The 
peritubular myoid cells, testis-specific smooth muscle cells that surround the testis cords, have also been 
proposed as a source of testicular activin A [162, 437].  Indeed, the diffuse pattern of INHBA protein I 
observed throughout the fetal testis interstitium suggested interstitial cells other than fetal Leydig cells 
could also secrete activin A (Fig. 2.1).  To investigate whether peritubular myoid cells are a potential 
source of activin A during testis morphogenesis, I collaborated with Roopa Nalam and Dr. Martin Matzuk 
at Baylor College of Medicine to study testis cord histology in a mouse model specifically lacking 
expression of Inhba in smooth muscle-related cells (Inhba peritubular myoid cell cKO, or Inhba PTM 
cKO).  I hypothesized that if peritubular myoid cells are an important source of activin A during fetal 
testis morphogenesis, Inhba PTM cKO newborn (E19.5) mice should exhibit stunted testis cord 
development similar to that of Inhba
-/-
 newborns. 
 In addition to my interest in discovering the cellular source/s of activin A, I also sought to better 
understand the signaling pathway triggered by testicular activin A during embryogenesis.  My analysis of 
Smad4 Sertoli cKO embryos (Chapter 2) confirmed Sertoli cells are the targets of activin A signaling; 
however, study of this mouse model could not inform me as to the receptors involved in transducing the 
activin A signal to the Sertoli cells.  Therefore, I collaborated with Dr. T. Rajendra Kumar at the 
University of Kansas Medical center to evaluate testis cord morphology in Acvr2a
-/-
 mice, which lack 
global expression of activin receptor type 2A (Acvr2a) [437].  Acvr2a is one of two possible type 2 
receptors demonstrated to directly bind activin A ligand, the other being activin receptor type 2B (Acvr2b) 
[437-438].  Very few studies have investigated the expression patterns of the type 2 activin receptors in 
murine fetal testes, particularly during the time of testis cord expansion (E15.5 to birth).  In situ 
hybridization analysis detected Acvr2b, but not Acvr2a, in murine gonads at E12.5; however, expression 
was not analyzed at later stages [160].  In developing rat embryos, Acvr2b mRNA localized to the testes 
at the time of testis cord expansion; however, testicular expression of Acvr2a was not observed at any 
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timepoint analyzed [170].  To investigate the potential contribution of Acvr2a during fetal testis 
development, I evaluated testis cord morphology in postnatal day 1 (PND1) Acvr2
-/-
 mice.  Although 
fetal/newborn testis histology had not previously been analyzed in Acvr2a
-/-
 mice, adult Acvr2
-/-
 mice are 
known to have delayed onset of fertility, reduced testis size, and decreased seminiferous tubule diameter 
[437].  The male reproductive defects present in adult Acvr2a
-/-
 mice result from decreased pituitary 
follicle-stimulating hormone (FSH) secretion as well as loss of local roles of Acvr2a in the testes [439-
440].  I hypothesized that Acvr2a is an important component of the activin A signaling pathway during 
fetal testis development, and that PND1 Acvr2a
-/-
 testes would display phenotypic similarities to newborn 
Inhba
-/-
 testes, namely enlarged testis cord diameter and a reduction in the number of testis cords.     
 
 
A.2:  MATERIALS AND METHODS 
A.2.1:  Testis samples 
 Tagln
cre/+
;Inhba
+/fl
 (referred to as Inhba PTM control) and Tagln
cre/+
;Inhba
fl/-
 conditional 
knockout mice (Inhba PTM cKO) were bred by Roopa Nalam in the laboratory of Dr. Martin Matzuk at 
Baylor College of Medicine [205, 443].  Newborn (E19.5) testes were collected, fixed for 1 hour at room 
temperature in Bouins fixative, and stored in 70% ethanol (see Chapter 2 for details).  Testis samples 
stored in 70% ethanol were mailed to me for histological analysis. 
 Acvr2a
+/-
 control and Acvr2a
-/-
 mice were bred by Dr. T. Rajendra Kumar at the University of 
Kansas Medical Center [438].  Postnatal day 1 testes were collected, fixed overnight in 4% 
paraformaldehyde, and stored in PBS (see Chapter 2 for details).  Testis samples stored in PBS were 
mailed to me for immunohistochemical analysis. 
 
A.2.2:  Histology: 
Processing, embedding, and staining of E19.5 testes was performed as described in Chapter 2. 
 
A.2.3:  Immunohistochemistry of frozen sections 
Immunohistochemistry using an antibody specific to laminin was performed as described in 
Chapter 2. 
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A.3:  RESULTS 
 Hematoxylin- and eosin-stained paraffin sections from newborn Inhba PTM control mice showed 
normal testis cord development, characterized by round or oval testis cord cross-sections occupying the 
majority of each section (Fig. A.1A).  Testis cord appearance in Inhba PTM cKO mice was similar to that 
of controls; specifically, testis cord cross-sections were present throughout each section (Fig. A.1B).  In 
contrast to Inhba PTM control or cKO mice, sections from Inhba
-/-
 newborn testes contained large areas 
of interstitial cells and few testis cord cross-sections (Fig. A.1C). 
 Laminin-stained frozen sections from PND1 Acvr2a
+/-
 control testes displayed many round or 
oval testis cord cross-sections, indicative of normal testis cord expansion and coiling during late fetal life 
(Fig. A.2A).  Testes from PND1 Acvr2a
-/-
 mice also contained many testis cord cross-sections, suggesting 
testis cord development was grossly normal (Fig. A.2B). In comparison, Inhba
-/-
 newborn (PND0) testes 
were characterized by fewer testis cord cross-sections, grossly increased testis cord diameter, and large 
expanses of laminin-positive interstitial cells (Fig. A.2C). 
 
 
A.4:  DISCUSSION 
 In adult testes, peritubular myoid cells are involved in critical communications with the Sertoli 
cell epithelium.  For example, an androgen-regulated paracrine factor produced by the peritubular myoid 
cells known as peritubular modulator of Sertoli cell function (PModS) has been established as an 
important indirect regulator of spermatogenesis [443-444].  Although PModS is not know to act directly 
upon germ cells, PModS modulates many Sertoli cell functions that are vital for successful 
spermatogenesis [444-448].  In contrast, a role for the paracrine signaling of fetal peritubular myoid cells 
is less well-understood.  While a few mouse models of improper peritubular myoid cell differentiation 
have been developed, changes in fetal testis development in these models can typically be traced back to 
improper laydown of the basal lamina surrounding the testis cords [61, 109, 126].  Thus, fetal peritubular 
myoid cells are better known for their structural rather than signaling contributions to fetal testis 
development. 
Since fetal peritubular myoid cells are putative sources of Inhba/activin A, I investigated whether 
activin A might be an important paracrine factor produced by this intriguing cell population [162, 437].  
Despite the documented expression of Inhba in the murine fetal peritubular myoid cells, genetic deletion 
of Inhba within these cells did not result in obvious changes in fetal testis histology (Fig. A.1) [162].  My 
observation of grossly normal testis development in Inhba PTM cKO indicates the contribution of 
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peritubular myoid cell-derived activin A to testis cord expansion and coiling is likely to be minimal.  
Instead, the deficits in testis cord expansion shared by both Inhba
-/-
 and Inhba FLC cKO fetal testes point 
to the fetal Leydig cells as the primary source of activin A during fetal testis development (Chapter 2).  
One possible confounding factor in my analysis of Inhba PTM cKO testes is the timing of cre 
recombinase expression in this conditional knockout model.  Cre recombinase expression in the Inhba 
PTM cKO model is driven by the transgelin (Tagln, also known as Sm22!) promoter, which has been 
shown to efficiently recombine target genes at high levels in the adult testis [449].  The expression pattern 
of Tagln-cre in the murine fetal testes has not been fully characterized but the available microarray data 
indicates Tagln is expressed in murine fetal testes after the time of peritubular myoid cell differentiation 
[450-451].  Therefore, if Tagln-cre expression in the Inhba PTM cKO mouse model mirrors that of the 
endogenous Tagln gene it is likely to result in deletion of Inhba in the fetal peritubular myoid cells around 
E13.5 [449-451].  Thus, my observation of grossly normal testis development in Inhba PTM cKO 
newborns carries the caveat that the precise timing and efficiency of Inhba deletion in this model is not 
known. 
 As was the case with Inhba PTM cKO mice, testis cord development in Acvr2a
-/-
 mice was 
grossly similar to that of controls.  Normal fetal testis development in the global absence of Acvr2a 
expression indicates Acvr2b is likely the critical modulator of activin A signaling during testis cord 
expansion.  The lack of an obvious testicular phenotype in PND1 Acvr2a
-/-
 mice coupled with the fact 
Acvr2a expression has not been detected in murine fetal testes strongly suggests Acvr2a may not be 
involved in local activin signaling during testis morphogenesis [160].  However, my analysis does not 
rule out the possibility that Acvr2a is important for fetal testes development but upregulation of Acvr2b in 
the absence of Acvr2a is able to ameliorate any testis dysgenesis phenotype.  Taken together with the data 
presented in Chapter 2, my study of Inhba PTM cKO and Acvr2a
-/-
 testes provides important information 
regarding the activin A signaling pathway in murine testis development.  Specifically, my analyses 
reinforce the importance of the fetal Leydig cells as the major source of activin A ligand and suggest 
Acvr2b may be the key activin type 2 receptor involved in this paracrine signaling from fetal Leydig cells 
to Sertoli cells.  Confirmation that murine fetal Sertoli cells express Acvr2b would be an important next 
step in fully characterizing the testicular activin A pathway in embryonic testes. 
 
 
 
 
Inhba PTM cKO 
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B 
Figure A.1:  Histology of newborn (E19.5) testes in Inhba PTM control (A), Inhba 
PTM conditional knockout (cKO) (B), and Inhba-/- (C) mice.  Scale bar = 250µm. 
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Inhba-/- Acvr2a-/- Acvr2a+/- 
A B 
Figure A.2:  Testis cord development in a postnatal day 1 (PND1) Acrv2a+/- control 
(A), PND1 Acvr2a-/- (B), and PND0 (newborn) Inhba-/- (C) mice.  Laminin (green) 
demarcates boundaries of the testis cords.  Scale bar = 100 µm. 
C 
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APPENDIX B:  IMMUNOLOCALIZATION OF IROQUOIS HOMEOBOX PROTEIN 3 IN THE 
TESTES OF INHBA
+/-
 AND INHBA
-/-
 EMBRYOS 
 
 
B.1:  INTRODUCTION 
 Iroquois homeobox 3 (Irx3) is a member of the Iroquois homeobox family of transcription factors 
that follows a female-specific expression pattern in developing gonads of the mouse [452].  This 
upregulation of Irx3 in female gonads suggests Irx3 may play important roles in female sex determination 
and development.  In the murine fetal ovary, Irx3 mRNA expression is restricted to somatic cells and is 
elevated between E12.5 and birth [452-453].  In both ovaries and testes, supporting somatic cell 
populations that arise from coelomic epithelial cells are critical for normal development of the germ cells 
during both fetal and adult life [3].  Under normal circumstances, supporting cell precursors in the ovary 
differentiate into granulosa cells whereas these same precursors give rise to Sertoli cells in the testis [68].  
Given the common origin of granulosa and Sertoli cells, abnormal differentiation of these cell lineages 
can result in aberrant expression of markers normally associated with the opposite sex.  For example, 
deletion of Sry-related HMG box gene 9 (Sox9) in murine pre-Sertoli cells prevents the expression of 
testis-specific markers such as anti-Müllerian hormone (Amh) and allows the upregulation of female-
specific genes such as bone morphogenetic protein 2 (Bmp2) and follistatin (Fst) [36]. 
 Although Sertoli cell development in fetal Inhba
-/-
 testes was sufficient to allow for testis cord 
formation and differentiation of other testis-specific cell lineages, there were signs that Sertoli cell 
differentiation might be compromised in this mouse model.  Specifically, Sertoli cells in newborn Inhba
-/-
 
testes tended to exhibit an abnormal flattened or trapezoidal nuclear shape as opposed to the rounded or 
oval shape of Sertoli cell nuclei in control testes (Chapter 2).  In addition, some Sertoli cells in Inhba
-/-
 
embryos were observed within the testis cord lumen, apparently dislodged from the basal lamina.  To 
investigate whether this potentially incomplete differentiation of Sertoli cells led to upregulation of 
female-specific factors, I performed immunohistochemistry for IRX3 in Inhba
+/-
 control and Inhba
-/-
 fetal 
testes. 
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B.2:  MATERIALS AND METHODS 
B.2.1:  Testis samples 
 Newborn (E19.5) Inhba
+/-
 and Inhba
-/-
 testes were collected as detailed in Chapter 2. 
 
B.2.2:  Immunohistochemistry of frozen sections 
Processing, sectioning, and tyramide signal-amplified immunohistochemistry was performed as 
described in Chapter 2.  The IRX3 antibody was provided courtesy of Dr. Joan Jorgensen (University of 
Wisconsin-Madison) and was used at a concentration of 1:1000. 
 
 
B.3:  RESULTS 
 IRX3 protein was detected throughout the interstitium of both Inhba
+/-
 (Fig. B.1A) and Inhba
-/-
 
(Fig. B.1B) testes at E15.5.  No signal was observed within the testis cords, indicating Sertoli and germ 
cells are not sources of IRX3 at this stage (Fig. B.1).  The relatively diffuse pattern of staining prevented 
the identification of specific IRX3-positive cell lineages at this early stage.  At E17.5, IRX3 staining was 
present in the nuclei of peritubular myoid cells of Inhba
+/-
 testes (Fig. B.1C).  The characteristic thin, 
flattened nuclear shape and location at the outer periphery of the testis cords confirmed the IRX3-positive 
cells as peritubular myoid cells.  IRX3 was also detected within the peritubular myoid cells of Inhba
-/-
 
testes at E17.5 (Fig. B.1D).  Interestingly, some Sertoli cells of E17.5 Inhba
-/-
 mouse testes showed strong 
nuclear and fainter cytoplasmic expression of IRX3 (Fig. B.1D).  This Sertoli cell expression of IRX3 
was not observed in E15.5 testes of either genotype or in E17.5 Inhba
+/-
 testes. 
 
 
B.4:  DISCUSSION 
 My observation of IRX3 protein throughout the interstitium of E15.5 Inhba
+/-
 and Inhba
-/-
 testes 
is consistent with previously published reports.  Although Irx3 is upregulated in ovarian somatic cells 
after E13.0, it continues to be expressed in testes albeit at a level well below that of female gonads [452].  
At E15.5, IRX3 protein was not detected within testis cords of either Inhba
+/-
 or Inhba
-/-
 embryos, 
indicating Sertoli cells do not express detectable levels of Irx3 at this time.  By E17.5, IRX3 expression 
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was nearly absent in the interstitial mesenchyme of Inhba
+/-
 and Inhba
-/-
 testes and had instead switched to 
the nucleus of peritubular myoid cells.  In addition to expression within peritubular myoid cells, some 
Inhba
-/-
 Sertoli cells expressed nuclear and cytoplasmic IRX3 at E17.5.  This difference in IRX3 
expression at E17.5 between Inhba
+/-
 and Inhba
-/-
 testes is intriguing, particularly given the similarities in 
IRX3 expression at E15.5.  Considering E15.5 is the timepoint immediately prior to the onset of testis 
cord expansion (Chapter 2), the differential expression of IRX3 during testis cord expansion at E17.5 
raises the possibility that the abnormal expression of IRX3 in Inhba
-/-
 testes could somehow be related to 
the defects of testis cord elongation and coiling in this mouse model.  Clearly, much more work is 
necessary to determine whether the change in IRX3 localization in Inhba
-/-
 testes is directly involved in 
testis cord dysgenesis in this model or is instead an interesting coincidence.  However, the abnormal 
expression of a female-specific factor in Inhba
-/-
 Sertoli cells points to their improper differentiation and 
raises the question of whether other female-specific genes might be abnormally expressed in Inhba
-/-
 
embryos.   
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Figure B.1:  Immunolocalization of iroquois homeobox protein 3 (IRX3) in the testes 
of Inhba+/- and Inhba-/- mouse embryos.  (A-B) Fluorescent staining for IRX3 is 
shown in sections from E15.5 Inhba+/- control (A) and Inhba-/- (B) testes.  Image 
magnification = 20X.  (C-D)  Immunofluorescence for IRX3 depicted in E17.5 Inhba
+/- (C) and Inhba-/- (D) mouse testes.  Image magnification = 40X. 
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APPENDIX C:  ALTERATION OF TESTIS CORD APPEARANCE IN MURINE FETAL 
TESTES EXPOSED TO DIETHYLSTILBESTROL IN VITRO 
 
 
C.1:  INTRODUCTION 
 In Chapter 5, I presented data from a study of the effects of gestational exposure to 
diethylstilbestrol (DES) or bisphenol A (BPA) on murine fetal testis development.  The aim of that study 
was to investigate whether estrogenic compounds such as DES and/or BPA might alter the testicular 
activin A pathway during embryogenesis.  Prior to conducting my in utero dosing study, I performed a 
preliminary tissue culture experiment to determine whether DES could elicit changes in testis cord 
morphogenesis in vitro.  I selected DES as a model estrogenic endocrine disruptor known to signal via 
estrogen receptor " (ER", also known as Esr1), which is expressed specifically by the murine fetal 
Leydig cells [178, 367-368].  As presented in Chapter 2, the fetal Leydig cells are the major source of 
activin A in the murine fetal testes; therefore, DES could theoretically disrupt Inhba/activin A expression.  
The most visually apparent phenotype I found in my knockout mouse models with disrupted testicular 
activin A signaling was impairment of testis cord expansion.  I reasoned that if testes exposed to DES in 
vitro exhibited normal testis histology it was unlikely DES treatment in vivo would significantly alter the 
testicular activin A pathway.  On the other hand, if testes cultured with DES showed underdevelopment of 
the testis cords it would provide very preliminary support for my hypothesis that gestational exposure to 
estrogenic compounds might be able to influence activin A signaling in the fetal testes.   
 
 
C.2:  MATERIALS AND METHODS 
C.2.1:  Testis samples 
 Pregnant CD-1 females were obtained as described in Chapter 5.  Testes removed from E15.5 
embryos were utilized for ex vivo organ culture. 
 
C.2.2:  In vitro culture of murine fetal testes 
 E15.5 testes were cultured on an agar block using a previously validated protocol [80].  The agar 
block was composed of Difco Labs BactoAgar (Detroit, MI) and Gibco 11995-065 DMEM medium 
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(Invitrogen, Carlsbad, CA) allowed to solidify on a 30 mm stainless steel mold that created three “wells” 
for samples.  Once solidified, the agar block was placed into a polystyrene 35 mm culture dish (Falcon, 
BD, Franklin Lakes, NJ) containing 1 mL of culture medium.  I used Gibco 11995-065 DMEM medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (BioWhittaker, Walkersville, 
MD), 50 µg/mL ampicillin, and either 5 µM DES (Sigma, St. Louis, MO), 25 µM DES, or DMSO vehicle 
control (Sigma, St. Louis, MO).  One agar block for each of the four treatment groups (non-treated 
control, DMSO vehicle control, 5 µM DES, 25 µM DES) was placed in an individual culture dish.  Agar 
blocks were allowed to equilibrate for at least 30 minutes in a 37°C incubator with 95%O2/5%CO2 air 
flow.  Four to six testes with epididymides attached were placed in the wells of each agar block and total 
medium volume in each dish was reduced to 750 µL.  Testes were cultured for 72 hours at 37°C with 
95%O2/5%CO2 air.  Treatment-appropriate medium was changed every 24 hours.  After 72 hours, testes 
were removed from the agar blocks and photographed via light microscopy. 
 
 
C.3:  RESULTS 
 My studies in Chapter 2 revealed murine testis cord coiling takes place between E15.5 and birth.  
I therefore decided to start my in vitro culture experiment at E15.5 and culture for 72 hours in order to 
maximize my chances of observing changes in testis cord development with DES treatment.  Following 
culture, light microscopy of non-treated control testes showed normal progression of testis cord coiling, 
as evidenced by the “honeycomb” pattern of light-colored testis cord cross-sections separated by small 
regions of darker interstitium (Fig. C.1A) (n=4 testes).  Testes cultured with DMSO vehicle control also 
showed grossly normal testis development (Fig. C.1B) (n=5 testes).  In the DMSO vehicle control testis 
pictured, small cord cross-sections on the lefthand side indicate a highly-coiled region, whereas the 
“striped” appearance of the righthand side represents a region of slightly less coiling.  This range of 
convolution was typical of many non-treated control and DMSO vehicle control testes.  A similar mix of 
coiled and under-coiled areas was visible in testes cultured with 5 µM DES (Fig. C.1C) (n=6 testes); 
however, testis cord diameter appeared slightly enlarged compared to non-treated or vehicle control 
testes.  The cords of testes cultured with 25 µM DES were visibly enlarged compared to non-treated and 
vehicle control testes (Fig. C.1D) (n=6 testes).  Testes exposed to 25 µM DES also had a more distinctive 
striped appearance than was observed in other treatment groups.  In addition, the epididymides of testes 
exposed to either dose of DES showed inflation of epididymal lumen, presumably related to the well-
documented effects of estrogenic compounds on fluid resorption within the rete testis and efferent ducts 
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[454-456].  Although qualitative, these observations suggested DES exposure altered testis cord 
morphogenesis in my tissue culture system. 
 
 
C.4:  DISCUSSION 
 The subtle changes I observed in testis cord appearance following in vitro DES exposure 
confirmed estrogenic compounds can induce underdevelopment of the murine fetal testes.  Since DES is 
known to signal via ER", which is expressed specifically by fetal Leydig cells, it is possible that DES 
exposure alters fetal Leydig cell expression of Inhba.  To test the hypothesis that estrogen-induced fetal 
testis cord dysgenesis results from disruption of Inhba expression and/or activin A signaling, I conducted 
the in vivo dosing study detailed in Chapter 5. 
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Figure C.1:  Effect of diethylstilbestrol (DES) on murine fetal testes in culture.  Light 
microscopy images of testes cultured in vitro for 72 hours in the absence of treatment 
(A), the presence of DMSO vehicle (B), the presence of 5 µM DES (C), or the 
presence of 25 µM DES (D).  Testes were dissected from E15.5 embryos and cultured 
for 72 hours.  Images were taken at the same magnification. T=testis, E=epididymis. 
Arrowheads indicate enlargement of the epididymis due to estrogen-induced fluid 
buildup. 
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